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ABSTRACT OF THESIS (Regulation 7.9)
Kinins are potent vasodilator peptides which increase capillary
permeability, stimulate prostaglandin synthesis, and when infused
intrarenally cause natriuresis and diuresis. Kinins are formed
from kininogens by plasma or glandular kallikreins. Plasma
kallikrein circulates as an inactive precursor,, and interacts
with coagulation, fibrinolytic and complement systems. Glandular
kallikreins are found in salivary glands, pancreas and kidney.
Previous studies found renal kallikrein only in distal tubular
cells. Activity of the renal kallikrein-kinin system is inferred
from urinary kallikrein excretion rate (UKall).
Methods are described for measurement of plasma prekallikrein
and urine kallikrein concentration, using specific synthetic
tripeptide chromogenic substrates.
In normal man, UKall increased promptly in response to saline
infusion, correlating with increased sodium and water excretion.
The ratio of plasma renin activity (PRA) to UKall was highly
correlated with urinary sodium excretion (UNaV) (r-0.91). This
correlation was also highly significant in normal man during a 9
hour clearance study under basal conditions (r—0.51).
Histological and immunocytochemical studies were performed to
characterise the granular glomerular peripolar cell. These cells
were found to contain kallikrein in secretory granules, and to
lie in close apposition to renin-containing cells.
UKall, factored for glomerular filtration rate, was increased in
patients with chronic renal failure. UKall fell in patients given
captopril, in association with an increase in plasma creatinine.
In patients with nephrotic syndrome (NS), UKall was raised, and
there was increased glandular kallikrein activity in plasma. A
role for kallikreins and kinins in the pathogenesis of NS is
proposed. The PRA/UKall ratio correlated with UNaV (r-0.53).
UKall, measured under clearance study conditions, was low in most
patients with hepatic cirrhosis, particularly those with ascites.
PRA/UKall was a strong correlate with UNaV (r -0.80).
In an ovine model of acute renal failure (ARF) due to sepsis,
reciprocal changes in PRA and UKall were observed, correlating
with increased plasma catecholamines. PRA/UKall correlated with
UNaV (r-0.82) and plasma albumin (r-0.82). This "sodium-
retaining" ARF may be due to neuro-endocrine mechanisms,
including kallikrein and renin. Acute euvolaemic lowering of
plasma protein concentration in sheep by plasmapheresis, did not
affect UKall, PRA, or sodium excretion.
The results support the concept that the renal kallikrein-kinin
system is natriuretic and diuretic. Kallikrein released from PPCs
may influence glomerular and tubular function. Relative activity
of the renin-angiotensin and kallikrein-kinin systems appears to
be an important determinant of renal function, and of sodium
excretion in particular, in both health and disease.
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1.1. The existence of kallikreins and kinins was
probably first recognised in 1906, when Abelous and Bardier
described the hypotensive properties of human urine when
injected into dogs (Abelous and Bardier, 1906). The chemical
properties of the active principle in this phenomenon
corresponded to later descriptions of kallikreins and
kinins, and the International unit for kallikrein was until
recently standardised in relation to the fall in blood
pressure induced by 5 ml of pooled normal human urine (Frey,
Kraut and Werle, 1950). This paper gave the first indication
that the kidney generates vasodepressor compounds. 80 years
later, the significance of this observation in relation to
human disease remains only marginally less obscure.
The basic chemistry of the kallikreins was defined in the
1930s by Frey, Haut and others (Kraut, Frey and Werle,
1930). Subsequently, knowledge of the structure and function
of these compounds has accumulated rapidly (Levinsky, 1979;
Mills, 1980; Mills, 1982; Scicli and Carretero, 1986; Fuller
and Funder, 1986).
1.1.1. Kallikreins
Kallikrein is the generic term for enzymes which generate
kinins from kininogen precursors. Kallikreins are widely
distributed, both phylogenetically (kallikreins are the
active principle in many wasp stings) and in human tissues
(Pisano, 1975). An important principle concerns the
separation of plasma kallikrein from other types,
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collectively known as glandular kallikreins. The fundamental
differences between these types of enzyme are shown in Table
1. The most important sources of glandular kallikrein are
the pancreas, submandibular glands, and kidney.
Glandular kallikrein Plasma kallikrein
Molecular weight 24,000 - 44,000 100,000 - 120,000
Isoelectric point 3.5 - 4.4 8.0 - 8.5
Substrate LMWK and HMWK HMWK
Inhibited by SBTI No Yes
Normally Active/inactive Inactive(prekallikrein)
found as
Physiological aprotonin C1 -esterase inhibitor
inhibitors ex. 1 -proteinase inhibitor
Antithrombin III- -
heparin
Abbreviations: LMWK - low molecular weight kininogen;
HMWK - high molecular weight kininogen; SBTI - soya
bean trypsin inhibitor.
Table 1 Characteristics of glandular and plasma
kallikreins
1 .1.2. Kinins
The first kinin to be recognised, bradykinin, was so named
because it produced a slow contraction of uterine smooth
muscle in a bioassay preparation. It is a nonapeptide, and
the decapeptide, lysyl-bradykinin, has similar actions.
Kinins have a wide range of biological effects, which vary
between tissues and between species (Regoli and Barabe,
1980). The following properties are relatively consistent,
however.
1 . Vasodilation. In vitro, kinins produce different
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effects on vascular tone in different preparations, but in
vivo exert a powerful vasodilator effect on capillary
vessels and arterioles. Bradykinin can antagonise the
vasoconstrictor action of Angiotensin II at equimolar
concentrations (Regoli, Barabe and Park, 1977). Infusion of
bradykinin into the renal artery increases renal blood flow
(Barraclough and Mills, 1965), an effect which is
only partially blocked by indomethacin (McGiff et al, 1976;
Vio, Bednar and McGiff, 1983). Kinins reduce the effect on
renal function of stimulation of the renal sympathetic
nerves (Inokuchi and Malik, 1984).
2. Increased capillary permeability. Kinins have
long been considered to be important mediators of
inflammation, and local reactions to injected kinins include
erythema, pain, oedema, and increased capillary protein leak
(Marceau et al, 1983).
3. Stimulation of prostaglandin synthesis. Kinins are
widely used by physiologists to stimulate release of
arachidonic acid from cell membranes, via activation of
Phospholipase A2 (Nasjletti and Malik, 1981). Some, but not
all, of the actions of kinins are mediated by prostaglandins
as second messengers (McGiff, 1980; Mullane and Moncada,
1980; Kramer et al, 1983).
Other actions of kinins include bronchoconstriction,
control of sperm motility, stimulation of cell
proliferation, stimulation of catecholamine release from the
adrenal medulla, release of histamine from mast cells, and
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facilitation of insulin-mediated glucose transport (Regoli
and Barabe, 1980).
1.1.3. Kinin receptors
Stewart, Regoli and others have worked to clarify the nature
of these receptors (Stewart, 1968; Vavrek and Stewart, 1987;
Regoli, Marceau and Lavigne, 1981). It is clear that at
least two types exist. The most important is the B2
receptor, which is widespread in its distribution, and
responds to both bradykinin and kallidin. It has recently
been found to be antagonised selectively by a highly
substituted kinin analogue, B3824 (Vavrek and Stewart,
1987). The B1 receptor has uncertain significance in
physiology, and appears to be confined to vascular tissue.
It is antagonised by [Leu-OMe8] des-Arg9-Bradykinin . Trace
quantities of bacterial lipopolysaccharide increase the
sensitivity of tissues to the B1 agonist, des-Arg9-
Bradykinin, and Kininase 1 produces kinin fragments which
have B1 agonist properties and prolonged plasma half-lives.
These mechanisms may allow potentiated effects of kinins
during endotoxaemia (Regoli and Barabe, 1980). Post-receptor
events involve an increase in intra-cellular cAMP, by either
increased adenyl cyclase or decreased phosphodiesterase
activity. This stimulates an energy-requiring calcium-
binding process, leading to a fall in intra-cellular calcium
and muscle relaxation (Bareis et al, 1983). The recent
discovery of competitive antagonists of both B1 and B2
receptors may help to answer many of the unresolved
questions regarding the actions of kinins.
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1.1.4. Inhibitors of the Kallikrein-Kinln systems
The important inhibitors of the plasma and glandular
kallikreins are shown in Table 1. The plasma kallikrein-
kinin system is normally completely inhibited by an excess
of <* 1 -proteinase inhibitor and C1 esterase inhibitor
(Schreiber, Kaplan and Austen, 1973). The importance of
endogenous inhibitors of glandular kallikreins is less
clear, although several tissues, including lung and kidney,
are rich in such compounds (Kunitz and Northrop, 1936). The
most important pharmacological kallikrein inhibitor,
aprotonin, is a polypeptide, molecular weight 6512, which
binds to trypsin, plasma kallikrein, plasmin, and glandular
kallikreins (Fritz and Wunderer, 1983)(Table 2). It is
prepared commercially as a purified extract of bovine lung
(Trasylol, Bayer FRG).
Enzyme Dissociation constant (Ki)
Trypsin 6.0 x 10-14
Glandular kallikrein 9.0 x 10-11
Plasmin 2.3 x 10-10
Plasma kallikrein 3.0 x 10-8
Neutrophil elastase 3.5 x 10-6
Table 2 Specificity of aprotonin
Kinins are rapidly metabolised by Kininase enzymes, so that
the plasma half-life of bradykinin is of the order of 15
seconds (McCarthy, Potter and Nicolaides, 1965). The most
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important enzymes are Kininase 1 and Kininase 2, and the
main sites of kinin metabolism are the lung and kidney.
Kininase 2 is identical to Angiotensin Converting Enzyme
(ACE), and ACE inhibitors may potentiate the kallikrein-
kinin system by slowing kinin metabolism (Erdos, 1975;
Carretero, 1981).
1.2. The plasma kallikrein-kinin system
Components of the plasma kallikrein-kinin system and its
important interactions are shown in Fig 1. Plasma kallikrein
normally circulates almost entirely as an inactive
precursor, prekallikrein, which is synthesised in the liver
and has a molecular weight of 130,000 (Kaplan, Meier and
Mandle, 1977). Activation of Hageman factor leads to
conversion of prekallikrein to kallikrein (M. Wt. 100,000)
(Bagdasarian et al, 1974). Hageman factor is also the
initiating enzyme of other contact-activated systems in
plasma, including blood coagulation, fibrinolysis, and
complement activation (Cochrane et al, 1972). Hageman factor
is activated by contact with exposed basement membranes,
collagen, other negatively charged surfaces, and by
bacterial endotoxin (Morrison and Cochrane, 1974). The
plasma kallikrein-kinin system has been considered one of
several interlocking networks which help to mediate cellular
and vascular responses necessary for defence and repair
(Fuller and Funder, 1987).
The principal substrate of plasma kallikrein is the high
molecular weight kininogen, M. Wt. 200,000, and the main
6
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product is bradykinin. Kininase 1 is responsible for 90% of
the kinin degrading activity of plasma, but Kininase 2
located in the lung is quantitatively more significant, so
that 90% of the biological activity of bradykinin is lost
during a single passage through the lungs (Erdos, 1976).
1 ,2,2, Physiology
Because injection of bradykinin lowers blood pressure, a
role for the plasma kallikrein-kinin system in the
regulation of blood pressure has been proposed (McGiff and
Nasjletti, 1976, Margolius, 1980). There is however little
evidence for such a mechanism under physiological
conditions, and it is difficult to conceive of such an
effectively inhibited enzyme system having such a role in
the systemic circulation (Waeber et al, 1988). The blood
pressure response to bradykinin infusion is in fact very
variable, and in some species, bradykinin increases blood
pressure, probably by a central effect (Mills, 1979). Indeed
it has been suggested that kinins function solely as local
tissue autocoids, and that plasma kinin generation only
becomes important under pathological conditions, or when
kinin degradation is inhibited (Fuller and Funder, 1987).
There is good evidence that the hypotensive effect of ACE
inhibitors in low-renin hypertensives and in anephric
subjects is related to increased plasma kinin concentrations
(Overlack, Stumpe and Kuhnert, 1981).
1.2.3. Pathophysiology
Using a radiolabelled enzyme substrate, p-toluene-sulphonyl-
L-arginine-methyl ester (TAME), in an activity assay, Colman
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and colleagues, and others, have described abnormalities of
the plasma kallikrein-kinin system in a wide range of
disease states (Colman and Wong, 1977). In hereditary
angioneurotic oedema, deficiency of C1 esterase inhibitor is
associated with recurrent episodes of kallikrein-kinin
system activation (Ratnoff et al, 1969). In septic shock,
reduced plasma concentrations of plasma prekallikrein,
increased "kallikrein-like activity", and decreased
kallikrein inhibitory activity have been documented,
probably as a result of endotoxin-induced Hageman factor
activation (Webster and Clark, 1959; Neiss et al, 1968;
Mason et al, 1 970; O'Donnell et al, 1 976; Cumming et al,
1984). Reduced plasma prekallikrein has also been observed
by Colman's group in a number of other disease states,
including disseminated intravascular coagulation, typhoid
fever, hepatic cirrhosis, coronary artery disease,
transfusion reactions, and in relation to haemodialysis and
extracorporeal bypass. It is unclear in these syndromes
whether the reduced plasma prekallikrein reflects
kallikrein-kinin system activation or reduced prekallikrein
synthesis, and the possible significance of the kallikrein-
kinin system abnormalities has not been tested by the use of
aprotonin or other more selective inhibitors. The role of
the plasma kallikrein-kinin system in human disease
therefore remains uncertain, although several provocative
experimental observations suggest that it may participate in
at least some clinical conditions. Recent studies using
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selective kinin antagonists are shedding further light on
this problem, eg suggesting a role for kinins in intra¬
cranial vascular spasm after cerebral haemorrhage (Heizer et
al, 1987; Waeber et al, 1988).
1.3 Renal kallikreln-kinin system
1,3.1 Renal kallikrein is one of several related
glandular kallikreins. They are glycoproteins, single
polypeptide chains with molecular weights 27-40,000. They
belong to a family of enzymes known as serine proteases,
because of the presence of a serine residue at the active
catalytic site. They act on either HMWK or low molecular
weight kininogen (LMWK) - M. Wt. 50,000 - and in general
form lysyl-bradykinin (kallidin) (Levinsky, 1979; Mills,
1982; Scicli and Carretero, 1986; Fuller and Funder, 1987).
A schematic representation of the renal kallikrein-kinin
system is shown in Fig 2. Renal kallikrein has been
localised to the luminal cells of the distal convoluted
tubule, between the JGA and the cortical collecting duct, in
a variety of species including man, and by a number of
techniques, including use of cDNA probes (Orstavvik et al,
1976; Scicli et al, 1976; Vio and Figueroa, 1985). The genes
regulating kallikrein synthesis, of which there are at least
three in the mouse, are located on Chromosome 7 (Mason et
al, 1 983). The derived mRNA codes for the synthesis of a
pre-prokallikrein, which is cleaved to prokallikrein in the
endoplasmic reticulum, and then to fully active kallikrein










conversion in vitro, the factors responsible for activation
of prokallikrein in vivo are unclear, as are the means
whereby this conversion is regulated (Fuller and Funder,
1987). Prokallikrein and kallikrein exist at both the
luminal and basolateral membranes of distal tubular cells,
although at the luminal surface the enzyme projects into the
tubular lumen, permitting it to function as an ectoenzyme
(Chao and Margolius, 1979). Secretion of kallikrein is
thought to occur both into the tubular lumen and into the
renal interstitium; kallikrein has been detected in both
renal lymph and, in trace quantities, in the systemic
circulation (De Bono and Mills, 1974, Proud et al, 1983, Vio
et al, 1983). Kallikrein in the tubular lumen probably acts
primarily on filtered LMWK, although kininogen has been
localised to tubular cells and could also be secreted
(Pisano, 1983). The proximal tubular brush border is rich in
kininase activity, so that any filtered kinin is degraded
before reaching the distal nephron (Carone et al, 1976).
Similarly, while kallikrein should not be filtered in
appreciable amounts by the normal kidney, the proximal
tubule has the capacity to reabsorb and metabolise any
filtered enzyme (Mills, Paterson and Ward, 1975) • The
circumstances therefore exist for the renal kallikrein-kinin
system to function as a local paracrine mechanism,
independent of the plasma system. The kallikrein enzyme in
urine has been shown to be identical to renal tissue
kallikrein (Orstavvik et al, 1976).
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1.3.2. Physiology of the renal kallikrein-kinin system
Several roles for the renal kallikrein-kinin system in renal
physiology have been proposed, some of which are mutually
exclusive. Despite a vast body of experimental evidence, no
true concensus has emerged. The most important possibilities
are outlined below.
1. Natriuresis. It has long been known that infusion of
kinin into the renal artery increases sodium excretion
(Barraclough and Mills, 1965). Interest in this as a
regulatory mechanism was stimulated by Mills, who while
working with De Wardener on the original experiments which
suggested the existence of a "natriuretic hormone",
postulated that the rapidity of the changes in sodium
excretion seen in these experiments was only compatible with
an intra-renal mechanism, rather than extra-renal synthesis
and release of a hormone. In a series of subsequent
experiments he accumulated evidence for the participation of
renal kallikrein in a "natriuretic cascade", involving
interactions with dopamine, prostaglandins, and low
molecular weight ATP-ase inhibitors, and inhibited by
adrenergic mechanisms (Adetuyibi and Mills, 1972; Mills et
al, 1976; Mills, Newport and Obika, 1979; Mills, 1982). This
concept is supported by the observed increase in kallikrein
excretion in response to acute sodium-loading in dogs
(Mills, 1976), and chronic salt loading in rats (Croxatto et
al, 1976); the increase in kallikrein excretion during the
DOCA escape phenomenon (Bonner et al, 1981); and by the
impressive decreases in sodium excretion induced in some
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experimental situations by anti-kinin antibodies (Marin-
Grez, 1974) and by the kallikrein inhibitor aprotonin
(Kramer et al, 1984). The major objection to the hypothesis
was that kinins had not been shown by micropuncture to
directly influence proximal tubular sodium transport (Stein
et al, 1 972); this does not however preclude an effect
mediated by second messengers in the intact kidney, a
primarily distal effect, or an effect on deep nephrons
inaccessible to micropuncture. It is also possible that
kinins may alter medullary blood flow and the medullary
osmotic gradient (Scicli and Carretero, 1986). One study by
Kauker suggested that intra-luminal kinins may reduce efflux
of sodium from the late proximal tubule (Kauker, 1980).
2. Sodium retention. The uncertainty regarding the role
of the renal kallikrein-kinin system is demonstrated by the
fact that Marks and Keiser, established workers in this
field, proposed as recently as 1983 that kallikrein was a
sodium retaining mechanism, which mediated the tubular
effects of aldosterone and other mineralocorticoids (Marks
and Keiser, 1983). While urinary kallikrein excretion is
increased in primary aldosteronism, Bartter's syndrome, and
during DOCA administration, it is normal or low in other
circumstances where plasma aldosterone is increased, eg 2-
kidney 1-clip renovascular hypertension (Geller et al, 1972;
Margolius et al, 1974; Halushka et al, 1977; Scicli and
Carretero, 1986). Administration of aldosterone itself does
not increase kallikrein excretion (Adam and Clappison,
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1982). It is therefore possible that the increased
kallikrein excretion is a response to mineralocorticoid-
induced sodium retention, rather than a direct effect.
3. Facilitates water excretion by antagonising ADH.
Most studies have found that water loading increases
kallikrein excretion, and in rabbits subjected to
independent alterations in sodium and water intake, the
principal correlation was between kallikrein excretion and
water intake (Mills and Ward, 1975). Bradykinin, in concert
with prostaglandins, can antagonise the hydrosmotic actions
of ADH on isolated distal tubules and collecting duct
(Schuster, Kokko and Jacobsen, 1984). ADH has been shown to
stimulate both the release of kallikrein and intra-renal
kinin formation in animals (Fejes-Toth, Zahajsky and Filep,
1 980). Such a role would obviously be in keeping with the
distal location of tubular kallikrein.
4. An intra-renal vasodilator system which antagonises
the vasoconstrictor effect of locally generated Angiotensin
II. The concept that the renal kallikrein-kinin system and
the renin-angiotensin system are parallel and opposing
systems was propounded by Mills and others, and is supported
by considerable evidence (Mills et al, 1972). Infusion of
Angiotensin II into the renal artery increases kallikrein
excretion; this coincides with the development of
tachyphylaxis to the effects of All on renal blood flow and
sodium excretion (Macfarlane, Adetuyibi and Mills, 1974).
Conversely, both renal kallikrein and kinins can stimulate
renin release from superfused kidney slices (Arakawa, 1980;
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Beierwaltes, Prada, and Carretero, 1985); aprotonin
inhibits basal and frusemide-stimulated renin release (Seto
et al, 1983). Kallikrein can convert prorenin to renin in
vitro, but it is not certain whether this process is
important in vivo (Sealey et al, 1 978). In the isolated
perfused kidney, kallikrein and renin release change in
parallel in response to changes in perfusion pressure and
renal blood flow (Bevan, MacFarlane and Mills, 1974).
Evidence therefore exits for a functional link between these
two systems, although the significance of this relationship
in the regulation of renal function is not clear.
5. "Passive washout". Urinary kallikrein excretion rate
increases in response to most experimental manoeuvres which
increase urine flow, and after repeated stimuli such as
mannitol infusions, the increase becomes progressively less
marked (Bonner et al, 1981). This has been interpreted as
indicating passive washout of kallikrein from tubular cells
(Seeber, Vila and Catanzaro, 1982). Such a phenomenon is
also seen with most other urine enzymes. It does not
however preclude a functional role for intra-renal
kallikrein , particularly if it acts to facilitate water
excretion, as described above. The reduction in urine flow
in volume-expanded rats given aprotonin, and the
potentiation by aprotonin of the effect of AVP on urine
flow, argue in favour of such a functional role (Kramer et
al, 1984). Fejes-Toth et al have recently clearly shown
that urinary kallikrein excretion is not flow-dependent in
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the conscious rat (Fejes-Toth et al, 1983).
The renal kallikrein-kinin system therefore appears to
interact in a complex fashion with other intra-renal
neuroendocrine mechanisms. Despite extensive study, the
precise nature of these interactions and their importance in
regulating renal function have not been fully established.
1.3.3. Pathophysiology
Reduced urinary kallikrein excretion in essential
hypertension was described in 1934 (Elliot and Nuzum, 1934),
and has since been confirmed; the ratio of active to
inactive kallikrein is also abnormally low in essential
hypertension (Leiberthal et al, 1983). Kallikrein excretion
is lower in families with high blood pressure, and lower in
black than in white children (Zinner et al, 1 978). The
reduced kallikrein excretion is not related to aldosterone
or plasma renin activity (Lawton, 1980). In spontaneously
hypertensive rats, reduced active kallikrein excretion is
present before and during the development of hypertension
(Geller et al, 1975). Kallikrein excretion is also reduced
in both clinical and experimental renovascular hypertension,
and in the hypertension of chronic parenchymal renal disease
(Marin-Grez, 1982; Margolius et al, 1974; Adetuyibi and
Mills, 1 972; Abe et al, 1981; Mitas at al, 1 978 ). It has
been reported that oral administration of kallikrein lowers
the blood pressure in essential hypertension (Overlack et
al, 1979), and a stimulatory effect on the renal kallikrein-
kinin system has been thought responsible for the
antihypertensive effect of some drugs, eg thiazide diuretics
1 7
(O'Connor et al, 1977). Urinary kallikrein excretion is
increased in some, but not all, patients with primary
aldosteronism, and in Bartter's syndrome; this is probably
secondary to other hormonal changes (Scicli and Carretero,
1986). In Bartter's syndrome, kallikreins and kinins may be
involved in the vascular insensitivity to Angiotensin II,
which is substantially reversed by aprotonin (Rodriguez-
Portales et al, 1985). Urinary kallikrein excretion falls
during normal pregnancy, and is lower in hypertensive
pregnancy (Millar and Campbell, 1986). Urinary kallikrein
excretion is elevated in the syndrome of inappropriate
secretion of ADH (Shiigia et al, 1983). Excretion of both
active and inactive kallikrein is reduced in
uninephrectomised kidney donors, and is lower still in
transplant recipients (Spragg et al, 1985). It is also low
in patients with cadmium toxicity (Iannaccone, Porcelli and
Boscolo, 1983); in both situations, this may reflect loss of
functional renal tissue mass. Patients with hepatic
cirrhosis and renal impairment have been described as
excreting less kallikrein than other cirrhotic patients,
despite secondary aldosteronism (Zipser et al, 1981; Perez-
Ayuso et al, 1984).
Overall, while abnormalities of the renal kallikrein-kinin
system have been recognised in a number of disease states,
it is unclear in most situations whether these changes are
primary or secondary, and whether they have functional
significance.
1 8
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Figure 3. The natriuretic cascade
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CHAPTER 2 METHODS
Study of kallikreins and kinins has been beset by
methodological problems, and there remains controversy
concerning the optimal methods for assessing activity of
both the plasma and renal kallikrein-kinin systems.
2.1. Plasma kallikrein-kinin system
The original studies of this system were based on bioassays
using guinea-pig or cat ileum, or, most commonly, the rat
uterus, to measure circulating kinins (Erspamer, 1948).
However, several other agents were shown to be active in
these assays, eg 5-HT, angiotensin, acetyl choline and
prostaglandins. Vane and colleagues tried to improve the
specificity by using multiple superfused tissues in
sequence, but even using such a complex system, the results
are influenced by peptides such as Substance P and
cholecystokinin (Ferreira and Vane, 1967; Regoli and Barabe,
1980). These assays are not sufficiently sensitive to
measure kinins in normal blood. They have been used to
estimate plasma kininogen, after in vitro activation of
kallikrein to convert kininogen to kinin. A fall in
kininogen is taken to indicate activation of the plasma
kallikrein-kinin system. However, blood contains a high
concentration of kininogen (4-12 ug/ml) in relation to the
kinin concentration (pg/ml) even in pathological states, so
that a detectable change in plasma kininogen may well be
absent (Regoli and Barabe, 1980).
Several groups have developed radioimmunassay (RIA) methods
20
for measurement of plasma kinins (Talamo and Goodfreind,
1979). The principal problems are the weak immunogenic!ty of
kinins, the tendency of anti-kinin antibodies to cross-react
with kininogen and with kinin fragments, spontaneous kinin
formation after blood sampling, and the rapid degradation
of kinins by plasma kininases. Carretero and colleagues have
developed an assay which yields plasma kinin concentrations
in the pg/ml range and high recoveries, but the sampling
technique involves taking blood directly into absolute
alcohol, and is impractical in many types of study (Scicli,
Diaz and Carretero, 1983).
An alternative is to measure the plasma prekallikrein
concentration. An RIA technique has been described (Saito,
1979), but a more common method is to activate the
prekallikrein in the sample completely, then measure
activity against a substrate of plasma kallikrein (Webster
and Peirce, 1961). Kallikrein is the principal esterase in
plasma under alkaline conditions, and ability to hydrolyse
substrates such as TAME at a high pH has been used in many
studies (Colman and Wong, 1977). An advantage of this
approach is that spontaneous "kallikrein-like" activity and
the kallikrein inhibiting activity of plasma can also be
measured, giving an overall assessment of plasma kallikrein-
kinin system activity (Mason et al, 1970). The principal
disadvantage has been the limited specifity and sensitivity
of the assays. Recently, development of synthetic tripeptide
chromogenic substrates, against which kallikrein has
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relatively high specific activity, has significantly
improved these techniques (Friberger et al, 1979; Gallimore
and Friberger, 1982).
2.2. Renal kallikrein-kinin system
The difficulties in measurement of plasma kinins referred to
above are equally applicable to urine measurements. Bladder
urine contains both kinin-forming and kininase activity, and
most authorities believe that direct urine collection from
ureteric catheters is the only acceptable method (Shimamoto
at al, 1978; Talamo and Goodfreind, 1979; Scicli, Diaz and
Carretero, 1983). Again this is impractical for the majority
of studies.
As a result, most workers have assessed activity of the
renal kallikrein-kinin system by measurement of urinary
kallikrein excretion. This can be done using a kinin RIA to
measure kininogenase activity (Carretero et al, 1976); by
measurement of urinary alkaline esterase activity, against
substrates such as TAME (Feidler, 1979); by estimating
activity against synthetic tripeptide chromogenic
substrates of urinary kallikrein (Amundsen et al, 1979); or
by direct RIA for urinary kallikrein (Oza et al, 1981). The
latter will measure inactive and inhibitor-bound kallikrein,
in addition to the active enzyme. This is useful in certain
contexts, and permits calculation of the ratio of active to
inactive kallikrein - normally in the region of 50%.
However, the factors which activate prokallikrein in vivo
are unclear, and the physiological significance of this
ratio is unknown (Leiberthal et al, 1 983 ). There is no
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evidence that the ratio of active to inactive kallikrein
alters as urine passes down the nephron, and measurement of
enzyme activity in urine seems most likely to reflect
intrarenal events (Ryan et al, 1979; Bonner et al, 1984).
Several studies have failed to find a correlation between
urinary kinin excretion and urinary kallikrein excretion
(Scicli, Diaz and Carretero, 1983; Weinberg et al, 1987).
This is perhaps not surprising in view of the problems
associated with both estimations, and particularly with
kinin measurements. Urine kallikrein estimations are
technically simple and reproducible, and appear to give
useful and consistent results in a wide range of
experimental and clinical situations (Bonner and Marin-Grez,
1981). However, the extent to which either urinary kinin or
kallikrein estimations reflect the activity of the intra¬
renal kallikrein-kinin system remains unproven (Fuller and
Funder, 1987).
2.3. Assays used in this project
For the purposes of these studies, the recently developed
synthetic tripeptide chromogenic substrate kallikrein assays
referred to above were chosen, on the grounds of
convenience, cost, reasonable specificity and sensitivity,
reproducibility, and good correlation with the results of
other more complex assays (Gallimore and Friberger, 1982;
Amundsen et al, 1979; Bonner and Marin-Grez, 1981).
2.3.1 . Plasma prekallikrein
This was measured by the method of Gallimore and Friberger
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(1982). For all blood studies, citrated plasma (1 part 0.1M
sodium citrate, 9 parts blood) was used. Blood was taken
with a minimum of stasis into plastic tubes, to avoid
contact activation of Hageman factor by glass. After
centrifugation at room temperature, plasma was removed with
plastic pipettes and stored in plastic tubes at -20°c. A
standard plasma pool was prepared using samples from 20
healthy donors. Plasma samples were thawed at 20°c prior to
assay, and were assayed within 4 hours.
Prekallikrein activator was obtained from AB Kabi
Diagnostica; it is an ellagic acid-phospholipid type
containing FXII and HMW kininogen, and allows complete
activation of prekallikrein even in Factor II and kininogen-
deficient plasmas.
Chromogenic substrate for plasma kallikrein was obtained
from AB Kabi Diagnostica; S-2302 (H-D-Pro-Phe-Arg-pNA) 2
mmol/1 was prepared by dissolving 25 mg in 20 ml distilled
water.
Buffer - a Tris-HCl buffer, 0.05 mol/1, pH 7.9, was prepared
by dissolving 7.88 g Tris-HCl in 800 ml distilled water and
titrating to pH 7.9 with 1M NaOH.
Plasma dilutions were made in plastic tubes, and
spectrophotometrie determinations were performed in
siliconised semimicro cuvettes, using a Gemstar




1. Factor XII contact activation >Factor Xlla
2. Prekallikrein FXIIa >Kallikrein
3. H-D-Pro-Phe-Arg-pNA +H20 kallikrein >Peptide + pNA
The normal plasma pool was diluted with buffer to give
standard values-
Standard (%) Plasma (ul) Buffer (aiI)
125 50 2400
100 50 3000





Test plasma were diluted as for the 100% standard.
Method Into each cuvette, at 37®c, was pipetted -
200 ill prekallikrein activator (at 37°c)
200 ul plasma dilution
After 2 mins incubation at 37*c, 200ul S-2302 was
added
After 2 mins incubation at 37°c, 200ul 50% acetic
acid was added to stop the reaction, and the
absorbance was read at 405nm.
Blanks were prepared by adding the reagents in reverse order
without incubation, and the values obtained subtracted from
the test values.
A typical standard curve is shown in Fig 4. Activity was
stable at -20°c for up to 3 months. Inter-assay coefficient
of variation (CV) was 8.2% and intra-assay CV, 6.5%. Normal
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% DILUTION OF STANDARD POOL
Figure 4. Plasma pre—kallikrein standard curve
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pool (mean _+ 2.5 SD). Gallimore et al have shown a
correlation between prekallikrein concentrations measured by
this assay and by an immunochemical method (rocket
Immunoelectrophoresis) of 0.84.
2.3.2. "Kallikrein-like" activity
This was measured as described by Gallimore and Friberger
(1982), using an identical method to the prekallikrein
assay, but substituting buffer for the prekallikrein
activator. Test plasma was diluted as for the 100% standard.
None of the normal plasmas generated an absorbance
significantly different from the blank.
2.3.3. Urinary kallikrein
This was measured by the method of Amundsen et al (1 979 ).
This assay has recently been validated by comparison with
measurement of urinary kininogenase activity using a kinin
radioimmunoassay (Bonner and Marin-Grez, 1981). Urine for
kallikrein estimations was taken directly into plastic
containers, and frozen at -20°c after a maximum of 24 hours
at room temperature. Samples were thawed at 20°c, and
centrifuged prior to assay; all samples were assayed within
4 hours of thawing.
Urinary kallikrein was measured using the chromogenic
substrate S-2266 (H-D-Val-Leu-Arg-pNA)(AB Kabi Diagnostica).
A Tris buffer, pH 8.2, was prepared as above.
A Trasylol (lyophilised aprotonin, Bayer FRG) buffer was
prepared to a concentration of 20 KlU/ml. This was added to
a sample blank for each assay. Since Trasylol is a potent
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inhibitor of urinary kallikrein, but does not inhibit
urokinase, the only other alkaline esterase enzyme in urine,
subtraction of the result of this blank from the sample
value increased the specificity of the assay, in addition to
correcting for the intrinsic urine colour.
Determination of urinary kallikrein
H-D-Val-Leu-Arg-pNA+H20 urinary kallikrein >peptide+pNA
500 juI of buffer at 37° c was added to 400 ,ul urine and
incubated at 37°c for 5 minutes. 100 >ul of S-2266 was added
and incubated for 30 minutes. The reaction was then stopped
by addition of 100 ill of 50% acetic acid. A sample blank was
prepared, identical other than the use of the Trasylol
buffer. The absorbance of each sample was read against its
blank at 405 nm. Results were expressed as nkat/1, one nkat
being the amount of glandular kallikrein which cleaves 0.05
umol of substrate per minute under the given conditions.
This was calculated as nkat/1 = 146 x absorbance.
Urinary kallikrein was stable at -20°c for up to 1 year; all
samples were assayed within 3 months. Inter-assay CV was
8.2% and intra-assay CV 4.5%.
It has been suggested that removal of kallikrein inhibitors
from the urine by dialysis or gel filtration is necessary
when measuring urinary kallikrein activity, and that
dilution of the sample may influence the result by altering-
kallikrein - inhibitor binding (Zschiedrich et al, 1980). We
measured urinary kallikrein activity as above in 19 4-hour
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urine collections from normal subjects; we measured neat
urine, urine diluted 1:2 with assay buffer, and urine eluted
from a column of Sephadex 150 (Sigma), 15cm in length and
2cm diameter. The eluate collected 3-6 minutes after
application of the sample to the column contained virtually
all the kallikrein activity. As shown in Table 3, neither
gel filtration nor sample dilution had any significant
effect on the urinary kallikrein activity. Similarly,
dialysis for 24 hours against running tap water had no
effect on kallikrein activity.
Mean SD SEM
Urine volume (ml/4h) 31 1 .4 1 65.7 38.0
Urine sodium (mmol/1) 1 40.6 61 .8 14.2
Urinary kallikrein activity (nkat/1)
Neat urine 11.21 6.60 1.51
Gel filtration 11.46 8.13 1.89
Dilution 1:2 11.85 7.07 1.62
Mean coefficient of variation between three assay methods,
- 15.4%
Table 3. Analysis of 19 4-hour urine collections from
normal subjects.
To investigate the influence of urine pH and glucose
concentration on urine kallikrein activity, urine aliquots
from 5 healthy subjects were titrated to pH5 with
hydrochloric acid and to pH8 with sodium hydroxide. Glucose
was added to a concentration of 1% and 2%. Results are




Urine from 5 normal subjects 11.66 + 7.20
pH 8 10.75 + 6.53
pH 5 11 .27 + 7.14
1% glucose 11 .98 + 7.45
2% glucose 12.39 + 7.41
Table 4 Effect of pH and glucose concentration on urine
kallikrein activity.
The stability of urine kallikrein activity at room
temperature was tested by placing freshly voided normal
urine in a glass or a plastic container; 5 ml aliquots were
taken at 30 mins, 1 hour, 4 hours, 8 hours, and 24 hours.
Results are shown in Figures 5 and 6. There was no change in
kallikrein activity with time; the mean coefficent of
variation in plastic containers was 4.25% and in glass
containers, 6.8%.
Normal range for 24 hour urinary kallikrein excretion in 20
normal volunteers was 11 + 5.6 nkat/24 hours. There was no
diference between male and female subjects (males 10.2 ± 4.1
nkat/24h, n = 11, female 12 ± 7.4 nkat/24h, p >0.05).
Studies in 10 normal subjects confirmed a diurnal variation
in kallikrein excretion as previously described (Abe et al,
1981; Bell et al, 1987). A median value of 83% (range 73 -
91%) of the daily urinary kallikrein was excreted between
rising in the morning and retiring at night, and 17% (range













Figure5. Kallikreinconcentrationiu ine from5healthysubjects,ov r24 hoursatroontempe aturein plasticcontainer. Meancoefficientfvariation4.25%
URINARYKALLIKREINCONCENT ATION







Figure6. Kallikreinconcentrationiu ine from5healthysubjects,ov r24 hoursatroomtemperature, glasscontainer. Meancoefficientfvariation6.8%
Statistical analysis was performed using either the "Oxstat"
or "Minitab" statistical packages. The standard tests
employed were the Student's t-test and Mann-Whitney U test
for comparison of group means; linear product-moment
correlation coefficients for analysis of correlation, with
log transformation of non-parametric data; and one-way
analysis of variance to assess changes in a variable with
time. Where ANOVAR showed such a change, mean values at each
time-point were compared with baseline values by Student's
t-test. Unless otherwise stated, results are shown as mean +_
SD, and values of p <0.05 were taken as significant. I am
grateful to Dr Robert Elton (Dept of Medical Statistics,
University of Edinburgh) for statistical advice in relation
to several parts of this work.
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CHAPTER 3 URINARY KALLIKREIN EXCRETION DURING SALINE
INFUSION IN NORMAL MAN
3.1. If the renal kallikrein-kinin system is involved
in the regulation of sodium excretion, then the rapid
administration of a large saline load would be predicted to
influence urinary kallikrein excretion, and some correlation
would be expected between kallikrein excretion and sodium
excretion. This hypothesis was tested by infusion of 3
litres of normal saline over 1 hour into healthy volunteers.
3.2. Subjects and methods
Ten normal male subjects (age 30 + 6 years) with no history
of renal disease or hypertension were studied.
Protocol
Subjects were fasted from 22.00 hours on the evening before
the study, and were asked not to smoke. At 08.00 the
following morning catheters were inserted into a vein in
each ante-cubital fossa. A control blood sample was
withdrawn. An infusion of 5% dextrose containing 25 g/1
inulin and 1.15 mmol/1 para-aminohippurate (PAH), for
measurement of glomerular filtration rate and renal plasma
flow respectively, was commenced at rate of 1 ml/min and
continued throughout the study. Sodium chloride solution 150
mmol/1 was infused at 50 ml/min between 10.00 and 11.00
hours. Timed urine collections of approximately 30 minutes
each were made between 09.00 and 13.00 hours, apart from
during the saline infusion when urine was collected at 20
minute intervals. Subjects stood to void urine but otherwise
remained recumbent. Blood samples were withdrawn every 30
minutes. Blood pressure was measured with a standard
sphygmomanometer.
Urinary kallikrein excretion was measured as above. Plasma
renin activity (PRA) was measured by RIA of generated
Angiotensin I, using an established method which has been
fully validated in our laboratory (Roulston et al, 1983).
Plasma and urinary PAH and inulin were measured by
autoanalyser techniques (Harvey and Brothers, 1962; Dawborn,
1965); plasma and urinary sodium and plasma protein
concentration were measured by standard laboratory methods.
The 20 minute urine collections during saline infusion, the
30 minute collection immediately after the infusion, and the
final 30 minute collection (150-180 minutes after the start
of the infusion) were analysed for kallikrein and the
results included in statistical analysis. Results are
expressed as mean _+ SEM. Results for each variable were
compared by analysis of variance, and if a significant trend
was observed, results for each clearance period were
compared by Student's t-test. Standard correlation
coefficients were calculated. Values for p <0.05 were taken
as significant.
3.3. Results
There were no significant changes in systemic blood pressure
during the study. Urinary sodium excretion increased
significantly during saline infusion and remained elevated
at 90 and 180 minutes (Fig 7). There was a significant
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increase in urine flow (Vu) during saline infusion which
persisted at 90 minutes (Fig 7). Vu subsequently fell and
was only slightly above control values at 180 minutes. In 8
out of 10 subjects, renal plasma flow increased during and
after the infusion, returning to control values at 180
minutes; these trends were not statistically significant
because of considerable variability among subjects (Fig 8).
GFR showed a similar pattern, and again the changes did not
achieve statistical significance (Fig 8). PRA decreased
significantly after saline infusion (p<0.01) and remained
low at 180 minutes (Fig 9). Urinary kallikrein excretion
increased rapidly during the saline infusion, with peak
activity in the 40-60 minute collection, persistent
elevation at 90 minutes, and a return to control values at
180 minutes (Fig 9). Plasma protein concentration decreased
at 90 minutes (control 63.8 +.1.7 g/1, 90 min 52.5 +. 2.4
g/1, p<0.01) and was still depressed at 180 minutes (56.3 +
0.8 g/1, p<0.01).
Over the whole study there were weak correlations between
urinary kallikrein excretion and urine flow (r 0.45, p<0.01)
and urinary sodium excretion (r 0.35, p<0.02). These
correlations may have achieved significance because of
multiple observations in each individual.
In order to further assess the relationships between PRA,
kallikrein , urine flow and urinary sodium, studies of
correlation were performed on the results of blood and urine
samples taken in the control period prior to saline infusion































Figure 7. Urine sodium excretion and urine









































Figure 9. PRA and urinary kallikrein excret¬
ion, saline infusion study
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after the end of the infusion) (B), and between 150 and 180
minutes into the study (C). The correlations obtained by
including all these observations are shown in Table 5. Both
PRA and urinary kallikrein excretion correlated
significantly with Vu and UNaV; the correlation coefficient
(r) with UNaV was slightly higher than with Vu in each case.
There was also a significant inverse correlation between PRA
and urinary kallikrein excretion, suggesting a reciprocal
linkage between these two systems. To assess the possible
importance of this phenomenon, a ratio of PRA to UKallV was
calculated. The PRA/UKallV ratio fell after saline infusion
and was still depressed at 180 minutes (Fig. 10) The ratio
showed a non-parametric distribution and was therefore log-
transformed for the purposes of correlation analysis. There
was an extremely high degree of correlation between this










Table 1 Correlations between variables in saline
infusion study (periods A, B, and C).
These correlations might have been due in part to similar
directional changes in each variable in each subject. To














Figure 11. Log PRA/UKallV aginst UNav




Figure 12. Log PRA/UKallV against




Figure 13. Log PRA/UKallV against
UNaV, 180 minutes after start of infusion.
2 subjects unable to provide
appropriate sample
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test this, similar correlations were calculated for each of
the 3 individual study periods in the 10 subjects. The
correlation coefficients between log PRA/UKallV and UNaV
were in fact increased when individual clearance periods
were considered, and were 0.90 or greater in each case. As
shown in Figs 11, 12, and 13, the slope of the regression
line between log PRA/UKallV and UNaV differed markedly in
each clearance period. The pattern of slopes indicated that
in the control period, changes in log PRA/UKallV were
associated with relatively small changes in UNaV; after
saline infusion, the increased steepness of the regression
lines indicated that changes in log PRA/UKallV were
associated with much greater changes in UNaV.
3.3. Discussion
In previous studies, some workers have failed to
demonstrate an increase in kallikrein excretion after acute
volume expansion, and have not observed any correlation
with sodium or water excretion (Levy, Frigon and Stone,
1978; Marks and Keiser, 1983; Lewis et al, 1988). However,
Mills and colleagues found that infusion of either saline or
2.5% dextrose increased kallikrein excretion in the dog;
kallikrein excretion correlated with urinary sodium
excretion and urine flow after saline infusion (Mills,
1976). In the present study, saline infusion in man produced
a prompt and significant increase in kallikrein excretion,
which preceded the maximal increase in urine volume and
sodium excretion. This conforms to the predicted response if
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the renal kallikrein-kinin system has a role in the early
diuretic and natriuretic response to acute volume expansion.
Support for this concept comes from studies showing that
administration of anti-bradykinin antibodies , or of the
kallikrein inhibitor aprotonin, reduce sodium and water
excretion after saline infusion (Marin-Grez, 1974; Kramer et
al, 1984). It is difficult to reconcile these results with
the hypothesis that the renal kallikrein-kinin system is a
sodium retaining mechanism. While there was a correlation
with urine flow rate, this was weaker than the correlation
with urinary sodium excretion; the opposite would be
expected if passive "wash-out" was the major factor
controlling UKallV.
In this study, urinary kallikrein excretion and PRA changed
in an inverse fashion during saline infusion, and there was
a statistically significant inverse correlation between
them. Such reciprocal changes in putative markers of
activity of the renal kallikrein-kinin system and the renin-
angiotensin system, could have considerable significance.
The biological consequences of activation of these systems,
at least in terms of renal function, are almost certainly
opposite, with the renin-angiotensin system mediating renal
vasoconstriction and sodium retention, and the kallikrein-
kinin system favouring vasodilation and natriuresis, as
outlined above (Chapter 1, p12; Mills, 1972). It follows
that the observed increase in kallikrein excretion and
decline in PRA would favour renal vasodilation and
natriuresis to a greater extent than either change in
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isolation. In keeping with this hypothesis is the
observation that an "activity ratio" between the renin-
angiotensin system and the renal kallikrein-kinin system,
obtained by dividing PRA by UKallV, as described by Levy et
al (1977), was a very strong statistical determinant of
sodium excretion in this study, with an r value in the
region of 0.9. This indicates that approximately 80% of the
variability in sodium excretion in this study may be
attributed to changes in this ratio. Levy et al found a
correlation between this ratio and renal blood flow in
patients with hypertension; this correlation was absent in
our study. To my knowledge the association with sodium
excretion has not been previously documented.
It is of course apparent that other factors are involved in
the early response to saline infusion. Interestingly, plasma
atrial natriuretic peptide (ANP) and UKallV show a very
similar pattern of response, with an early rise during
volume expansion, followed by a fall to baseline values
(Lewis et al, 1988). It has been suggested that the primary
role of ANP is to promote renal vasodilation during volume
expansion; evidence for a direct tubular effect is less
convincing (Raine, Firth and Ledingham, 1989). ANP infusion
at high dosage increases UKallV in rats by up to 80%
(Thibault et al, 1984; Brownlee et al, 1986); while ANP has
not been shown to increase urinary kallikrein excretion in
man, it suppresses PRA (Weidmann et al, 1 986), and would
therefore be expected to decrease the PRA/UKA ratio. Recent
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studies have indicated that the natriuretic effect of a
given plasma concentration of ANP is very much greater if it
is induced by saline infusion, than if it is produced by
infusion of exogenous ANP. Other factors, eg renal dopamine,
renal vasodilator prostaglandins, and suppression or
inhibition of ADH, are also probably involved in the renal
response to acute volume expansion (Ball and Lee, 1977;
Bennet, Tighe and Wegg, 1982; Abe et al, 1981; Yamada et al,
1989), and the fall in plasma protein concentration should
theoretically promote natriuresis (Green, Windhager and
Geibisch, 1974). Such mechanisms could be relevant to the
increased slope of the regression line between the
PRA/UKA11V ratio and sodium excretion after volume
expansion, which is in keeping with a degree of "gain"
influencing this relationship. This possibility will be
discussed further in the final chapter.
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CHAPTER 4 ASSOCIATIONS BETWEEN PLASMA RENIN ACTIVITY.
URINARY KALLIKREIN EXCRETION, URINE VOLUME
AND URINARY SODIUM EXCRETION UNDER BASAL
CONDITIONS IN NORMAL MAN
4.1. Introduction
As documented in Chapter 3, a significant correlation was
observed in man between the ratio of PRA to urinary
kallikrein excretion (log PRA/UKallV) and urinary sodium and
water excretion. This correlation held both after and,
surprisingly, before acute volume expansion by saline
infusion. This suggested that reciprocal changes in the
activity of the renin-angiotensin and kallikrein-kinin
systems in the kidney might have a regulatory influence on
renal function even under basal, unstimulated conditions. To
test this hypothesis further, these variables were measured
in normal subjects at rest, over a 9 hour period, under
conditions of modest water diuresis.
4.2. Subjects and methods
11 healthy male volunteers, with no history of renal disease
or hypertension and on no medication, were studied. After
an overnight fast, infusions of PAH and inulin were
established as in Chapter 3. Subjects drank 100 ml water at
the start of the study and hourly thereafter. Blood and
urine were sampled hourly for 9 hours. Subjects remained
supine at rest during the study, other than rising to pass
urine immediately after each blood sample. No drugs or other
agents were administered during the study.
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Variables measured were urine volume (Vu), urinary sodium
excretion rate (UNaV), clearance of PAH (CPAH) and inulin
(Cinulin), plasma renin activity (PRA) and urinary
kallikrein excretion rate (UKallV). Methods were as
previously described.
4.3. Results
Urine volume, Cinulin and CPAH remained constant during the
study. There was a tendency during the study for urinary
sodium excretion to fall, although this was not significant
by one-way analysis of variance (Fig 14). This may have
reflected the absence of sodium intake during the study.
There were also non-significant trends for UKallV to fall
and PRA to rise (Fig 15). There was a weak but significant
correlation between PRA and Vu (r -0.26, p<0.01). The
correlation between PRA and UNaV was relatively strong (r -
0.48, p<0.001). UKallV did not correlate significantly with
Vu, but correlated weakly with UNaV (r 0.27, p<0.01). The
ratio of PRA to UKallV (log PRA/UKallV) did not correlate
with Vu (r -0.20) but correlated very strongly with UNaV (r
-0.51, p<0.0001). There was no significant correlation
between PRA and UKallV in this study (r 0.10, p>0.05).
4.4. Discussion
The subjects in this study, while water replete throughout,
showed some evidence of a renal response to ongoing negative
sodium balance over the 9 hour period. These changes were
not however of sufficient magnitude or consistency to
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achieve statistical significance. Studies of correlation
suggested an influence of both renin and kallikrein on
sodium excretion under these conditions, with renin as
perhaps the stronger determinant. When these variables were
combined as a ratio, a very highly significant relationship
was observed with sodium excretion. One must of course
interpret the results of correlation studies with great
caution; in particular, causality cannot be assumed on such
a basis. Nevertheless the findings are again in keeping with
a role of renin-kallikrein interactions in the regulation of
sodium excretion, and suggest that this relationship may be
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CHAPTER 5 CELLULAR DISTRIBUTION OF RENAL KALLIKREIN;
THE GLOMERULAR PERIPOLAR CELL
5.1. Introduction
The results described in Chapters 3 and 4 appeared to
indicate interesting relationships between the renal
kallikrein-kinin system, the renin-angiotensin system, and
renal function. As outlined in the introduction, there are
other reasons to speculate that these two systems might
operate in a counter-regulatory fashion. Attention has also
been drawn to the very close homology between them in their
enzymatic organisation, suggesting perhaps a parallel
development in evolution ( Fig 16 )(Pisano, 1975). A very
major objection to this hypothesis, however, is the apparent
absence of any close anatomical relationship between renin-
and kallikrein-containing structures in the kidney. This has
been confirmed in a number of studies, which have found
kallikrein to be confined to the cells of the distal
convoluted tubule (Scicli et al, 1976; Orstavvik et al,
1976; Orstavvik and Inagami, 1982; Vio and Figueroa, 1985;
Barajas et al, 1986). Orstavvik et al in 1982 described the
results of an immunocytochemical study as follows; " Since
the present study demonstrates the localisation of
kallikrein at a tubular level distal to the juxtaglomerular
apparatus, kallikrein released into the tubular lumen will
not pass renin-containing structures. Moreover, at no point
was a close anatomical relationship observed between the
kallikrein- and the renin-containing structures. From an
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anatomical point of view, it is therefore difficult to
visualise how it would be possible for kallikrein within the
kidney, either through the tubular lumen or the interstitial
space, to reach and directly act upon renin-containing
structures." Similar findings were reported by Vio et al in
1 985. In 1 979, Ryan et al first described the granular
glomerular peripolar cell (PPC) in sheep (Ryan, Coghlan and
Scoggins, 1979). These cells, thought to be of epithelial
origin, lie in a "cuff" around the vascular pole of the
glomerulus (Fig 17). They vary in number and prominence
between species, being particularly obvious in sheep; one
recent textbook stated that they do not exist in man, but
careful studies have confirmed their existence in human
kidneys (Gardner and Lindop, 1985). Exocytosis of granule
contents into Bowman's space has been shown (Ryan et al,
1982), but the function of PPCs, and the nature of their
secretory product, remains uncertain, although it is known
that the cells do not contain renin (Gardner and Lindop,
1985). We therefore investigated the possibility that PPCs
might contain renal kallikrein, using a specific antibody to
human urinary kallikrein and immunoperoxidase staining.
5.3. Materials and methods
5.3.1 . Tissue processing
Kidney tissue was obtained from normal sheep killed in an
abbatoir; from the macroscopically normal parts of ten human
kidneys removed by nephrectomy for carcinoma (7), calculus
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Figure 16. Homology between the kallikrein-
kinin system and renin-angiotensin system.
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Figure17.Locationoflome ular peripolarc lls.
of patients with renal disease. For light microscopy, kidney
tissue was fixed in 10% formal saline and impregnated with
paraffin wax at 56°C; sections were cut with a Lietz rotary
microtome at a thickness of 3-4jum. For electron microscopy,
tissue was fixed in glutaraldehyde, post-fixed in 1 % osmium
tetroxide, and embedded in araldite. Sections 1am thick were
cut and stained with toluidine blue. If PPCs were detected
by light microscopy, 50-60nm sections were cut on an LKB III
ultramicrotome, stained with uranyl acetate and lead
citrate, and viewed on a Jeol 100S electron microscope.
5.2.2. Staining
Paraffin-embedded sections were stained by the Dunn's
Crystal Scarlet method. This trichrome stain, in which
Orange G, Brilliant Crystal Scarlet and Analine Blue are
used sequentially, was found to be superior to other methods
for the identification of PPCs in both sheep and human
kidneys. In the process of the study, some sections were
also stained with a toluidine blue/ Jones methenamine silver
stain.
5.2.3. Immunocytochemistry
A highly specific polyclonal rabbit anti-human urinary
kallikrein antibody was gifted by Dr Ervin Erdos, Dept of
Pharmacology, University of Chicago, USA. The antibody was
prepared by separating human urinary active kallikrein on
DEAE-cellulose and octyl-Sepharose columns, and purifying it
to homogeneity by affinity chromatography, gel filtration
and hydrophobic h.p.l.c. An antibody to the purified
preparation was raised in rabbits. The antibody was shown to
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react with both active kallikrein and with prokallikrein,
but not with plasma kallikrein or other protease enzymes
(Takada, Skidgel and Erdos, 1985). The antibody was applied
to paraffin-embedded sections of human kidney in
concentrations from 1:20 dilution to 1:1000, and incubated
correspondingly from 30 mins to 18 hours. Subsequent
incubations were a) swine antirabbit antibody (Dakopatts,
Glostrup, Denmark) at 1:30 dilution for 30 minutes b)
rabbit peroxidase-antiperoxidase reagents (Dakopatts,
Glostrup, Denmark) at 1:100 dilution for 30 minutes.
Endogenous peroxidase activity was not observed. Control
studies were carried out by preabsorbing the antibody with
purified human urinary kallikrein (Protogen AG,
Laufelfingen, Switzerland, supplied by Dr Michael Gallimore,
Deal, UK).
5.3. Results
Light microscopy confirmed the location of PPCs at the
vascular pole at the point of reflection of Bowman's
capsule, and their close association with the afferent
arteriole, but not the efferent arteriole (Fig 18). PPC
cytoplasm was densely packed with granules in both sheep and
human kidneys; human PPCs were fewer, less prominent, and
had fewer granules than sheep cells (Fig 19). In both sheep
and human tissue, PPCs were more numerous in the outer than
the inner cortex.
Electron microscopy showed PPCs closely adherent to the
basement membrane of Bowman's capsule (Fig 20). PPC granules
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were round and homogeneous, but of variable diameter (200-
1700 nm, mean 950 nm). Apparent exocytosis of granule
contents into the urinary space was observed (Fig 21). PPCs
had sparse rough endoplasmic reticulum and few mitochondria,
suggesting a relatively low synthetic capacity. Renin
granules were seen in myoepitheloid cells; they were sparse
and smaller than PPC granules (mean diameter 350 nm). PPCs
and myoepitheloid cells were often separated only by the
basement membrane of Bowman's capsule (Fig 22).
The character and distribution of PPCs in renal biopsy
tissue from patients with renal disease was not obviously
different from normal, although quantification in these
patients was difficult because of the relatively small
number of glomeruli. PPCs were detected in cases of
membranous glomerulonephritis (Fig 23), Bartter's syndrome,
Conn's syndrome, mesangial proliferative glomerulonephritis,
and renal artery stenosis.
In human kidney, PPCs stained positively for kallikrein. In
some cells there was a dense granular staining throughout
the cell cytoplasm (Fig 24); in others, individual granules
were visible in the cell (Fig 25). In keeping with previous
studies, strong immunoreactivity was also seen in segments
of the distal tubule (Fig 25). There was weak staining in
all proximal tubular cells. No staining was seen in the
juxtaglomerular apparatus, including the macula densa, any
other glomerular cells, arterioles or interlobular arteries.
Preabsorption of the antibody with purified urinary
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Figure 18. Sheep peripolar cell; Dunn's
Crystal Scarlet
Figure 19. Human peripolar cell; Toluidine
Blue
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Figure 20. Sheep peripolar cell; electron
micrograph
Figure 21. Sheep peripolar cell; exocytosis
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Figure 22. Sheep kidney; peripolar cell and
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Figure 23. Human kidney, MSB stain. Peripolar
cell in a case of membranous
glomerulonephritis
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Figure 24. Human kidney, stained with anti-
kallikrein antibody (immunoperoxi-
dase technique)
Figure 25. As Fig. 24
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kallikrein blocked the staining in PPCs, distal tubular
cells and proximal tubules.
5.4. Discussion
Use of special stains, and careful inspection of multiple
sections through the vascular pole of the glomerulus,
permits recognition of PPCs in glomeruli from both normal
and diseased human kidneys. The location of these cells at
the vascular pole of the glomerulus affords the potential
for influencing glomerular haemodynamics, permeability, and
possibly proximal tubular function, and for interacting with
other local neuro-endocrine mechanisms. The paucity of
organelles for protein synthesis seen in PPCs does not
preclude them from being active secretory cells; studies of
the kallikrein-secreting granular tubular cell in the rat
submandibular gland have shown similar findings under basal
conditions, but in response to specific stimuli they
generate large amounts of endoplasmic reticulum, which
disappears when secretory granules have been restored
(Cutter and Chaudry, 1973).
The immunocytochemical studies clearly demonstrate that PPC
granules contain kallikrein. This important observation has
several implications for the functional role of kallikrein
in the kidney. Locally released kallikrein could generate
vasodilator kinins which could influence afferent arteriolar
tone (Barraclough and Mills, 1965). Kallikrein released
into the urinary space could generate kinins which could
influence proximal tubular function, both directly and via
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generated prostaglandins (Kauker, 1980). In disease states,
kinins could increase glomerular permeability, causing
proteinuria and changes in glomerular filtration (McFarlane,
Mills and Wraight, 1973). Perhaps the most interesting
aspect, however, is the potential for interaction with the
renin-angiotensin system. It is clear from our results that
PPCs and renin-containing cells are frequently in direct
apposition. When this is considered in the light of the
known biochemical and physiological links between the renal
kallikrein-kinin system and the renin-angiotensin system
(Pisano, 1975; Sealey, Atlas and Laragh, 1978; Mills, 1972;
Proud et al, 1984; Beierwaltes, Prada and Carretero, 1985),
and the findings described previously of an apparent
influence of the renin/kallikrein ratio on sodium excretion,
these findings provide a previously lacking anatomical basis
for a close functional association between these two
opposing intra-renal mechanisms. Further studies, perhaps
involving micropuncture and/or hybridisation histochemistry
to assess mRNA synthesis (Coghlan et al, 1985), are required
to clarify the role of PPC kallikrein synthesis, and
particularly its interactions with renin and Angiotensin II.
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CHAPTER 6 URINARY KALLIKREIN EXCRETION IN CHRONIC RENAL
FAILURE
6.1. Introduction
In chronic renal failure, renal function is characterised by
a high single nephron GFR, elevated glomerular capillary
pressure, and high fractional excretion of sodium (Hostetter
et al, 1981). The factors mediating these changes are
unclear, but increased activity of an intra-renal
vasodilator, natriuretic system such as the kallikrein-kinin
system would provide a possible explanation. Adetuyibi and
Mills found that 24 hour urinary kallikrein excretion was
reduced in CRF, but when adjusted for GFR, was in fact
increased compared with controls. They suggested that
increased kallikrein release by remaining nephrons might
increase fractional sodium excretion in CRF, enabling
patients to remain in sodium balance (Adetuyibi & Mills,
1972). In contrast, Mitas et al found reduced UKallV in CRF
even when adjusted for GFR, and found a negative correlation
between UKallV/ml GFR and blood pressure. They suggested
that a defect in kallikrein production contributes to
hypertension in CRF (Mitas et al, 1978). It was therefore of
interest to study the relationship between UKallV, GFR and
blood pressure in patients with CRF. The effect of the
Angiotensin converting enzyme inhibitor, captopril, was
examined in 5 patients with CRF; ACE inhibitors are known to
slow the metabolism of kinins, and have been regarded as
potentiating the kallikrein-kinin system (Erdos, 1976).
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6.2. Patients and methods
22 patients with CRF were studied (creatinine clearance 15 +
13 ml/min, mean _+ SD). 9 were normotensive (mean arterial
pressure [MAP] <105 mm Hg) and 13 hypertensive (MAP >105 mm
Hg). 11 healthy controls were studied; all were
normotensive, on no drug therapy, with normal serum
creatinine and creatinine clearance values and negative
urinalysis. Details of patients and controls are shown in
Table 6. All subjects were on an unrestricted intake of salt
and water; no diuretics or anti-hypertensive drugs were
given for at least 48 hours before study. Two 24 hour urine
collections were taken and the mean value used for analysis.
In the captopril component of the study, 5 patients with CRF
and hypertension were given captopril (Capoten, Squibb)
orally for 5 days, after a 72 hour period off drugs. Initial
dose was 12.5 mg daily, increasing as necessary to control
blood pressure (maximum dose 75 mg daily). Patient details
are in Table 7.
6.3. Results
Compared with controls, UKallV was reduced in both groups of
CRF patients (controls 12.4 _+ 5.2 nkat/day, normotensive 2.9
+ 1 .9 nkat/day, hypertensive 3.7 _+ 2.8 nkat/day; p<0.01 for
both groups versus controls)(Fig 26). There was no
difference between normotensive and hypertensive patients,
and no significant correlation between UKallV and blood
pressure. When the kallikrein excretion rate was divided by
















(mm Hg) /day /day
Normotensive
M 55 PAN 12.9 130/70 1 .70 90 4.7 .364
F 56 MM 5.5 150/80 2.76 11 4 3.4 .586
M 50 CP 4.6 150/80 2.14 1 03 3.1 .674
F 67 MCGN 26.4 150/80 1 .12 97 1 .3 .049
M 55 Amyl 29.8 120/70 1 .90 95 3.1 .1 04
F 40 CP 4.4 120/70 1 .27 73 0.6 .1 38
F 70 Memb 53.4 150/80 0.90 72 5.4 .11 8
M 65 IN 4.3 150/70 1 .50 133 4.6 1 .07
F 46 CP 0.6 130/80 2.80 1 22 0.2 .333
Mean
+SD 56. 1 15.8 1 38 + 1 3 1 .51 99 2.93 0.38
+ 9. 9 +17.5* 75 + 5 +0.73 + 21 + 1 .87* +0.34*
Hypertensive
160/90F 69 GS 12.5 1 .27 68 0.6 .077
M 67 GS 15.5 180/110 1 .83 1 09 4.5 .290
M 34 PGN 14.0 180/110 1 .78 78 4.4 .314
M 38 MCGN 10.0 180/110 1 .68 118 0.7 .074
M 44 HTNS 6.9 160/100 1 .38 95 2.8 .406
M 5 3 HTNS 29.6 200/140 1 .40 1 08 5. .1 98
F 51 HTNS 7.9 190/120 1 .47 1 3 6.7 .81 5
F 45 Amyl 1.4 170/100 0.80 52 0.7 .500
M 60 GS 9.2 160/90 2.56 1 02 1 .8 .1 92
F 40 PGN 11 .0 160/100 2.79 1 46 4.5 .409
M 33 PGN 27.0 220/130 3.08 1 29 10.3 .382
F 64 HTNS 21 .9 240/120 2.16 1 43 1 .8 .092
F 63 CP 43.6 160/90 1 .55 1 21 3.2 .077
Mean
+SD 50. 9 16.2 182+25* 1 .83 98 3.68 0.29
+ 1 2 .8 +11.5* 108+16* +0.65 + 3 8 +2.81 * +0.21 *
Controls
M 36 1 08 120/80 1 .88 1 57 8.7 .081
F 30 11 2 130/80 1 .49 1 53 16.0 .1 43
M 36 95 120/85 1 .67 1 78 6.2 .065
F 67 1 02 130/80 1 .78 1 38 16.4 .161
F 59 94 110/70 0.94 1 30 7.2 .077
F 42 1 1 4 125/80 1 .54 1 29 10.0 .088
M 38 11 5 120/85 2.08 1 59 24.5 .21 3
M 61 101 130/85 1 .73 169 10.0 .099
F 61 109 135/80 0.76 84 14.6 .134
F 39 11 9 120/80 1 .20 150 1 1 .7 .098
M 44 98 125/80 1.10 77 11.0 .112
Mean
+ SD 46. 6 106.1 124+7.0 1 .47 1 38 12.4 0.12
+ 1 2 .8 +8.6 80+4.2 +0.42 + 32 +5.2 +0.04
TABLE 6 Details of 22 patients with chronic renal failure and 11
controls.
♦different from controls (p <0.05)
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Table 6; abbreviations
U.Volume - urine volume
UKallV - 24 hour urinary kallikrein excretion
CCr - creatinine clearance
PAN - polyarteritis nodosa
MM - multiple myeloma
Amyl - amyloid
CP - chronic pyelonephritis
MCGN - mesangiocapillary glomerulonephritis
Memb - membranous glomerulonephritis
GS - glomerulosclerosis ? cause;
PGN - proliferative glomerulonephritis
HTNS - hypertensive nephrosclerosis
IN - chronic interstitial nephritis
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Name Sex Age Diagnosis Ccreat Pcreat(umol/1)
(years) (ml/min) (pre-C) (on C)
AP M 34 PGN 1 4 826 870
WM M 33 PGN 27 316 41 4
MJ F 51 HTNS 20 611 628
AM M 53 HTNS 20 235 286
MR M 58 HTNS 18 41 2 51 4
Mean+SD 4 6_+11.5 19.8+4 .7 480+239 542+222*
Name BP (mmHq) PRA (ng/ml/hr) UKallV (nkat/24h)
(pre-C) (on C) (pre-C) (on C) (pre-C) (on C)
AP 180/110 150/100 6.1 24.1 4.68 2.45
WM 220/130 150/100 26.8 42.7 10.35 3.40
MJ 190/120 160/80 15.1 30.8 6.25 0.80
AM 200/140 140/90 2.3 59.2 5.92 1 .15
MR 220/130 140/90 36.0 67.6 6.24 1 .35
Mean 202+18 148+8* 17.3 44.9 6.69 1 .83
jhSD 126+11 92+8* +14.1 +18.4* +2.15 + 1 .07*
Table 7 Details of 5 hypertensive patients with chronic
renal failure given captopril.
Abbreviations:
Ccreat - creatinine clearance
Pcreat - plasma creatinine
PRA - plasma renin activity
PGN - proliferative glomerulonephritis
HTNS - hypertensive nephrosclerosis
BP - blood pressure
C - captopril
* p <0.05 compared with pre-captopril
71
values were increased in CRF compared with controls
(controls 0.12 +_ .04, normotensive 0.38 +_ 0.34, hypertensive
0.29 +0.21; p<0.05 for both groups versus controls)(Fig 27).
Results were similar in normotensive and hypertensive
patients, and there was no correlation with blood pressure.
Neither UkallV nor UkallV/ml GFR correlated with age,
creatinine clearance, urine volume, or urinary sodium
excretion (p>0.05). In the captopril study, all patients
showed a fall in blood pressure and a rise in PRA after
treatment (Table 7). There were no consistent or significant
changes in urine volume or sodium excretion on captopril,
but all subjects showed a small increase in plasma
creatinine after 5 days (Table 7). On captopril, UKallV fell
in all patients, and was significantly reduced (p<0.05) on
Day 4 and Day 5 of therapy (Fig 27a) .The fall in urinary
kallikrein excretion tended to coincide with effective
lowering of blood pressure, and there was a positive
correlation between MAP and UKallV on captopril (Fig 28).
6.4. Discussion
The function of the remaining nephrons in CRF is the subject
of intense investigation at present. It has been suggested
that the hyperfiltration and increased glomerular capillary
pressure may contribute to the progression of CRF (Hostetter
& Brenner, 1981); prostaglandins and thromboxanes have been
implicated as chemical mediators of this effect (Bergman et
al, 1986). Since kinins are potent vasodilator substances
and stimulate arachnidonic acid metabolism, increased
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Fig^t 24 hour urine kallikrein excretion















Fig.77 UKdiVcorrected for creatinine clearance











Fig.27a Mean urine kaliikrein excretion in 5 patients with CRF
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activity of the kallikrein-kinin system in remaining
nephrons could contribute to this mechanism of progression
also. In order to preserve sodium balance in face of a low
whole-kidney GFR, tubular reabsorption of sodium must fall,
leading to an increased FENa. A natriuretic effect of kinins
at a tubular level could be implicated in this change also
(Kauker et al, 1980). While absolute excretion of kallikrein
is decreased in CRF, the reduction in UKallV is
proportionally less than the fall in GFR, as measured by
creatinine clearance. When adjusted for GFR, UKallV is
increased 2-3 fold in CRF. Since kallikrein in urine is
derived from cells of functioning nephrons (Orstavvik et al,
1976), one would predict that in the absence of altered
stimuli to kallikrein release, kallikrein in the urine of
patients with CRF would be reduced either in parallel, or in
excess of, the decline in GFR, depending on the degree of
hyperfiltration by remaining nephrons. The above
observations therefore suggest that kallikrein release by
remaining nephrons is increased in CRF. The location of
kallikrein in glomerular peripolar cells, described above,
increases the possibility of kallikrein-kinins influencing
glomerular and proximal tubular function in this context. No
experimental study has yet examined the effect of kallikrein
or kinin inhibition in CRF, either in an animal model or in
a clinical setting. Such studies could shed important light
on the pathogenesis of altered glomerular and tubular
function in CRF.
The pathogenesis of hypertension in CRF is undoubtedly
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complex and multifactorial. Unlike other studies, no
significant link was observed between blood pressure and
kallikrein excretion in CRF (Adetuyibi & Mills, 1972, Mitas
et al, 1978, Abe et al, 1981). It remains possible that the
overall balance between pressor and depressor influences is
disturbed in CRF, contributing to hypertension in some
cases, while others may be more affected by disturbed volume
homeostasis. More detailed analysis of the correlation
between the renal kallikrein-kinin system and other
vasoactive hormone systems may prove informative, as has
been found in essential hypertension. (Abe et al, 1981,
Pierucci et al, 1985, Levy et al, 1977).
The mechanism whereby captopril lowers kallikrein excretion
in CRF is unknown (Marin-Grez, Bonner & Gross, 1980).
Angiotensin converting enzyme in fact has a higher affinity
for bradykinin than for angiotensin I (Erdos, 1975). If
kallikrein release from submandibular glands is stimulated
in animals given captopril, profound hypotension ensues
(Scicli et al, 1983). It therefore seems likely that given a
constant degree of kallikrein release, ACE inhibition
potentiates the kallikrein-kinin system. This effect could,
however, be negated or reversed by a concomitant reduction
in kallikrein release, as suggested by the results of this
study. A negative feedback system, whereby increased
circulating kinins supress renal kallikrein release, has
been proposed as an explanation of the effect of captopril
on UKallV (Cunningham & Brouhard, 1980, Karlberg et al
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1980); this seems unlikely, since infusion of bradykinin
into the renal artery increases kallikrein excretion (Mills,
Newport & Obika, 1979). It has been suggested that
aldosterone is an important modulator of kallikrein release,
and plasma aldosterone falls during captopril therapy
(Geller et al, 1972). In the isolated perfused kidney there
is a direct correlation between renal perfusion pressure and
UkallV (Bevan, MacFarlane and Mills, 1974); the reduced
systemic blood pressure on captopril could therefore have
contributed to the reduction in UKallV. This is supported by
the observed correlation between kallikrein excretion and
MAP while on captopril, as shown in Figure 29.
It is of interest that ACE inhibitors have recently been
shown to slow the progression of chronic renal failure, even
at an advanced stage (Heeg, De Jong & De Zeeuw, 1 989); the
possibility that this is in part due to decreased renal
kallikrein-kinin activity merits investigation. Urinary
kallikrein excretion is inappropriately reduced in some
types of acute renal failure (Funaki et al, 1982), and
captopril is known to cause acute renal failure,
particularly in states of reduced renal perfusion (Hricik et
al, 1983). All the patients in this study showed some
increase in plasma creatinine in the short term. This acute
response could also relate to decreased renal kallikrein-
kinin activity. Overall it seems likely that the renal
kallikrein-kinin system is involved in the renal respone to
ACE inhibition, and that the conventional concept of a
stimulatory effect may be erroneous.
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CHAPTER 7. THE RENAL KALLIKREIN-KININ SYSTEM IN THE
NEPHROTIC SYNDROME
7.1. The nephrotic syndrome (NS) can occur in various
forms of renal disease; it is characterised by proteinuria,
usually >4 g/day, sufficient to cause hypoalbuminaemia, and,
in the untreated state, by the presence of peripheral
oedema. Two aspects of this disease state remain
problematical. Firstly, the pathophysiology of the profound
glomerular protein leak is often unclear (Brenner, Hostetter
and Humes, 1978). In many cases, there is obvious disruption
of the glomerular basement membrane by deposits of immune
material, eg in membranous glomerulonephritis. In other
cases, however, structural damage to renal tissue may be
slight or absent, eg in minimal change nephropathy. Subtle
changes in the surface charge of the glomerular basement
membrane have been blamed for the increase in capillary
permeability (Olson, Rennke and Venkatacham, 1981), but
other authors have postulated that a local or systemically-
derived permeability factor contributes to the protein leak.
Permeability factors derived from lymphocytes and from mast
cells have been described (Lagrue et al, 1 975; Strauss,
Freundlich and Zillevelo, 1984). The possibility that renal
kallikreins and kinins might play a role in the pathogenesis
of NS was first suggested in a paper by Murakami in Nature
in 1968. He showed that infusion of glandular kallikrein
into the renal artery of dogs caused heavy proteinuria. This
could be prevented by the concomitant administration of
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aprotonin and an anti-histamine (mepyramine), which was of
interest because of the known synergy between the effects of
histamine and kinins on capillary permeability (Murakami,
Hori and Masamura, 1968). In 1979, Brouhard described
increased urinary kallikrein excretion in children with
minimal-change nephropathy, which returned to normal when
remission was induced with steroids (Brouhard et al, 1979).
In subsequent correspondence, however, this phenomenon was
ascribed to the association between high plasma aldosterone
concentrations and increased urinary kallikrein excretion
which had been observed in the physiological studies of
Margolius and others (Geller at al, 1972; Margolius, 1980).
It was assumed that all NS patients were likely to have
secondary aldosteronism, as a result of hypovolaemia, and
that the increased UKall was merely a marker of this.
However, no measurements were made to confirm this
assumption, and no further studies of the significance of
the observation were made.
Without diuretic treatment, most patients with NS retain
sodium, although the degree of sodium retention varies
considerably between cases (Strauss, Freundlich and
Zillervelo, 1984). Traditionally this was ascribed to a
reduction in circulating plasma volume, consequent to the
reduced plasma oncotic pressure (Dourhout-Mees et al, 1979).
Hypovolaemia was thought to stimulate the renin-angiotensin-
aldosterone axis, causing an increase in tubular sodium
reabsorption. It seems clear that such a mechanism does
operate in some cases of NS (Meltzer et al, 1979). Equally,
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it is now clear that in others, the overall expansion of
extracellular fluid volume is such that plasma volume is
normal, or even increased, and that plasma renin activity is
normal or suppressed (Brown et al, 1982). In this
"hypervolaemic" type of NS, the reason for continued renal
retention of sodium is unclear; evidence supports an as yet
unidentified intra-renal defect in sodium excretion (Firth,
Raine and Ledingham, 1989).
It was therefore of interest to investigate the activity of
the renal kallikrein-kinin system in NS, both as a possible
mediator of increased capillary permeability, and as a
factor in the intra-renal regulation of sodium excretion.
7.2. PATIENTS AND METHODS
7.2.1 . Part 1
To clarify the relationship between NS and kallikrein
excretion, the first part of the study examined urinary
kallikrein excretion in 44 subjects. 32 were patients with
histologically proven glomerulonephritis (GN), 16 of whom
had NS (proteinuria >4 g/day, hypoalbuminaemia, and oedema).
12 healthy volunteers were controls (8m, 4f, mean age 41 _+
13 years). Age and sex were similar in each group. Details
of patients are shown in Table 8. Patients were not
receiving diuretics or drugs known to influence kallikrein
excretion. Two 24-hour urine collections were obtained from
each subject, while taking an 100-200 mmol sodium diet and
unrestricted oral fluids. Patients were studied in hospital
on a supervised diet; controls were not hospitalised but
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Sex Age Hist¬ Ccreat Protein¬ Plasma Urinary
ology ml/min uria albumin kallikrein
g/24h g/i nkat/24h
Glomerulonephrit is, not nephrotic
M 55 PGN 1 3 2.5 32 1 1
F 68 PGN 1 0 2.5 36 0.6
M 66 PGN 5 4.6 30 4.5
M 33 PGN 1 4 2.0 42 4.4
M 53 PGN 1 00 3.7 39 7.9
M 37 MCGN 1 0 1 5 32 0.7
F 55 PGN 5 5 31 3.4
F 49 PGN 4 0.5 32 3.5
M 43 PGN 1 0 2.0 43 2.8
M 27 PGN 20 <0.3 40 5.9
F 50 PGN 20 2.0 40 6.2
F 66 MCGN 40 1 .0 33 1 .3
F 54 PGN 30 1 .1 32 3.0
M 16 PGN 1 40 <0.3 40 6.8
F 55 PGN 1 5 3.0 36 4.5
Mean +^ 49+^14 29 + 38 2.9+^3.6 36.3+4.6 4.6+2.8
SD
Glomerulonephritis, nephrotic syndrome
M 75 memb 1 0 25 20 35
M 47 MCGN 1 0 1 4 24 33
F 15 PGN 30 1 0 30 1 2
F 69 PGN 7 1 0 23 1 7
M 16 ML 1 00 1 1 23 31
M 51 memb 1 00 30 21 35
F 20 memb 1 20 5 28 9.5
M 1 9 MCGN 30 30 23 1 9
M 78 memb 50 1 0 24 20
M 74 MCGN 45 1 0 29 32
M 42 PGN 60 35 20 28
F 21 memb 80 1 7 22 41
M 26 ML 1 20 8 20 27
F 25 MCGN 1 5 8 28 43
M 27 PGN 30 1 2 24 21
M 65 MCGN 40 1 1 16 21
+ 42 + 24 53 + 39 15.4+9 23.4+3.7 26.7+9.9
SD
Table 8 Details of 32 patients with glomerulonephritis
PGN = proliferative glomerulonephritis
MCGN = mesangiocapillary glomerulonephritis
ML = minimal lesion glomerulonephritis
memb = membranous glomerulonephritis
Ccreat = creatinine clearance
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were instructed to take 100-200 mmol sodium daily; urine
sodium excretion was measured in all subjects.
Since active kallikrein might become bound to protein in
urine, affecting the results in heavy proteinuria, a
solution of human albumin, 43 g/1, was added to four control
urine samples, to a protein concentration equivalent to
nephrotic urine (10 g/1). Kallikrein activity was compared
with and without protein in each sample.
To investigate the possibility of leakage of kallikrein from
plasma, citrated plasmas from 5 nephrotic patients were
incubated with the chromogenic substrate, as in the urine
assay, and activity compared with urine from the same
patient.
PRA and plasma aldosterone concentration were measured by
established radioimmunoassay methods in 5 patients with NS
(Roulston et al, 1983; Al-Dujaili and Edwards, 1978).
7.2.2. Part 2
In this part of the study, examining further the
relationship between PRA and UKallV in NS, we studied 16
patients with NS and 22 healthy controls. Details of
subjects are shown in Table 9; all had greater than 4G
proteinuria per day and plasma albumin below 30 G/L. The
mean age and male/female ratio were similar in each group,
except for the fact that patients in the normal renin
nephrotic group were significantly older than those in the
high-renin group, but not significantly older than the
controls (Table 9). Patients and controls were studied
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C Cr UNaV UKV PRA U KallV
Age Hist- ml/ Uprot Palb mmol mmol ng/ml nkat
Sex yrs ology min g/24h g/1 /24h /24h /hr /24h
High renin
M 16 ML 97 1 1 1 7 47 49 11 .6 31
M 51 memb 95 20 24 75 50 3.0 35
F 46 MP 78 15.2 22 2 38 35.6 29.9
M 40 ML 84 1 7 1 8 2 56 12.8 66.5
F 21 memb 80 1 7 23 75 84 10.8 41 .5
F 51 memb 78 4.7 23 28 52 3.6 20.7
M 1 6 ML 1 20 1 2 1 7 21 65 14.5 48.6
M 30 MCG 20 25 22 97 60 4.6 49.3
Mean 33.8 81 .5'"15.2"' 20.8" "43. 4 ~ "56.8 12.1 40.4
SEM 5.3 10.1 2.2 1 .0 12. 7 4.8 3.7 5.1
Normal renin
F 73 MP 59 4.9 25 40 27 1 .8 29.0
M 65 MCGN 46 1 1 1 7 52 48 .64 23.9
M 74 MCGN 1 6 16.2 27 59 73 .50 35.1
M 35 MP 123 7.9 20 77 54 .59 22.0
F 37 ML 95 6.8 20 64 74 .92 34.4
F 73 MCGN 20 5.1 27 45 22 .10 17.1
F 69 memb 1 9 5.6 18 33 36 2.7 1 8.9 -
M 41 MP 63 1 6 23 40 30 2.3 25.0
58.'4* 55.1 ~ 9.2~~ 22.1~~ 51 .3" "45.5 1 .2** 25.7~*
6.2 13.7 9.2 1 .4 5.2 7.2 .30 2.4
Normals (n=22)
Mean 44.2 ml 3 110 <0.3 40.2 1 21 60.5 1 .45 1 2.0
SEM 7.2 f9 3.6 1.46 3.2 8.9 .22 1.1
p<.05 different from normals
p<.01 " " "
* p<.05 different from high renin group
** p<.01
Table 9
Urinary kallikrein-PRA study. Details of subjects with
high-renin nephrotic syndrome (n=8), normal-renin nephrotic
syndrome (n=8) and healthy controls (n=22).
memb - membranous; ML - minimal lesion; MP - mesangial
proliferative; MCGN - mesangiocapillary; C Cr - creatinine
clearance; Uprot - urinary protein excretion; Palb - plasma
albumin; UNaV - urinary sodium excretion; UKV - urinary
potassium excretion.
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under similar conditions to Part 1 of the study. Mean
daily urinary sodium excretion in the control subjects was
121 + 3.2 mmol/day (Table 9). UKallV was measured in two
consecutive 24-hour urine collections and a mean of the two
values calculated. Blood for PRA estimation was taken at 8
am after the subject had been supine for one hour. Plasma
volume was measured in 8 of the patients, by estimating the
volume of distribution of 1125-labelled radio-albumin over
one hour. Normal values for this assay have been
established previously in 20 healthy subjects (International
Commitee for Standardisation in Haematology, 1973). In the
NS subjects, the volume/weight adjustment was made on the
basis of a "dry" weight, established after subsequent
abolition of oedema by diuretic therapy. On average, 1 .8%
of the total administered radioactivity appeared in urine
during the 1 hour study.
In order to assess the possibility of glandular kallikrein
reaching the systemic circulation in NS, we compared the
activity of plasma against glandular kallikrein substrate in
10 patients with NS, 17 patients with glomerulonephritis who
were not nephrotic, and 10 normal subjects. Samples were
taken at 8 am after overnight fast. Details of these
subjects are shown in Table 10. Age and sex ratio were
similar in the three groups; creatinine clearance was
significantly lower and urinary protein excretion higher
than the controls in the NS and glomerulonephritis groups.
Urinary protein excretion was significantly greater and
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Age Hist¬ C Cr UProt P Alb P G1 Kail
Sex yrs ology ml/min g/24h g/i absxl0-3
Nephrotic syndrome
M 40 ML 84 17 1 8 10
M 1 6 ML 120 12 1 7 0
F 69 memb 1 9 5.6 1 8 5
M 30 MCGN 20 25 22 1 2
F 1 5 ML 67 4.1 1 9 8
F 73 MP 59 4.9 25 1 1
M 65 MCGN 46 11 17 23
M 35 MP 1 23 7.9 20 0
F 61 MP 99 4.1 29 8
M 45 MCGN 60 8.2 21 6
Mean 44.9 69.7" 1 0"** 20.6 ""** 8.3~~:
SEM 6.8 11 .7 2.1 1 .2 2.09
Glomerulonephritis, no NS
M 25 FNP 38 2.3 32 0
M 31 MCGN 11 0 .5 38 0
M 42 MP 90 .9 46 1
M 49 memb 1 5 2.6 41 2
F 55 MP 64 <.3 41 2
F 69 MCGN 19 2.5 35 0
F 50 MP 25 1.5 45 0
M 24 MP 110 .6 48 4
M 59 MP 62 1.4 39 0
M 50 FNP 21 2.2 39 3
F 20 MP 102 .8 38 3
F 22 MP 103 .5 40 0
F 16 MP 11 0 .8 44 2
M 36 MP 1 22 1 .2 40 4
F 32 MP 69 1.3 46 3
M 27 memb 1 20 3.5 32 0
M 1 6 MP 87 .6 40 1
Mean 36. 7 74.5" 1 .4"" 40.2 1 .47
SEM 3.9 9.3 .2 1.1 .36
Normals (n =10)
Mean 40. 4 6m 4f 108.3 <.3 41 .5 1 .7
SEM 6.1 6.4 .65 .45
-
P< .05 different from normal
P< .01
tt If it
* P< .05 different from GN
** P< .01
II II ii
FNP = Focal necrotising proliferative; P G1 Kali -- plasm;
glandular kallikrein activity
Table 10
Plasma glandular kallikrein study; details of patients with
nephrotic syndrome (n=10), glomerulonephritis without
nephrotic syndrome (n=17) and healthy controls (n=10)
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plasma albumin lower in the nephrotic group than the
glomerulonephritis group.
In this part of the study , activity of plasma against S2266
was measured using the method of Gallimore et al for
estimation of "kallikrein-like" activity in plasma
(Gallimore and Friberger, 1982; Chapter 2, Section 2.3.2).
The method was as previously described, except for the
replacement of S2302, a specific substrate of plasma
kallikrein, by S2266, the glandular and renal kallikrein
substrate. 50 ul of plasma was diluted with 3000 ul buffer,
then incubated for 2 minutes at 37dc with a further 200 nl
buffer. 200 -ul of S2266 was then added. After 2 minutes
incubation at 116c, 200 ul of 50% acetic acid was added.
The absorbance was measured at 405 nm; from this was
subtracted the absorbance of a blank prepared by adding the
same reagents in reverse order.
7.3. RESULTS
7.3.1 . Part 1
As shown in Fig 29, UKallV was reduced in GN compared with
controls, but was increased in NS. Only two NS patients had
a value within 1 SD of the mean in controls. Urine volume
was similar in each group (controls 1.47 _+ 0.44 1/day, GN
1.69 _+ 0.53 1/day, NS 1.28 _+ 0.54 1/day). Urinary sodium
excretion was lower than the controls in GN and NS (controls
150 _+ 47 mmol/day, GN 109 _+ 57 mmol/day, NS 85 _+ 42
mmol/day), but only the control/NS difference was
















Fig.21Daily excretion of urinary kallikrein in normal controls,
patients with GN and patients with both GN and nephrotic syn¬
drome.
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significantly lower than controls in GN and NS (Table 8).
UKallV did not correlate with urine volume, urinary sodium,
or creatinine clearance. In the 32 patients with renal
disease, UKallV correlated positively with urinary protein
excretion (r 0.65, p<0.001) and negatively with plasma
albumin (r-0.73, p<0.001).
When corrected for dilution, urinary kallikrein
concentration in control urines was not affected by addition
of albumin (control 6.20 _+ 0.52 U/l, urine + albumin 6.81 _+
0.42 U/l, p>0.05).
Incubation of NS patients plasma with the chromogenic
substrate showed activity averaging 17.5 +_ 9.3% of the
corresponding urine value (Table 11).
In the 5 NS patients in whom PRA and aldosterone were
measured, PRA was normal in 4 and slightly elevated in 1 ,
compared with the laboratory reference range ( mean 1.92 ^
1.15 ng/ml/hr, normal range 0.2 - 2.7 ng/ml/hr). Plasma
aldosterone was normal or low in all 5 (mean 37 _+ 17 pg/ml,
normal range 50 - 140 pg/ml). Kallikrein excretion was
markedly elevated in all 5 patients (mean UKallV 27 ± 8.9
nkat/day).
7.3.2. Part 2
Of the 16 patients with NS in this part of the study (PRA vs
UKallV in NS), PRA was elevated in 8 (mean ± SEM 12.1 + 3.7
ng/ml/h, normals 1.45 ± 0.22 ng/ml/h) and normal in 8 (1.2 _+
0.3 ng/ml/h) (Fig 30). The normal renin subjects were
significantly older than the high-renin group (58.4 _+ 6.2
years vs 33.8 +_ 5.3 years, p <0.05). Differences between
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Name Plasma kalli¬ Urine kalli¬ Plasma/urine
krein (nkat/1) krein (nkat/1) ratio (%)
RA 1 .5 22.1 6.6
JS 8.2 31 .1 26.3
PN 4.4 39 11 .2
RL 4.7 30.2 15.5
AS 7.3 26.3 27.8
Mean+SD 5.2+2.6 29.7+6.3 17 . 5 +9.3
Table 11 Plasma and urine glandular kallikrein
concentrations (calculated from activity against S2266) in 5
patients with nephrotic syndrome.
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these groups in creatinine clearance, urinary protein
excretion, plasma albumin and urinary sodium excretion were
not significant, although both groups differed from the
healthy controls in all these variables, as shown in Table
9. Patients with NS in both high- and normal-renin groups
were in positive sodium balance during the study (urinary
sodium excretion 43.4 _+ 12.7 and 51.3 _+ 5.2 mmol/day) and
all nephrotic subjects gained body weight during the study.
In the high renin group, mean UKallV was markedly increased
(40.4 +_ 5.1 nkat/24 h, normals 12.0 +_ 1 .1 ) (Fig 30). Plasma
volume was reduced in the three patients in this group in
whom it was measured (Fig 31). In the normal renin group,
mean UKallV was elevated (25.7 _+ 2.4 nkat/24 h) but less so
than in the high-renin patients (p <0.05). Plasma volume
was measured in 5 of these patients; it was normal in 3
cases and reduced in 2 (Fig 31). In the 16 patients with NS,
UKallV correlated with plasma renin activity (r 0.53, p
<0.05), with urinary protein excretion (r 0.78, p <0.01),
and with urinary potassium excretion (r 0.53, p<0.05).
Correlations between UKallV and urinary sodium excretion,
urine volume, plasma potassium and creatinine clearance were
not significant (p >0.05).
When the ratio of PRA to UKallV was calculated, the ratio
correlated with urinary sodium excretion (r -0.53, p 0.035).
Neither PRA (r -0.218) nor UKallV (r -0.088) alone
correlated with UNaV, and the PRA/UKallV ratio did not









































Figure 31 . Plasma volumes in high- and
low -renin nephrotic syndrome.
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Fig 32 shows the activity of plasma against S2266 in healthy
control subjects, and in patients with glomerulonephritis,
with and without nephrotic syndrome. Activity in controls
was low or undetectable (absorbance 1.7 x 10-3 _+ 0.45 x 10-
3) and similar results were obtained in glomerulonephritis
(1.47 x 10-3 +_ 0.36 x 10-3). Significant activity was
observed in 8 of 10 nephrotic subjects (8.3 x 10-3 +_ 2.1 x
10-3); this value was significantly higher than those
obtained in the other groups (p <0.05). In the
glomerulonephritis and nephrotic groups, there was a
significant overall correlation between plasma activity
against S2266 and urinary protein excretion (r 0.44, p
<0.05).
7.4. Discussion
The reduction in UKallV in GN wihout NS probably reflects
the presence of renal impairment in these patients, as
discussed in Chapter 6. In contrast, patients with NS
excrete supranormal amounts of urinary kallikrein, despite
renal impairment in many cases. It seems unlikely that
filtration from plasma can explain this finding. Plasma
kallikrein has only 4% of the activity of glandular
kallikrein against the substrate used in this assay
(Amundsen et al, 1979). Plasma from the nephrotic patients
contained only 20% of the activity against the substrate
compared to undiluted urine. This value could reflect the
presence in plasma of non-kallikrein proteolytic enzymes



















glandular kallikrein in plasma , as discussed below (Rabito
et al, 1983). When labelled glandular kallikrein is injected
intravenously, less than 10% appears intact in urine (Mills,
Paterson and Ward, 1975; Rabito et al, 1985). Glandular
kallikrein would therefore have to cleared from the
circulation at approximately 70 ml/min to explain the
urinary kallikrein findings on the basis of filtration from
plasma, which seems inconceivable for a protein of molecular
weight 40,000. It therefore seems likely that kallikrein is
released by the kidney into the urine in NS. We found that
kallikrein activity in normal urine was unaffected by the
addition of a protein solution; this suggests that
kallikrein does not bind actively to protein, and that the
elevated UKallV in NS is not simply due to proteinuria.
Urinary kallikrein frequently increases in association with
diuresis and natriuresis, and passive washout of tubular
enzyme has been postulated (Seeber, Vila and Catanzaro,
1 982 ). However, the NS patients in this study had lower
urine volumes and urinary sodum excretion than the other
patient groups. The explanation for increased UKallV in NS
is therefore not immediately apparent.
During sodium restriction or hypovolaemic haemorrhage,
plasma renin activity and urinary kallikrein activity change
in parallel (Levy et al, 1977; Maier and Binder, 1979).
This has been interpreted as indicating a functional link
between the renin-angiotensin-aldosterone systems and the
renal kallikrein-kinin system, whereby the vasodilator
properties of kinins counteract the vasoconstriction due to
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locally generated angiotensin II in the kidney, as
previously discussed. Our finding of increased UKallV in NS
could therefore have reflected activation of the renin-
angiotensin-aldosterone system resulting from hypovolaemia.
In the second part of this study, however, we confirmed the
findings of other workers that at least 50% of patients with
NS have normal PRA and plasma volumes (Meltzer et al. 1979).
Despite this, they show a significant increase in UKallV
compared with normal subjects. The increased UKallV in NS
is, therefore, not solely a reflection of either
hypovolaemia or hyperreninaemia, although UKallV was
significantly greater in the high-renin group, suggesting a
partial link between the two systems. The stimulus to
kallikrein excretion in the normal-renin group is not clear.
These patients have presumably compensated for a reduced
plasma oncotic pressure by retaining sufficient sodium to
expand their extracellular fluid volume (ECF) massively
(Glassock, 1980). Kallikrein excretion is known to increase
during acute expansion of the ECF, as previously discussed.
It may be, therefore, that the marked expansion of ECF
volume drives renal kallikrein release either directly or
via other neural/humoral mediators. In some patients,
UKallV has fallen to normal following effective diuretic
therapy, but this has not been uniformly seen, (AD Cumming,
unpublished observations) and the known stimulating effect
of most diuretics on the renal kallikrein-kinin system makes
interpretation of these findings difficult (Bonner et al,
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1982; Mackay et al, 1985). Studies of kallikrein excretion
in other oedematous states would be of interest in this
regard; patients with alcoholic cirrhosis of the liver
excrete less urinary kallikrein than normal, despite dietary
sodium restriction and severe oedema and ascites (21). The
possibility exists that hypoproteinaemia per se could
influence kallikrein excretion, perhaps by an effect on
delivery of sodium to the distal nephron (Green, Windhager
and Geibisch, 1974; Grausz, Leiberman and Earley, 1972).
However, as discussed in Chapter 10, an acute reduction in
plasma protein concentration induced in sheep by
extracorporeal plasmapheresis, does not alter urinary
kallikrein excretion.
Recent studies have indicated a relationship between dietary
potassium intake and urinary kallikrein excretion in rats
(Vio and Figueroa, 1987), although the underlying mechanism
is unclear. In this study, kallikrein excretion was
positively correlated with potassium excretion, but not with
excretion of sodium or water. This could indicate a link
with mineralocorticoid activity, as previously suggested
(Geller et al, 1 972), although in the first part of this
study it was demonstrated that the increased kallikrein
excretion in NS was seen in patients with normal plasma
aldosterone concentrations, and could not be explained
purely on the basis of secondary aldosteronism. Other
compounds with mineralocorticoid activity could, however, be
important in this respect. The renal kallikrein-kinin system
interacts in a complex fashion with other vasoactive hormone
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systems, including the sympathetic nervous system, dopamine,
prostaglandins, vasopressin, and atrial natriuretic peptide
(Tulassay et al, 1987). Assessment of these mechanisms in
parallel with kallikrein studies in nephrotic syndrome,
combined where appropriate with the use of pharmacological
inhibitors, may clarify the cause of the increased
kallikrein excretion in NS.
Glandular kallikreins are known to be released into the
systemic circulation from submandibular glands, pancreas
and kidney (De Bono and Mills, 1 974; Rabito et al, 1 983;
Scicli et al, 1983) but a role for these enzymes in
physiological or pathological states has not been
demonstrated, other than perhaps in acute pancreatitis
(Fuller and Funder, 1987). Experimental studies in the
rabbit have recently shown that when kallikrein release
from the submandibular gland is stimulated and combined
with kininase II inhibition, profound hypotension ensues,
suggesting that under certain conditions glandular
kallikreins could exert systemic effects (Rabito et al,
1983). Renal kallikrein has been identified in renal venous
effluent and renal lymph (De Bono and Mills, 1974; Proud et
al, 1983). Studies of renal kallikrein generation in NS
are lacking. It seems likely, however, that the increased
plasma activity against the glandular kallikrein substrate,
S2266, seen in NS reflects release of renal kallikrein,
since the urine in NS also shows very high activity against
the same substrate, and exceeds the plasma activity five-
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fold. The ability of this enzyme to cause systemic effects
in NS would depend on the rate of release, the rate of
degradation (which occurs primarily in the kidney) and the
efficiency of the kininase system. The reported occurrence
of proteinuria and NS in patients receiving inhibitors of
angiotensin converting enzyme, which is identical to
kininase II, is therefore of some interest (Atkinson and
Robertson, 1979). Infusion of glandular kallikrein into the
renal artery of dogs causes proteinuria, which can be
abolished by the kallikrein inhibitor, aprotonin (Murakami,
Hori and Masamura, 1968). Intraperitoneal injection of
renal homogenates into nephrectomised rats produces a
syndrome resembling nephrosis, and it has been suggested
that this might be due to a factor of renal origin which
increases capillary permeability - possibly kallikrein
(Asscher and Anson, 1963). Increased glomerular synthesis
of thromboxane has been suggested as a cause of proteinuria
in nephrosis (Remuzzi et al, 1985); bradykinin and related
kinins are potent stimulators of phospholipase A2, and
promote synthesis of arachidonic acid metabolites, including
thromboxane A2 (Regoli and Barabe, 1980). The localisation
of kallikrein within the granular peripolar cell, at the
vascular pole of the glomerulus, as described in Chapter 5,
facilitates a role for kallikrein in glomerular pathology,
including a possible effect on glomerular capillary
permeability. These observations would all be compatible
with participation of the renal kallikrein-kinin system in
the pathogenesis of NS. Pharmacological inhibitors of both
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kallikreins and kinins are available (Chapter 1) and a
single uncomfirmed report suggests that they may be of value
in the treatment of this frequently refractory condition
(Murakami, Hori and Masamura, 1968).
The significance of the correlation between the PRA/UKallV
ratio and urinary sodium excretion in NS is discussed fully
in Chapter 11. As mentioned above, the reason for sodium
retention in NS is unclear in many cases, and has been
ascribed to an intra-renal defect in sodium handling (Firth,
Raine and Ledingham, 1989). The finding of a positive
correlation between the activities of these two intra-renal
hormone mechanisms and sodium excretion in NS is therefore
of considerable interest, although the degree of correlation
is not particularly strong, suggesting that other factors
are involved in what is likely to be a multi-factorial
phenomenon.
In summary, our results provide evidence for disordered
activity of the renal kallikrein-kinin system in NS. The
increased urinary kallikrein excretion is partially, but not
wholly linked to increased activity of the renin-angiotensin
system. Kallikrein generated by the kidney, in addition to
appearing in the urine, may reach the systemic circulation.
Alterations in the relationship between the renin-
angiotensin and kallikrein-kinin systems may be involved in
the sodium retention of NS.
1 □□
CHAPTER 8 THE PLASMA AND RENAL KALLIKREIN-KININ SYSTEMS
IN HEPATIC CIRRHOSIS
8.1. Introduction
The cause of renal retention of sodium in patients with
hepatic cirrhosis and ascites is not known, and a number of
factors are likely to be involved (Epstein,1983). As in
septic shock, the renal functional pattern resembles a "pre¬
renal" state, with oliguria, negative free water clearance,
and reduced absolute and fractional sodium excretion.
Provided the patient has not developed the "hepatorenal
syndrome", GFR and renal plasma flow are, however, not
markedly reduced; GFR is reduced in some patients but does
not relate to the degree of sodium retention (Chaimovitz et
al, 1972). Most studies have found that measured plasma
volume is normal or even increased (Tristan & Cohn, 1967).
The concept of a reduced "effective plasma volume" in face
of a low systemic vascular resistance has been invoked,
although measures to increase central volume, such as water
immersion, do not normalise sodium excretion (Bichet, Groves
& Schrier, 1983). Other possibilities for the "afferent"
signal to the kidney include a hepatic mechanoreceptor
responding to increased intra-sinusoidal pressure, which
would stimulate renal sodium retention via a neural reflex
arc and lead to ascites by an "overspill" mechanism of
overall ECF expansion (Leiberman, Denison & Reynolds, 1970).
It is possible that both these hypotheses are correct.
The "efferent" mechanism promoting renal tubular sodium
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reabsorption in cirrhosis and ascites is also controversial.
There is evidence of increased efferent renal sympathetic
nerve activity (ERNSA), which could directly influence
tubular function, although direct confirmation of this in
man is lacking (Di Bona, 1984). Attention has also focused
on other neuro-endocrine mechanisms, including the renin-
angiotensin system, aldosterone, AVP, prostaglandins,
thromboxanes, prolactin, and ANP (Epstein 1983; Better &
Schrier, 1983). The possibility of a "defect" in the
kallikrein-kinin system in cirrhosis was raised by Colman et
al, who described a reduction in circulating prekallikrein
in cirrhotic patients (Wong, Talamo & Williams, 1977). It
seems likely, however, that this is due in part to reduced
hepatic synthesis, rather than activation; there is also
very little evidence to support a role for plasma kinins in
the regulation of renal function. Zipser described an
"parodoxical" reduction in urinary kallikrein excretion in
cirrhosis; PRA, aldosterone, and urinary PGE2 excretion were
increased in those patients with ascites, but their subjects
were taking a 10 mmol sodium diet, which in itself will
stimulate the renin-angiotensin-aldosterone and
prostaglandin systems (Zipser, 1981). It has been
recommended that, for maximum clinical relevance, studies of
sodium-retaining syndromes should be conducted under
conditions of positive sodium balance (Brown et al, 1982).
It was therefore of interest to study the activity of the
plasma and renal kallikrein-kinin systems in cirrhotic
patients, with and without ascites, on an 100 mmol sodium
1 02
diet, during sodium accumulation.
8.2. Patients and methods
12 patients with established cirrhosis were studied. Six had
ascites, defined as the unequivocal presence of free
intraperitoneal fluid detected on clinical examination; they
were studied prior to the initiation of diuretic therapy.
Six did not have ascites and had never had diuretic therapy.
Age and sex were similar in each group. All patients were
studied in hospital, after at least 48 hours on a 100 mmol
sodium diet and unrestricted oral fluids, and on no
medication. The study consisted of -
1. 24 hour urine collection for volume, sodium, potassium,
and kallikrein.
2. After an overnight fast, measurement of PAH and inulin
clearance, as described for the control periods of the
saline infusion study (Chapter 3).
3. After 30 mins supine, at 9 am, blood sampling for PRA,
Ang II, aldosterone, prekallikrein, catecholamines, ANP,
AVP.
4. Urine sampling during clearance study for sodium,
potassium, osmols, kallikrein.
PRA, Ang II, aldosterone, ANP, and AVP were measured by
established radioimmunoassays. Plasma catecholamines were
measured by HPLC using electrochemical detection.
8.3. Results
Urine volume, urinary sodium excretion, and FENa were all
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significantly lower in the ascitic group than the non-
ascitic patients ( Table 12 ). GFR, measured as inulin
clearance, and renal plasma flow, measured as PAH clearance,
were identical between the two groups, although there was
considerable variation within groups { Table 12). Urinary
kallikrein excretion was very low in 2 of the 6 ascitic
patients, and also in two of the 6 non-ascitic patients, so
that the difference between groups was not significant. PRA
was higher in the ascitic group, but the difference did not
achieve significance. PRA was above the reference range
(>2.7 ng/ml/hr) in 3 of the 6 ascitic subjects and none of
the non-ascitic patients. When the PRA/UKallV ratio was
calculated as before, and log-transformed because of its
extreme non-parametric distribution, the ratio was
significantly higher in the ascitic patients; there was
little overlap between ascitic and non-ascitic patients. The
PRA/UKallV ratio correlated strongly with urinary sodium
excretion (r -0.80, p 0.002)(Fig 33). Other correlations
are shown in Table 13.
Compared with normals, cirrhotic patients had reduced plasma
prekallikrein concentrations; there was no difference
between ascitic and non-ascitic subjects (normals, 108jf1 4%
of pooled normal human plasma, ascitic 40.44 _+ 3.82%, non-
ascitic 55.78 _+ 9.13%).
Plasma Angiotensin II was higher in the ascitic group, the
difference being barely significant. There were no
significant differences between the two groups in plasma
aldosterone, plasma atrial natriuretic peptide, plasma
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ASCITIC NO ASCITES £
Urine volume 0.55 +_ 0.10 3.41 _+ 0.80 0.005
ml/min
Urine sodium 54.2 _+ 25.2 234.3 ± 56.2 0.01 5
umol/min
FENa 0.38 + 0.14 1.66 + 0.51 0.035
%
Inulin clearance 95.1 ± 12.9 115.0 _+ 12.9 NS
ml/min
PAH clearance 577.0 _+ 1 1 0.5 572.7 ± 86.4 NS
ml/min
Urine kallikrein 5.03 _+ 2.06 5.95 ± 1.81 NS
nkat/min x 10-3
Plasma renin 2.77 ^ 0.98 0.58 _+ 0.20 NS
ng/ml/hr
PRA/UKallV ratio -.070 + 0.325 -1.024 + 0.177 0.025
(log 10)
P prekallikrein 40.44 _+ 3.82 55.78 _+ 9.13 NS
%NHP
P aldosterone 19.00 _+ 8.1 7 3.33 ± 2.85 NS
ng/100ml
P Angiotensin II 24.75 _+ 10.29 3.38 _+ 0.77 0.045
pg/ml
Plasma ANP 71.23 + 17.75 52.78 + 13.81 NS
pg/ml
P noradrenaline 5.175 _+ 0.606 3.425 _+ 1.019 NS
nmol/1
P adrenaline 0.425 _+ 0.025 0.356 +_ 0.034 NS
nmo1/1
Table 12 Renal function and neuro-endocrine regulatory
factors in patients with hepatic cirrhosis with ascites
(n = 6) and without ascites (n =6). Mean +_ SEM.
P = plasma
FENa = fractional sodium excretion
NHP = normal human plasma pool
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UNaV ( umol/ min )
Figure 33. Correlation between log PRA/UKallV
and UNaV in 12 patients with cirrhosis.
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noradrenaline, or plasma adrenaline ( Table 12 ).
In the ascitic group, plasma osmolarity was lower, urine
osmolarity higher, and free water clearance lower than the
non-ascitic group (Table 14).
jr. 2
Vu v UKallV 0.54 NS
PRA -0.37 NS
log PRA/UKallV -0.73 0.007
UNaV v UKallV 0.50 NS
PRA -0.42 NS
log PRA/UKallV o00•oI 0.002
Table 13 Correlations between urine volume and urinary
sodium excretion, and urinary kallikrein excretion and PRA,
in 12 patients with cirrhosis.
ascitic non-ascitic
Plasma osmolarity 267 + 12 282 + 9 *
Urine osmolarity 741 + 103 369 + 29 *
Free water clearance -1.0 + 0.14 +0.82 + 0.06 *
* p< 0.05
Table 14 Indices of renal water handling in 12 patients
with cirrhosis.
8.4. Discussion
As in a previous study, the plasma prekallikrein
concentration was found to be reduced in cirrhosis (Wong,
1977). It is still unclear to what extent this reflects
activation or reduced synthesis, but even if activation of
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the plasma kallikrein-kinin system is present, it seems
unlikely that a direct effect on renal function occurs. Such
kallikrein-kinin activation could, however, be involved in
the systemic vasodilation seen in cirrhosis, which, by
reducing central "effective volume", could act as a stimulus
to sodium-retaining mechanisms (Nicholls et al, 1986).
Endotoxin is a potent activator of the plasma kallikrein-
kinin system, and endotoxaemia is frequent in patients with
advanced liver disease (Wardle, 1982). It would be of
interest to study the effect of kallikrein inhibition in
such patients.
The results clearly show that the profound sodium and water
retention seen in cirrhosis with ascites is independent of
renal haemodynamics, and represents primarily an alteration
in renal tubular handling of salt and water. A number of
factors are likely to be involved in this syndrome. The
plasma and urinary osmolarity data are pathognomonic of
increased circulating AVP in the ascitic group; plasma AVP
is being measured, but the results are not available at the
time of writing (Skowsky & Fichman, 1984). AVP alone cannot
explain the sodium retention, however; sodium retention is
not a feature of the syndrome of inappropriate AVP secretion,
for example, and non-pressor AVP analogues suppress PRA and
increase UNaV (Malayan & Reid, 1982). Schrier's group have
emphasised the role of the sympathetic nervous system in
promoting sodium retention and AVP release, and have
observed increased plasma catecholamines in cirrhosis, which
correlated with sodium excretion (Nicholls et al, 1986).
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Epstein's group have not confirmed these results, however
(Epstein, 1983). In the present study, we found no
difference in plasma catecholamines between sodium
retaining, ascitic subjects and the non-ascitic group; while
plasma catecholamines are at best a poor index of overall
sympathetic nervous system activity, the results suggest
that the sympathetic nervous system is not a "prime mover"
in the sodium retention.
The role of aldosterone has been emphasised (Wilkinson et
al, 1979); while plasma aldosterone tended to be higher in
the ascitic group, the difference was not significant at the
5% level. Similarly, Epstein's group have studied cirrhotic
subjects under rigidly controlled conditions, off diuretics,
and found elevated plasma aldosterone in only 4 of 28
patients (Epstein, 1983). A renin-angiotensin effect is
possible, and is supported by the trend to higher PRA and
significant elevation of plasma Angiotensin II concentration
in the ascitic group. A pure tubular action of All would
be unusual, however (Kotchen, 1983). PRA was not
significantly elevated in the ascitic patients, and did not
correlate with sodium or water excretion overall (Table 13).
There is no evidence that blockade of the renin-angiotensin
system is beneficial in cirrhosis (Schroeder et al, 1976),
and hypotension frequently results. We found no difference
in UKallV between ascitic and non-ascitic subjects; while
some patients in each group had very low values, overall the
results were exactly comparable to basal values in normal
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subjects (Figures 9 & 15). UKallV alone did not correlate
with water or sodium excretion (Table 13). We have
therefore not confirmed the findings of Zipser et al (1981)
and of Perez-Ayuso et al (1984), of reduced urinary
kallikrein excretion in cirrhosis. Both these groups used
a less specific kallikrein assay, and their results may have
been influenced by a very low sodium diet. Therefore,
neither PRA nor UKallV alone stand as determinants of
sodium handling in our study. However, the degree of
correlation between the PRA/UKallV ratio in this study is
such that approximately 65% of the variability in sodium
excretion can be ascribed to changes in this ratio. No other
variable, to my knowledge, has correlated with UNaV to this
extent in previous studies. Comparison of the regression
line with those seen in normal subjects (Chapter 3)
indicates a similar curve overall; the ascitic patients lie
to the left of the curve (high ratio, low UNaV). This can be
interpreted as indicating that the PRA/UKallV - UNaV
relationship is influenced in the direction of anti-
natriuresis in ascitic subjects. Further discussion of the
factors which could effect this change is contained in
Chapter 11.
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CHAPTER 9 THE RENAL KALLIKREIN-KININ SYSTEM AND OTHER
VASOACTIVE HORMONE SYSTEMS IN THE RENAL
RESPONSE TO NON-HYPOTENSIVE SEPSIS
9.1. Introduction
Sepsis and acute renal failure are frequently associated
(Werb and Linton, 1 979 ), and up to 50% of cases of acute
renal failure are due to septicaemia (Beaman et al, 1987).
The pathogenesis of this syndrome is poorly understood. The
importance of endotoxin in mediating renal damage has been
emphasized (Wardle, 1982); experimental endotoxaemia is
ordinarily associated with hypotension, systemic and renal
vasoconstriction, and intrarenal coagulation with glomerular
thrombosis (Balis et al, 1978; Conger, Falk and Guggenheim,
1981). However, both clinical and experimental observations
indicate that acute renal failure may supervene in sepsis
in the absence of hypotension and structural renal damage
(Richmond et al, 1 985; Walker et al, 1 986 ). It has been
suggested that this is a type of "functional" renal failure
associated with reduced glomerular filtration and sodium
retention, despite adequate renal perfusion (Walker et al,
1986); it may progress to established acute tubular
necrosis, but initially may be amenable to appropriate
therapy. The renal kallikrein-kinin system and other neuro¬
endocrine mechanisms known to influence renal function could
be involved in the pathogenesis of this form of acute renal
failure; this possibility was investigated in a large animal
(ovine) model of intra-peritoneal and systemic sepsis.
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9.2. Materials and Methods
The technique of surgical induction of peritonitis was
modified from that of Wichterman (Wichterman, Baur and
Chaudry, 1980). Sixteen healthy sheep aged 12-18 months
and weighing 40-50 kg underwent general anaesthesia and
cannulation of the common carotid artery, and the pulmonary
artery via the external jugular vein with a triple-lumen
Swan Ganz catheter. The bladder was catheterized per
urethra. After recovery from anaesthesia, animals were
housed in metabolic cages and volume-loaded with 8 litres of
Ringer's lactate intravenously (IV) over 24 hours. After
control haemodynamic measurements and blood and urine
sampling, animals underwent a second general anaesthetic;
peritonitis was induced by devascularization and proximal
ligation of 6-8 cm of distal caecum, combined with partial
omentectomy and a 2 cm puncture in the caecal tip. The
abdomen was closed and the animal allowed to recover from
anaesthesia. Post-operatively all animals received 50 mg
pethidine and 25 mg chlorpromazine IV and were continued
thereafter on an IV infusion of pethidine, 50 mg/6 hours.
IV infusion of Ringer's solution, 8 litres/24 hours,
continued for the duration of the experiment. Follow-up
haemodynamic measurements and blood and urine collections
were made 24 hours after induction of sepsis. Animals were
supervised continuously during the study. Any animal seen
to be restless, agitated or showing other evidence of
discomfort or distress despite pethidine infusion was
sacrificed immediately by IV injection of pentobarbital
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(Euthanol). Animals surviving through 24 hours were
sacrificed as above; an open renal biopsy was taken at the
time of death.
Haemodynamic parameters measured were mean arterial pressure
(MAP), central venous pressure (CVP), mean pulmonary artery
pressure (PAP), pulmonary capillary wedge pressure (PCWP),
and thermodilution cardiac output. Cardiac index (CI) and
systemic vascular resistance index (SVRI) were derived by
standard formulae. Blood samples were taken from the aortic
cannula; white cell count, serum creatinine, sodium and
albumin were measured by standard autoanalyzer techniques.
Plasma renin activity (PRA) was measured by radioimmunoassay
(Haber et al, 1969). Arterial plasma norepinephrine and
epinephrine were measured by high-performance liquid
chromatography and electrochemical detection (Bioanalytical
Systems Inc., 1985). The lower limit of detection in this
assay was 100 pg/ml; some samples showed undetectable
plasma epinephrine and were arbitrarily allocated a value of
100 pg/ml for statistical purposes. Urine was collected for
4 hours on the morning of each study day and the volume
recorded; creatinine and sodium were measured, and urinary
kallikrein concentration assayed as previously. The urinary
concentration of 6-keto PGF lot and thromboxane B2 were
measured by radioimmunoassay (Ali and McDonald, 1980) and
urinary excretion rates calculated. Effective renal plasma
flow was measured as the clearance of orthoiodinated
hippuran labelled with 1128 (Dubovsky and Russel, 1982).
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Clearance from plasma of technetium-chelated
diethylenetriamine pentaacetic acid (99m-Tc-DTPA) which is
handled by the kidney in a manner similar to inulin, was
measured as an additional indicator of glomerular filtration
rate (Bianchi, 1979). In each case, the isotope-labelled
compound was injected via the venous catheter and all blood
samples taken from the aortic cannula. Kidney tissue was
examined by light microscopy using standard methods (Solez
et al, 1980).
For each variable, within-group comparisons between results
at baseline (pre-sepsis) and after 24 hours of sepsis and
between-group comparisons for each variable at baseline and
at 24 hours were made by Student-t test and where
appropriate by non-parametric tests (Wilcoxon Signed Rank or
Rank Sum Tests). Results are shown as mean +_ SEM.
The study conformed to the regulations regarding the care of
experimental animals of the Canadian Council on Animal Care,
and the protocol was approved by the hospital committee
supervising care of experimental animals and the Ethics
Committee of the University of Western Ontario.
9.3. Results
As in the studies performed to establish and validate this
experimental model (Richmond et al, 1986), all 16 animals
had a polymicrobial peritonitis and bacteremia after 24
hours. Organisms grown on blood culture included E.Coli,
Serratia, Enterobacter, Pseudomonas and Bacteroides species;
autopsy showed generalised purulent peritonitis and an
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inflammatory mass in the right lower quadrant. Eight of the
16 animals studied developed acute renal failure, as shown
by an increase in serum creatinine. Since the primary
interest v/as in mechanisms of acute renal failure, the
animals were divided retrospectively into those with an
increase in serum creatinine (Group 1, n = 8) and those
without (Group 2, n = 8), for the purpose of statistical
analysis. As shov/n in Table 15 and Figs 34-36, the increased
serum creatinine in Group 1 animals was accompanied by a
fall in GFR as measured by creatinine clearance and
clearance of DTPA, and marked reductions in urine flow rate
and both absolute and fractional excretion of sodium. This
renal functional change was noted despite maintained
systemic blood pressure, increased CI, reduced SVRI and
maintained CVP and PCWP (Table 16), and despite only a
slight and non-significant reduction in renal plasma flow
(Fig 35). Group 2 animals showed a moderate reduction in
urinary sodium excretion, but no change in GFR. The
increase in CI and fall in SVRI did not achieve significance
in Group 2; MAP, CVP, PCWP and renal plasma flow were
maintained at pre-sepsis levels. In addition to the
changes in CI and SVRI in Group 1 , other markers of severe
sepsis in these animals were an increase in PAP and a more
marked fall in WBC and plasma albumirr than in Group 2 (Table
16).
No consistent or striking changes in renal histology were
noted either in animals developing renal failure or in those
which did not. The changes which were observed included
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Group 1 (n=8) Group 2 (n=8)
Baseline 24 hours Baseline 24 hours
Serum creatinine
(umol/1) 76+4 124+16** 76+6 74+5
Creatinine
Clearance
(ml/min) 142+15 43+8** 152+30 123+14
C DTPA
(ml/min) 134+14 39+17** 152+18 140+12
ERPF(Chippuran)
(ml/min) 875+96 674+75 792+19 746+120
Urine volume
(ml/4h) 1219+165 178+72** 1005+260 771+246
Urinary sodium
excretion
(mmol/4h) 134+15 6+2** 117+18 81+31*
Fractional sodium
excretion {%) 2.9_+0.5 0.5+0.2** 2.6J+0.5 2.0+0.7
* different from baseline (p <0.05)
** different from baseline (p <0.01)
Table 15. Indices of renal function at baseline and 24 hours
after surgical induction of peritonitis (mean +_ SEM).





















Figure 34. Serum creatinine and creatinine




























Figure 35. DTPfl clearance and renal plasma

























Figure 36. Urine volume and sodium excretion
in 16 sheep; sepsis study.
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Group 1 Group 2
Baseline 24 hours Baseline 24 hours
Mean arterial
pressure
(mm Hg) 108+5 90+3* 96+4 100^6
Cardiac index
(L/min/m2) 4.4+0.6 7.6+0.9** 4.1+0.4 4.8+0.4
SVRI 2183+243 1038+107* 2026+244 1677+179
(d/sec/cm-5/m2)
Central venous
pressure 2. 8jh 1 .1 4.4 +0.5 3 . 9j+1 .1 4.0^1.1
(mm Hg)
PCWP
(mm Hg) 9.3+0.8 10.5+1.2 9.5+1.4 10.4+1.1
Pulmonary artery
pressure
(mm Hg) 16+1.3 22+1.1* 18^1.8 21+1.0
White cell count
(x 109/L) 8.8+1.1 2.1+0.2** 0.4+1.0 5.4+0.8
Plasma albumin
(g/dl) 30.3+1.4 20.8+1.9** 32.1+1.5 27+1.1
* different from baseline (p <0.05)
** different from baseline (p <0.01)
Table 16. Haemodynamic variables and indicators of sepsis before
and 24 hours after surgical induction of peritonitis (mean _+ SEM)
SVRI = systemic vascular resistance index
PCWP = pulmonary capillary wedge pressure
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hyperplasia of the juxtaglomerular apparatus (6 animals),
mild tubular dilatation (8 animals), very occasional foci of
tubular regeneration (4 animals), patchy interstitial
infiltrate of mononuclear cells (11 animals) and small foci
of medullary calcification (10 animals). These changes were
evenly distributed among animals with and without renal
failure.
Hormonal changes accompanying sepsis are shown in Table 17
and Fig 37. In Group 1, PRA and urinary excretion rate of
6-keto PGF1<* increased after 24 hours of sepsis. Urinary
kallikrein excretion was reduced compared with baseline
values. Urinary TXB2 excretion rate was unchanged. In
Group 2, PRA and excretion rates of 6-keto PGF1* , TXB2 and
kallikrein were unchanged after 24 hours.
All animals in Group 1 showed at least a 2-fold increase
in plasma norepinephrine after 24 hours of sepsis (mean _+
SEM pre-sepsis, 473 _+ 115 pg/ml, post sepsis 1183 ± 159
pg/ml, p <0.001) (Figure 38). Plasma epinephrine in Group 1
increased in 5 animals, and the increase in mean was
significant (pre-sepsis, 108 _+ 8 pg/ml, post-sepsis 309 _+ 70
pg/ml, p <0.05). In Group 2, neither plasma norepinephrine
or epinephrine increased significantly after 24 hours
(Figure 38).
Studies of correlation indicated that in the 16 animals
studied, there were significant correlations (p <0.05)
between serum creatinine and indicators of severe sepsis,
namely CI (r 0.49), SVRI (r -0.55), WBC (r -0.52) and total
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Group 1 Group 2
Baseline 24 hours Baseline 24 hours
Plasma renin
activity
(ng/ml/hr) 1.12+.48 6.48+1.86** 0.41+.06 0.62^.16
Urine kallikrein
excretion
(nkat/4h) 4.34+1.28 1.11+0.41* 2.05+0.23 2.08+0.51
Urine
6-keto PGF1*
(ng/min) 1.6 +2. 19.9+9.0* 6.2+2.1 9. 6±2.8
Urine
TXB2
(ng/min) 24.5+11.3 19.4+10.1 24.9+13 18.2+6.1
Table 17. Hormonal changes before and 24 hours after surgical



























Figure 37. PRfl and Urinary kallikrein












Figure 38. Plasma catecholamines in 16
sheep: sepsis study.
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protein (r -0.45). Plasma renin activity correlated with
serum creatinine (r 0.50) and inversely with C DTPA (r -
0.52), urine volume (r -0.67), urinary sodium excretion (r -
0.74) and plasma albumin (r -0.52). Urinary kallikrein
excretion correlated positively with urine volume (r 0.74),
urinary sodium excretion (r 0.57), and plasma albumin (r
0.75). In the renal failure group, urinary kallikrein
excretion correlated with urine volume (r 0.76) and serum
albumin (r 0.76). Overall, there were significant inverse
correlations between plasma norepinephrine and SVRI {r -
0.62), serum albumin (r -0.70), white cell count (r -0.60),
and DTPA clearance (r -0.57), and a positive correlation
with CI (r 0.64) and plasma epinephrine (r 0.58). Plasma
epinephrine correlated with plasma renin activity (r 0.61).
Combining the PRA and the urinary kallikrein excretion rate
as a PRA/UKallV ratio revealed a highly significant
correlation between the ratio and urinary sodium excretion
(r -0.82, p<0.01). There were weaker (p<0.05) correlations
between the ratio and plasma norepinephrine (r 0.55) and
plasma albumin (r -0.62).
9.4. Discussion
The animal model of sepsis utilised in this study differs
from most other experimental models of sepsis and
endotoxemia in that it reproduces the state of volume-
loaded, normotensive or near-normotensive, and vasodilated
septic shock typically seen in clinical practice (Kikeri et
al, 1986). Use of a large animal provides sufficient sample
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size to permit simultaneous assessment of several vasoactive
hormone systems in the same animal. In this model, acute
renal failure reliably ensues in the presence of severe
sepsis, as manifested by increased CI, decreased SVRI,
increased PAP, and a large decline in white cell count and
plasma albumin (Walker et al, 1986). The pattern of renal
dysfunction, ie, reduced GFR, reduced urine volume and very
low absolute and fractional sodium excretion, resembles
that associated with reduced renal perfusion - "pre-renal"
renal failure (Pru and Kjellstrand, 1985). In severe
sepsis, however, it occurs despite normal systemic blood
pressure, maintained CVP and PCWP, and preserved renal
plasma flow. There is no evidence of severe renal
structural damage, either to glomeruli or tubules,
sufficient to account for the marked reduction in GFR and
sodium/water excretion. This type of "sodium-retaining"
acute renal failure characterised by low fractional sodium
excretion, but distinct from renal hypoperfusion and
intrinsic renal damage, has recently been documented in
early experimental endotoxemia in rats (Kikeri et al, 1986)
and in several clinical contexts, including sepsis, burns,
myoglobinuria, and hepatic cirrhosis (Saha et al, 1987).
The pathophysiology underlying this syndrome remains
unclear, but it may reflect at least in part the influence
of systemic and intra-renal vasoactive hormone systems known
to affect renal function (Schaller et al, 1985). Decreased
urinary kallikrein excretion, with increased PRA and
increased excretion of 6-keto PGF1<*, was observed in animals
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developing renal failure. The explanation for these
observations, in the absence of significant hypotension or
volume contraction, is not readily apparent. It is known,
however, that under physiological conditions, activation of
the sympathetic nervous system either by nerve stimulation
or catecholamine infusion, can mediate increased renal renin
release (Johnson, Schrier and Barger, 1979), decreased
urinary excretion of kallikrein (Albertini et al, 1981), and
can activate phospholipase enzymes leading to increased
renal synthesis of prostanoids (Vandongen, O'Dwyer and
Barden, 1 982). It is therefore of interest that all the
animals which developed renal failure during sepsis showed
at least a two-fold increase in plasma norepinephrine, and
the majority also showed a rise in plasma epinephrine.
Statistically plasma norepinephrine correlated inversely
with GFR, and also correlated with several indicators of
systemic sepsis - raised CI and reduced SVRI, serum albumin
and WBC. This suggests that systemic sepsis sufficiently
severe to cause a hyperdynamic, vasodilated circulation is
associated with increased sympathetic activity, secondary
changes in intra-renal neuro-endocrine systems such as
renin-angiotensin and kallikrein-kinin, and the development
of renal failure. The statistical correlations could,
however, be casual and do not demonstrate a functional
relationship. The reciprocal changes in PRA and kallikrein
excretion seen in our study resemble the effects of SNS
stimulation under physiological conditions, and contrast
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with the effect of other experimental procedures such as
sodium depletion or hypotensive hemorrhage, which in general
alter these parameters in parallel (Maier and Binder, 1979).
The overall effect of the renin-angiotensin-aldosterone
system on kidney function is vasoconstrictor and sodium-
retaining (Kotchens and Roy, 1983), whereas the renal
kallikrein-kinin system may mediate vasodilatation and
facilitate sodium and water excretion, as previously
discussed. These indirect effects of SNS stimulation in
sepsis could therefore augment any direct effects on renal
function.
As in other contexts described in previous Chapters, the
strongest determinant of sodium excretion in this study was
the PRA/UKallV ratio. The studies of correlation suggested
an influence of the sympathetic nervous system on this
parameter. They also suggested that the serum albumin
concentration, which fell rapidly during sepsis, might be an
important influence on these intra-renal systems. This
possibility is explored further in Chapter 10.
Plasma epinephrine correlated with PRA; this is of interest
since intravenous infusion of epinephrine is more effective
in raising PRA than norepinephrine in conscious dogs
(Johnson, Schrier and Barger, 1979). In addition,
angiotensin II potentiates neuromuscular transmission and
stimulates release of epinephrine from adrenal medulla
(Harrison, Birbari and Seaton, 1973); this mechanism could
amplify the neuro-endocrine response to sepsis.
The initial event which triggers systemic vasodilation in
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sepsis, leading to the compensatory responses described
above, is unclear. However, bacterial endotoxins are potent
activators of the plasma "contact systems", through Hageman
factor; these include the plasma kallikrein-kinin system, as
outlined in the introduction (Kaplan, Meier and Mandle,
1977). It is known that the plasma kallikrein-kinin system
is activated in septic shock, and kinins may well be
important in the systemic vasodilation and increased
capillary permeability seen in sepsis (Mason et al, 1970).
We were unable to measure plasma prekallikrein in sheep
because of very low activity of sheep kallikrein against
S2302. Figure 39, however, shows plasma prekallikrein in 9
patients with septic shock and acute renal failure; all
patients had values below the normal range, and the
survivors showed a return to normal during recovery.
Experimental studies of the effect of kallikrein inhibition
with aprotonin in the sheep model are in progress in our
laboratory. While inhibition of the renal kallikrein-kinin
system might exaggerate the renal response if the above
hypotheses are correct, this might be outweighed by a
beneficial effect on systemic haemodynamics because of
reduced plasma kinin generation. An outline of the
hypothetical mechanisms leading to sodium-retaining acute
renal failure during non-hypotensive sepsis is shown in
Figure 40, indicating the putative involvement of the plasma
and renal kallikrein-kinin systems. Clinical studies of


















Figure 39. Plasma prekallikrein in 9




































Figure 40. Outline of hypothetical mechanism
for the ocurrence of "sodium-retaining" acute
renal failure in sepsis, indicating possible
roles of plasma and renal kallikrein-kinin
systems.
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"sodium-retaining" acute renal failure does occur in
patients with sepsis, and that a similar pattern of renal
function and of neuro-endocrine systems is seen. Figs 41 and
42 show detail of a 42-year old female with a wound
infection after spinal surgery, and Serratia marcensens on
blood cultures, during a period of acute renal failure and
during convalescense.
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Wound infection after spinal surgery (serratia on blood culture)
ARF after 5 days





















































CHAPTER 10 INFLUENCE OF THE PLASMA PROTEIN CONCENTRATION
ON URINARY KALLIKREIN EXCRETION
10.1. Introduction
In nephrotic syndrome (Chapter 7), cirrhosis (Chapter 8),
and septic shock (Chapter 9), abnormal excretion of urinary
kallikrein was observed in association with a reduction in
plasma protein concentration, although the relationship was
not qualitatively consistent. Experimental evidence suggests
that the plasma protein concentration is an important
determinant of glomerular and tubular function (Green,
Windhager and Geibisch, 1974). For example, after acute
volume expansion, the plasma protein concentration falls
acutely; this is thought to increase renal plasma flow by
reducing plasma viscosity, to increase GFR because of a
lower oncotic pressure in glomerular capillaries, and to
impair tubular sodium reabsorption because of a lowered
oncotic pressure in proximal peritubular capillaries (Earley
and Freidler, 1965; Grausz, Leiberman and Earley, 1972;
Blantz, Rector and Seldin, 1974; Baylis et al, 1977; Baum
and Berry, 1985). This last effect would increase distal
delivery of sodium and water, and could thereby influence
renin release from the macula densa and kallikrein release
from the distal tubule (Hall and Guyton, 1976; Thurau,
1966). It was therefore of interest to examine the effect on
renal function, and on kallikrein excretion, of an acute
fall in plasma protein concentration. This can be achieved
in animals by a form of plasmapheresis, involving removal of
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whole blood and reinfusion of packed cells and crystalloid
(Kramer et al, 1982; Manning and Guyton, 1983). The fall in
plasma oncotic pressure is associated with loss of fluid
from the systemic circulation, which could influence renal
function directly (Knox et al, 1983); to avoid this, central
volume was monitored with a Swann-Ganz pulmonary artery
catheter, and additional crystalloid infused to maintain the
pulmonary artery occlusion pressure (PAOP).
10.2. Materials and Methods
7 healthy female sheep were studied, weighing 40-50 kg. On
Day 1 they underwent brief general anaesthesia. An
introducer was inserted in the external jugular vein for
Swann-Ganz catheterisation and IV infusion; an arterial line
was inserted in the carotid artery for blood removal and
blood pressure monitoring; a urethral catheter was inserted.
400 ml blood was removed via arterial line, centrifuged, and
the plasma separated. The cells were reconstituted with an
equivalent volume of 0.9% sodium chloride, and the blood
stored at -4 C. A background infusion of Ringers solution
1 00 ml/hr and 5% dextrose 50 ml/hr was begun and continued
throughout the study. A 16 hour urine collection was
performed.
The protocol on Day 2 is shown in Fig 43. The plasmapheresis
procedure consisted of the removal of 3 units of 400 ml
whole blood, with the simultaneous reinfusion of 3 units of
cells reconstituted with saline, using the unit from Day 1
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pressure, systemic blood pressure and cardiac output were
monitored at 15 minute intervals, and Ringers solution
infused as required to maintain PAOP.
Blood samples were analysed for creatinine, total protein,
albumin, sodium, potassium, osmolarity, haematocrit and PRA.
Urines were analysed for creatinine, sodium, potassium,
osmolarity and kallikrein.
Control studies were performed in 5 sheep, using the
identical protocol, except that after centrifugation of the
removed blood, the cells and plasma were reconstituted and
reinfused together.
10.3. Results
In the saline replacement animals, the mean volume of plasma
removed was 820 ml, and the mean volume of Ringers solution
infused to maintain PAOP was 1300 ml/study. In controls, the
mean volume of plasma separated and reinfused was 810 ml,
and the additional Ringers solution infused during line
flushing and priming was 250 ml. As shown in Fig 44, plasma
total protein and albumin fell by 21% and 24% respectively
during plasmapheresis. PAOP and mean arterial pressure were
maintained during the study (Fig 45). There was no
significant change in urine volume, urinary sodium
excretion, FENa, or creatinine clearance (Figs 46,47,48).
There was a significant rise in urine osmolarity, and a fall
in free water clearance and plasma osmolarity (Figs 48,49),
following plasmapheresis. PRA and urinary kallikrein
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Figure 45. Pulmonary capillary wedge
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Figure 49. Plasma and urine osmolarities;
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In the control studies, there was a transient increase in
urine volume and urinary sodium excretion after
plasmapheresis, with no change in any other parameters (Fig
51 ) .
10.4. Piscussion
The modest natriuresis and diuresis seen in control
experiments probably reflected the crystalloid
administration which was required for line priming and
flushing during the "sham" plasmapheresis procedure. Perhaps
surprisingly, the acute reduction in plasma protein/albumin
concentration in the plasmapheresis experiments was
associated with no alteration in renal function, other than
some changes in water handling. While we v/ere not able to
measure plasma AVP in sheep, the increase in urine
osmolarity and fall in free water clearance, in face of a
reduction in plasma osmolarity, is pathognomonic of AVP
release (Skowsky and Fichman, 1984). This link between
hypoproteinaemia and non-osmotic release of AVP is of
considerable interest, and could relate to abnormalities of
renal function in nephrotic syndrome and cirrhosis, as
discussed in Chapter 8 (Wilkinson et al, 1979).
The absence of an effect on sodium excretion could have
several explanations. The changes in proximal tubular
function seen in micropuncture experiments may not occur in
intact kidneys, or be confined to those superficial nephrons
accessible to micropuncture (Baylis et al, 1977).
Alternatively, there may be a compensatory fall in GFR,
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although our creatinine clearance measurements argue against
this, or the distal tubule may compensate by an increase in
tubular sodium reabsorption (Ichikawa et al, 1983). The
absence of any effect on renin release or urinary kallikrein
excretion perhaps suggests that there is no major change in
distal fluid delivery. The results suggest that the plasma
protein concentration is not a major determinant of urinary
kallikrein excretion, in the absence of changes in
circulating volume. Alternative explanations for the altered
kallikrein excretion in clinical hypoproteinaemic states,
such as the nephrotic syndrome, are required.
CHAPTER 11 DISCUSSION
11.1. Plasma kallikrein-kinin system
Despite extensive study, the role of the plasma kallikrein-
kinin system in health and disease remains unclear.
Conceptually, it seems unlikely that such an effectively
inhibited system has a major role in homeostasis. The plasma
concentrations of kallikrein inhibitors such as C1 esterase
inhibitor and 1 -proteinase inhibitor greatly exceed that
required for maximal inhibition under normal conditions
(Ratnoff et al, 1969), and plasma kinins are almost
completely destroyed during a single pass through the lungs
(Regoli and Barabe, 1980). Rabito showed elegantly that
glandular kallikrein reaching the circulation only
influenced systemic haemodynamics if kininase activity was
simultaneously blocked by captopril (Rabito et al, 1983).
Under physiological conditions, kallikrein inhibition by
aprotonin has no effect on systemic haemodynamics, or on
renal function (Royston et al, 1987; Kramer et al, 1984).
Similarly, the newly synthesised kinin receptor antagonists
do not appear to influence blood pressure in normotensive or
hypertensive animals (Waeber et al, 1988). While further
work with these compounds is necessary for confirmation, it
seems reasonable to conclude that the plasma kallikrein-
kinin system is an "off" system under basal conditions, and
does not have a significant role in physiology.
In contrast, it seems likely that the plasma kallikrein-
kinin system is involved in the pathogenesis of at least
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some disease states. Kinins are the most potent known
vasodilator compounds, and are important mediators of local
inflammatory responses and tissue injury (Marceau et al,
1983). Kallikreins are chemotactic for human neutrophils
(Kaplan, Kay and Austen, 1971), and as described above, the
plasma kallikrein-kinin system interacts importantly with
the coagulation, fibrinolytic and complement systems, and
with the arachidonic acid metabolic pathways (Kaplan, Meier
and Mandle, 1977). Abnormalities of the plasma kallikrein-
kinin system have been described in a wide variety of
clinical states, but in most cases this consisted of a
reduction in plasma prekallikrein. Current methodology makes
it difficult to ascribe this to either increased activation
and metabolism, or decreased synthesis, with any degree of
certainty. We too have observed low plasma prekallikrein in
disease states, namely septic shock and hepatic cirrhosis.
We found spontaneous "kallikrein-like activity" against
S2302, within the detection limit of the assay, to be
extremely rare, such that the results are not amenable to
detailed analysis, and have not been presented here. This
does not exclude kallikrein-kinin system activation, since
free kallikrein would bind to inhibitors in plasma, and has
a plasma half-life of aproximately 5 minutes (Friberger et
al, 1979). The reduced plasma prekallikrein must however be
regarded as suggestive, rather than confirmatory, of plasma
kallikrein-kinin system activation in these conditions.
The next step in defining the sigificance of these
observations would be studies using inhibitors of the plasma
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kallikrein-kinin system. It has recently been found that the
dose schedule for aprotonin used in all previous
experimental and clinical studies is too low to inhibit
plasma, as opposed to glandular, kallikrein, by a factor of
approximately 20 (Fritz and Wunderer, 1983; Dr F Schumann,
Bayer FRG, personal communication). In any case, previous
studies of aprotonin in cirrhosis are lacking, and studies
in sepsis are of doubtful quality (Sumida, 1979;
Rosengarten, 1979); in particular, none involved any
measurements to ensure effective kallikrein inhibition. I am
currently studying the effect of high-dose aprotonin in the
ovine septic shock model described in Chapter 9; preliminary
results suggest a marked beneficial effect on systemic
haemodynamics, and in particular, prevention of progressive
vasodilation.
The most potent trigger to the plasma kallikrein-kinin
system is activation of Hageman factor by endotoxin.
Endotoxin in plasma is increased in both septic shock and
cirrhosis (Wardle, 1982; Papper, 1982). Interestingly, these
two conditions also have in common a tendency to systemic
vasodilation, and a pattern of renal function involving
sodium retention despite normal renal plasma flow. This
pattern of renal function has been ascribed to a low
"effective plasma volume" (Nicholls et al, 1986). It is
possible that kallikrein-kinin activation promotes a fall in
systemic vascular resistance; the subsequent fall in blood
pressure is minimised by reflex activation of pressor
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systems such as the sympathetic nervous system and renin-
angiotensin. This induces similar changes in renal function
to "genuine" plasma volume contraction. Plasma volume
expansion would tend to promote further vasodilation, partly
via release of the vasodilator prostaglandin PGI2 from
endothelium (Hamilton, Rosza and Hutton, 1981); kinins could
exaggerate this effect by activation of Phospholipase A2
leading to increased arachidonic acid substrate (Regoli and
Barabe, 1930). This would explain the "volume-resistance"
seen in both clinical contexts. A study of patients after
instrumentation of the urinary tract found associations
between endotoxaemia, a reduction in plasma prekallikrein
concentration, and a fall in systemic vascular resistance
(Robinson et al, 1975). While this hypothesis (Figure 40) is
speculative, it is in keeping with known physiological and
pathophysiological mechanisms; it is also testable with the
availability of kallikrein and, more recently, kinin
inhibitors. It is also relevant to the introduction of anti-
endotoxin antibodies and purified 1-proteinase inhibitor
for prophylactic and interventive use.
11.2. Renal kallikrein-kinin system
11.2.1. Anatomical location and functional implications
The findings described in Chapter 5, that kallikrein is
located in the glomerular peripolar cell in addition to the
cells of the distal tubule, are of considerable importance.
Confinement of renal kallikrein to cells of the distal
nephron would not necessarily preclude an effect on
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glomerular or proximal tubular function, or on renal
vascular tone, since release of immunoreactive kallikrein
into the renal interstitium and renal lymph has been
demonstrated (Proud et al, 1983). Nevertheless, such
release, with subsequent uptake by lymphatics, would be a
relatively inefficient and variable mechanism in biological
terms, and would not facilitate precise interaction with
other intrarenal regulatory systems.
In vitro, kinins and prostaglandins antagonise the actions
of AVP on distal tubular and collecting duct epithelium, and
some in vivo studies have found correlations between
kallikrein and water excretion (Schuster, Kokko and
Jacobsen, 1984; Mills and Ward, 1975). It is tempting to
speculate that this is the primary function of the distally
located kallikrein and the kinin which is generated at this
locus. Kramer and Dusing have shown that aprotinin markedly
potentiates the effects of DDAVP on urine flow and urine
osmolarity in the rat (Kramer at al, 1 984). It would be
predicted in this case that the effect of distally released
kallikrein on water handling would depend critically on the
prevailing AVP concentration. This has not been tested
experimentally, and detailed studies of the relationship
between AVP and kallikrein effects on collecting duct
function would be of interest.
In all the studies described in this thesis, the correlation
of kallikrein excretion with sodium excretion has been
stronger than that with water excretion; this aspect of the
findings is discussed below. Sodium excretion is dependent
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on glomerular filtration rate, proximal and distal tubular
sodium reabsorption, and the function of the tubulo-
glomerular feedback mechanism (De Wardener et al, 1978;
Licht and Danovitch, 1983). The juxtaglomerular apparatus is
centrally involved in the regulation of each of these
parameters (Fray, 1980). The finding of kallikrein at this
site therefore greatly increases the potential role of
kallikrein in the regulation of sodium excretion. The
stimuli to release of kallikrein from cells are imprecisely
defined (see introduction). The juxtaglomerular apparatus is
richly innervated by sympathetic nerve fibres, incorporates
a baroreceptor-like mechanism, and also responds to changes
in volume and composition of distal tubular fluid (Dzau,
Burt and Pratt, 1988). It is of interest that in the
isolated perfused kidney, there is a direct association
between the renal perfusion pressure and kallikrein
excretion (Bevan, McFarlane and Mills, 1974), and that both
renal nerve stimulation and infusion of noradrenaline appear
to supress kallikrein excretion (Albertini et al, 1981;
mills, 1980). The potential importance of renin-kallikrein
interactions at the juxtaglomerular site is discussed below.
Injected radio-labelled kallikrein is largely degraded
before reaching the final urine (Mills, Paterson and Ward,
1 975; Rabito et al, 1 985); some of this metabolism is
ascribed to uptake by the proximal tubule. It must therefore
be asked to what extent measurement of urinary kallikrein
gives information regarding release from peripolar cells.
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The pattern of immunoperoxidase staining shown in Chapter 5
suggests that quantitatively, most of the kallikrein in
kidney is in distal tubular cells, and it therefore seems
likely that most of the kallikrein in urine derives from
this source. Micropuncture studies have suggested that most
kininogenase activity enters the tubular lumen at the level
of the distal tubule and collecting duct (Scicli et al,
1976). It is possible, however, that the peripolar cells and
the kallikrein-containing distal tubular cells react in a
similar fashion to relevant stimuli, in which case the
urinary kallikrein excretion rate would be a measure of
release at both sites. It even conceivable that proximal
kallikrein release might in itself tend to stimulate release
from distal sites, by increasing delivery of fluid to the
distal tubule. Many of the situations in which urinary
kallikrein excretion is increased are characterised by
increased distal fluid delivery; these include acute volume
expansion, infusion of renal vasodilators, and
administration of loop diuretics, as discussed previously.
Further studies are required to confirm or refute this
hypothesis.
11.2.2. Relationship to sodium excretion
A fundamental question regarding the renal kallikrein-kinin
system concerns its influence on sodium excretion. Since the
pioneering work of Mills and colleagues in the 1970's, it
was generally held that kallikreins and kinins facilitated
sodium excretion (Mills, 19S2). In 1983, Marks and Keiser
challenged this assumption, and suggested that kallikrein-
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kinin was a sodium retaining system (Marks and Kieser,
1983). Their main evidence was a study involving modest
volume expansion with normal saline in rats. As in our human
studies, they observed an early increase in urinary
kallikrein excretion, peaking within 1 hour. Thereafter,
however, UKallV fell, and at times was lower than control
values. There was no correlation between UNaV and UKallV.
Adrenalectomy reduced basal UKallV by 50%, but the response
to volume expansion was unaffected. They also took account
of previous work, showing that kallikrein stimulates sodium
transport in the isolated toad hemi-bladder (Orce, Castillo
and Margolius, 1981).
Against this rather tenuous evidence must be set a
considerable body of data favouring a natriuretic effect of
renal kallikrein-kinin activation. While none of these
experiments is conclusive in itself, I would suggest that
overall they suffice to make any other view untenable. As
described in Chapter 1 , infusion of kinins into the renal
artery increases sodium excretion (Mills, 1979); cross-
clamping experiments suggest that this is primarily a renal
vasodilator effect, although the action of intra-luminal
kinins may be different (Kauker, 1980). Systemic infusion
of glandular kallikrein produces a shock-like syndrome, and
the effects on renal function are difficult to interpret
(Mills, 1979). Both the kallikrein inhibitor aprotonin and
anti-kinin antibodies reduce sodium excretion, although the
aprotonin effect is only seen in volume expanded animals
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(Kramer et al, 1984). Kallikrein excretion increases in
response to increased dietary sodium, and to acute infusion
of isotonic sodium chloride. Lewis et al (1988) recently
found no increase in kallikrein excretion in man after a 2
litre saline infusion, whereas the study described in
Chapter 5 clearly shows such an increase after a 3 litre
infusion, suggesting that there may be a threshold for the
acute effect of volume expansion on UKallV. This v/ould also
explain some other divergent results in animal studies of
this response. It should be noted that in the studies
described in this thesis, the correlation between urinary
kallikrein excretion rate and sodium excretion rate was
always positive rather than inverse. This was true in
situations ranging from normal man under basal and
stimulated conditions, through to man and experimental
animals in the presence of renal and extrarenal disease, and
contrasted to the correlations between PRA and UNaV, which
were always inverse. The statistical significance of the
UKallV / UNaV correlation was usually weak; this might be
expected in view of the multitude of factors influencing
sodium excretion and the imprecise manner in which urinary
kallikrein excretion probably reflects intrarenal events
(Fuller and Funder, 1987). Accepting that studies of
correlation must be interpreted with caution, it would be
expected that if the renal kallikrein-kinin system was
either antinatriuretic or neutral in relation to sodium
excretion, an inverse or absent correlation would have
occured in at least some of these experiments. Overall, it
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seems clear that the renal kallikrein-kinin system is indeed
a natriuretic mechanism, although the precise relationship
with other natriuretic and sodium-retaining systems must be
defined.
11. 2. 3. Relationship to the renin-angiotensin system
The concept that the renal kallikrein-kinin system and the
renin-angiotensin system are functionally linked is not new.
However, in these studies, use of modern immunocytochemical
methods and powerful computer-based statistical techniques
has shed additional light on this relationship.
Writing in 1975, Pisano pointed out the strikingly close
homology in the organisation of these two systems (Fig 16).
He suggested on this basis that they had evolved in parallel
as counter-regulatory mechanisms. In 1977, Levy et al first
calculated the ratio of PRA to urinary kallikrein excretion,
in a study of hypertensive patients and their relatives
(Levy et al, 1977). They found a close correlation between
this ratio and renal blood flow, which was reduced in the
hypertensive subjects. They did not comment on any other
correlations, such as with sodium excretion. Mills had
previously suggested that one possible action of the renal
kallikrein-kinin system might be to protect the renal
vasculature against the vasoconstrictor action of locally
generated Angiotensin II (Mills et al, 1972). It was
suggested that renal release of kallikrein was under dual
control. Sodium loading increased UKallV, as described
above, possibly through a volume or pressure-sensing
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mechanism. UKallV was also increased, however, during sodium
restriction or hypotensive haemorrhage; this could be
secondary to activation of the renin-angiotensin system.
Studies infusing Angiotensin II into the renal artery tended
to support this idea, with an increase in UKallV coinciding
with development of resistance to the vasoconstrictor effect
(McFarlane, Adetuvibi and Mills, 1974). A further boost to
interest in this relationship came when Sealey and Laragh
described the ability of renal kallikrein to activate
prorenin (Sealey et al, 1978) ; aprotonin was shown to
reduce captopril-stimulated renin release, and bradykinin
was also shown to stimulate renin release from kidney slices
(Beierwaltes, Prada and Carretero, 1985). Subsequently,
however, doubt was cast on the significance of the studies
of Sealey et al, and this area has received little attention
in recent years (Hsueh, 1980).
Teleological considerations would favour a link between the
kallikrein-kinin system and the renin-angiotensin system. In
all our studies, the correlation of PRA with sodium
excretion was stronger than that between UKallV and sodium
excretion, suggesting that the renin-angiotensin system has
"primacy" in this area. In evolutionary terms the first
requirement of land-based organisms would be a mechanism to
retain sodium and water and preserve ECF volume. Later, as
access to salt and water increased, a counter-regulatory
mechanism to prevent sodium overload, hypertension, and
heart failure would be advantageous. Such secondary
evolution would fit with the relative paucity of peripolar
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cells in most species. It is of interest that sheep, which
exist in a low-sodium environment, have a very prominent and
cellular juxtaglomerular apparatus, readily increase PRA in
response to stimuli, and have the largest number of
peripolar cells in species so far examined.
There are obviously a number of other candidates for the
type of counter-regulatory action described above; these
include renal prostaglandins, dopamine, atrial natriuretic
peptide, and endogenous oubain-like Na-K ATPase inhibitors.
It is likely that some or all of these do function in
concert with the renal kallikrein-kinin system, either as a
"cascade" (Mills, 1982), or in a "network" fashion. The
kallikrein-kinin system differs, however, in that a close
anatomical relationship with the "control centre" of the
renin-angiotensin system has now been demonstrated; such a
localisation would be predicted to optimise rapid and
effective functional linkage. The observed correlations
between the PRA/UKallV ratio and sodium excretion in these
studies, in some cases as high as r =0.91, suggest that the
relative activity of the renin-angiotensin system and the
renal kallikrein-kinin system is a powerful determinant of
sodium excretion. This conclusion is subject to various
caveats. Statistical association does not prove causality.
However, when a correlation recurs with a high degree of
significance in a large number of independent experimental
situations, as here, it cannot be ignored. The use of
derived ratios is often regarded with scepticism.
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Nevertheless, this ratio is firmly based on anatomical,
biochemical and physiological considerations, as reviewed
above, rather than eclectic considerations. It might be
suspected that the observed correlations were a result of
combining two relatively weak correlations into a single
strong one. In fact, the combination of two variables in
this manner is equally likely to weaken or destroy any
correlation, as to strengthen it (Dr Robert Elton, Dept of
Medical Statistics, University of Edinburgh, personal
communication). In every case described here, the degree of
correlation of the ratio with sodium excretion was greater
than PRA or UKallV alone. If a single agent was found to
correlate with UNaV to this extent, there would be little
doubt about its recognition as an important determinant of
sodium excretion.
If, as suggested by the results described, up to 80% of the
variability in sodium excretion can be accounted for by
changes in the PRA/UKallV ratio, it is tempting to speculate
that other factors which influence sodium excretion might
operate by modulation of this central relationship, rather
than functioning in a parallel fashion. For example, both
intrarenal dopamine and atrial natriuretic peptide tend to
supress renal renin release, but have no supressive effect
on kallikrein release (Brownlee et al, 1986; Firth, Raine
and Ledingham, 1989); they would therefore be predicted to
lower the PRA/UKallV ratio, in association with natriuresis.
These mediators of course have their own receptors in the
kidney; however, the extent to which kallikrein-kinin
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blockade inhibits their renal actions is not known.
Conversely, renal nerve stimulation will increase PRA and
tend to lower UKallV, in association with a reduction in
urinary sodium excretion (Albertini et al, 1981). An outline
of this hypothesis is shown in Fig 52.
At the time of writing, studies of the renin-kallikrein-
sodium relationship have proved informative in the nephrotic
syndrome, in hepatic cirrhosis, and in acute renal failure
due to sepsis. Collection of similar data is in progress in
essential hypertension (Levy et al, 1977), in diabetes
mellitus (Mayfield et al, 1 985 ) > and in cardiac failure. In
addition to aiding understanding of pathophysiology, these
studies may have therapeutic implications. For example, in
sodium-retaining acute renal failure, the ideal intervention
would be an agent which supressed the renin-angiotensin
system while potentiating or maintaining kallikrein-kinin
activity. Captopril, which fulfills the former requirement,
has been used in experimental studies of ARF, but has
proved disappointing; for example, in the sheep sepsis
model, it was associated with rapid deterioration in renal
function (Dr FJ Walker, personal communication). It is
therefore of interest that we observed profound reductions
in UKallV during captopril therapy. Loop diuretics, which
stimulate UKallV (Overlack et al, 1982), have also proved of
little value in ARF (Werb and Linton, 1979); this could
reflect the concomitant stimulation of the renin-angiotensin












Figure 52. Diagram of hypothetical counter-
regulatory linkage between renin-angiotensin
and kallikrein-kinin systems in the kidney.
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Dopamine, which does appear of value, would be expected to
lower the PRA/UKallV ratio, as discussed above. ANF infusion
is likely to have a similar effect, and early results in
ARF are encouraging (JD Conger, personal communication).
11.2.4 Kallikreins and kinins as mediators of renal
inflammation
In this and previous studies of the renal kallikrein-kinin
system, attention has focussed on the role of these
compounds in the regulation of renal function, rather than
on a possible role as mediators of intra-renal inflammation.
In this and a few previous studies, no abnormality of
urinary kallikrein excretion was found in
glomerulonephritis without heavy proteinuria (Glasser and
Michael, 1976). This does not exclude an effect of
kallikreins and kinins in the pathogenesis of renal disease
in these patients; however, it seems likely that in most
circumstances, the ability of the kidney to degrade
kallikreins and kinins prevents such an effect. In contrast,
urinary kallikrein excretion is elevated in most patients
with nephrotic syndrome, sometimes to extremely high values.
Taken in conjunction with the known potent effect of kinins
on capillary permeability (Regoli and Barabe, 1980), and the
known ability of intra-renal kallikrein infusion to cause
heavy proteinuria (Murakami, Hori and Masamura, 1968), this
finding engenders speculation that the renal kallikrein-
kinin system is of pathogenetic importance in this
syndrome. Recently, increased salivary kallikrein has been
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observed in patients with chronic recurrent parotitis, a
disease of previously unknown aetiology. In addition,
patients with this condition were found to respond rapidly
and completely to systemic infusion of high dose aprotonin
(Maier et al, 1935). The parallel with nephrotic syndrome is
readily apparent, and studies of the effect of aprotonin in
nephrotic syndrome are in progress. Murakami in 1968 claimed
to have abolished proteinuria in patients by giving
aprotonin, but this claim has never been substantiated or
repeated. The nature of the stimulus to kallikrein release
in nephrotic syndrome, and the mechanism whereby the renal
kallikrein-kinin system "escapes" from inhibition in this
condition, are unclear, although important inhibitors such
as «1-proteinase inhibitor, C1-esterase inhibitor and
endogenous aprotonin will be lost in urine in nephrotic
syndrome, perhaps leading to a "vicious circle" phenomenon.
It is likely that these proteinase inhibitors will soon be
available for therapeutic use as a result of recombinant DMA
technology.
11. 2. 5. Future trends
The studies described in this thesis have left many
questions unanswered. This has, however, been true of all
previous studies in this field, and over the years many
eminent researchers have abandoned study of the kallikrein-
kinin system without reaching definitive conclusions. Recent
developments have opened exciting new avenues of research.
The availability, after years of searching for these
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compounds, of specific kinin receptor antagonists, should
lead to an increased understanding of kinin actions in the
kidney and elsewhere (Vavreck and Stewart, 1987). Advances
in methodology and assay technology, such as the use of
monoclonal antibodies in specific enzyme-linked
immunoadsorbent assays for kallikrein, offer improved
assessment of enzyme levels in biological fluids. Perhaps
most exciting is the cloning of kallikrein genes in mouse,
human and other species, and the availability of
complementary DNA probes for these genes (Mason et al, 1983;
Bell et al, 1 984). I am currently involved in studies
correlating urinary kallikrein excretion <vith the presence
of restriction fragment length polymorphisms around the
kallikrein genes in patients with contrasting risks of
hypertension. I am also developing techniques of in situ DNA
hybridisation to assess kallikrein gene expression in kidney
tissue, in parallel with studies of renin gene expression.
These and other powerful molecular biology techniques hold
the promise of an answer to many of the unanswered questions
regarding kallikrein and kinins, and their importance in
health and disease.
1 66
List of publications describing results in this thesis
Cumming AD and Robson JS.
Urinary kallikrein excretion in glomerulonephritis and
nephrotic syndrome.
Nephron, 1985; 39: 206-210.
Watson ML, Cumming AD, Lambie AT and Oates JA.
Urinary kallikrein and systemic prostacyclin synthesis
during sodium chloride infusion in normal man. Clinical
Science, 1985; 58: 537-543.
Cumming AD and Lambie AT.
Urinary kallikrein excretion in chronic renal failure;
relationship to blood pressure and the acute effect of
captopril.
Renal Failure, 1987; 10: 159-165.
Cumming AD, Driedger AA, McDonald JW, Lindsay RM, Solez K
and Linton AL.
Vasoactive hormones in the renal response to systemic
sepsis.
American Journal of Kidney Diseases, 1988; 11: 23-32.
Cumming AD, Kline R and Linton AL.
Association between renal and sympathetic responses to non-
hypotensive systemic sepsis.
Critical Care Medicine, 1988; 16: 1132-1137
Cumming AD, Jeffrey S, Lambie AT and Robson JS.
The kallikrein-kinin and renin-angiotensin systems in
nephrotic syndrome.
Nephron, 1989; 51: 185-191.
1 67
ACKNOWLEDGEMENTS
I acknowledge the invaluable assistance of the many people
who have contributed to the work described in this thesis,
and who have supported and encouraged me since it began. Dr
Anne Lambie has shown unfailing interest and enthusiasm for
the project, and has offered invaluable advice. Professor
James Robson, in addition to providing much of the practical
support which has made this work feasible, has also been a
source of constructive criticism and advice. Dr Michael
Watson approved my initial interest in this field and
provided invaluable early collaboration. My other colleagues
in Edinburgh, including Dr Robin Winney, Dr Charles
Swainson, Professor Michael Lee and Professor Ian Bouchier,
in addition to letting me study patients under their care,
have been available for helpful discussions and have helped
to clarify several areas of uncertainty. In Canada, Dr Adam
Linton was a great source of encouragement, and gave me
access to a wide range of research facilities. In the
Department of Pathology, Dr Mary MacDonald and Dr David
Thomson provided support and practical resources. I am also
grateful to my junior colleagues who have collaborated in
different aspects of this work; Dr Tim Walsh, Dr Tom
McDonald, Dr Frank Walker and Dr Peter Hayes.
The bulk of the technical assistance in this project has
been provided tirelessly by Sheena Jeffrey, who has never
objected to the extra work involved over and above her
service commitments. Kate Craig and Anne Macnicol have
been indispensable in many of the patient studies, and
1 B 8
Kate has also spent many hours feeding data to computers for
analysis. Bella Sanger and the technical staff of the Renal
Laboratories, and in Canada, Ande Honan and Brian Dennis,
gave essential technical help and support, and John Cowie
has provided his expertise in the field of computing. Dr
Robert Elton has enlightened me on finer points of
statistics and reassured me that I was not studying a
numerical accident. I am grateful to Agnes McGregor for
supplementing my inexpert typing, and to Margaret Rodriguez
and Wendy Dunnet who have also typed sections of the
manuscript.
I thank the many volunteers, healthy and patients, who have
tolerated investigative procedures in connection with this
work. Finally, and most importantly, I am grateful to my
wife Lindsay, and my children David and Jane, for
tolerating my absence from home, and preoccupation with
substances with unpronouncable names, particularly during
the gestation of this manuscript.
The work was supported by funds from -
Medical Renal Unit Research Fund
Bayer, FRG
Kidney Foundation of Canada
Upjohn Co., USA
University of Western Ontario Research Fund
1 69
References
Abe K, Imai Y, Sato M, Haruyama T, Sato K, Hiwatari M, Kasai
Y, Itoh S, Yasujima M, Seino M, Yoshinaga K. Exaggerated
fractional sodium excretion in hypertension with advanced
renal disease: the role of renal prostaglandin and
kallikrein. Clinical Science 1981; 61: 327s-330s.
Abe K, Sato M, Imai Y, Haruyama T, Sato K, Hiwatari M, Kasai
Y, Yoshinaga K. Renal kallikrein-kinin; its relation to
renal prostaglandins and renin-angiotensin-aldosterone in
man. Kidney International 1981; 19: 869-80.
Abelous J-E, Bardier E. Les substances hypotensives de
l'urine humaine normal. Comptes Rendus de la Societe de
Biologie (Paris) 1909; 66: 511-512.
Adam W R, Clappison B H. The relationship between urinary
kallikrein excretion and mineralocorticoids in the rat.
Clinical and Experimental Pharmacology and Physiology
1982; 9: 283-287
Adetuyibi A, Mills I H. Relation between urinary kallikrein
and renal function, hypertension and excretion of sodium and
water in man. Lancet 1972; ii: 203-207.
Albertini R, Ladron de Guevara R, Asjeno F, Boric M.
Effect of renal nerve stimulation on urine and tissue
kininogenase activity in cats. Hypertension 1981; II: 50-54.
Al-Dujaili E A S, Edwards C R W. The development and
application of a direct radioimmunoassay for plasma
aldosterone using 1251-labelled ligand - comparison of three
methods. Journal of Clinical Endocrinology and Metabolism
1978; 46: 105-113.
Ali M, McDonald J W D. Synthesis of thromboxane B2 and 6-
keto-prostaglandin F1« by bovine gastric mucosal and muscle
microsomes. Prostaglandins 1980; 20: 245-254.
Amundsen E, Putter J, Friberger P, Knos M, Larsbraten M,
Claeson G. Methods for the determination of glandular
kallikrein by means of a chromogenic tripeptide substrate.
Advances in Experimental Medicine and Biology 1979; 120A:
83-95.
Arakawa K. Ability of kallikrein to generate angiotensin II
- like pressor substance and a proposed "kinin-tensin enzyme
system". Nature 1980; 288(5792):705-6
Asscher A W, Anson S G. A vascular permeability factor of
renal origin. Nature 1963; 198: 1097-1099.
1 70
Atkinson A B, Robertson J I S. Captopril in the treatment
of clinical hypertension and cardiac failure. Lancet 1979;
2: 836.
Bagdasarian A, Lahiri B, Talamo R C, Wong P, Coleman R W.
Immunochemical studies of plasma kallikrein. Journal of
Clinical Investigation 1974; 54; 1444-1454.
Balis J V, Rappaport E S, Gerber L, Fareed J, Buddingh F,
Messmore H L. A primate model for prolonged endotoxin shock.
Blood-vascular reactions and effects of glucocorticoid
treatment. Laboratory Investigation 1978; 38: 511-523.
Ball S G, Lee M R. The effect of carbidopa administration on
urinary sodium excretion in man. Is dopamine an intrarenal
natriuretic hormone? British Journal of Clinical
Pharmacology 1977; 4; 115-119.
Barajas L, Powers K, Carretero 0, Scicli A G, Inagami T.
Immunocytochemical localization of renin and kallikrein in
the rat renal cortex. Kidney International 1986; 29: 965-
970.
Barraclough M A, Mills I H. Effect of bradykinin on renal
function. Clinical Science 1965; 28: 69-74.
Baum M, Berry C A, Peritubular protein modulates neutral
active sodium chloride absorption in rabbit proximal
convoluted tubule. American Journal of Physiology 1985; 248:
F790-F795.
Baylis C, Ichikawa I, Willis W T, Wilson C B, Brenner BM.
Dynamics of glomerular ultrafiltration . IX. Effects of
plasma protein concentration. American Journal of Physiology
1977; 232: F58-F71.
Beaman M, Turney J H, Rodger R S C, McGonigle R S J, Adu D,
Michael J. Changing pattern of acute renal failure.
Quarterly Journal of Medicine 1987; 237: 15-23.
Beierwaltes W H, Prada J, Carretero O A. Effect of
glandular kallikrein on renin release in isolated rat
glomeruli. Hypertension 1985; 7: 27-31.
Beirwaltes W H, Prada J, Carretero O A. Kinin stimulation
of renin release in isolated rat glomeruli. American
Journal of Physiology 1985; 248: F757-F761.
Bell G I, Quinto C, Quiroga M, Valenzuela P, Craik C S,
Rutter W J. Isolation and sequence of a rat chymotrypsin B
gene. Journal of Biological Chemistry 1984; 259: 14265-
14270.
1 71
Bell G M, Reid W, Ewing D J, Cumming A D, Watson M L, Doig
A, Clarke B F. Abnormal diurnal sodium excretion in
diabetic autonomic neuropathy. Clinical Science 1987; 73:
259-265.
Bennett E D, Tighe D, Wegg W. Abolition, by dopamine
blockade, of the natriuretic response produced by lower-body
positive pressure. Clinical Science 1982; 63: 361-366.
Bergman R, Boim M A, Draibe S, Ajzen H, Schor N. Acute and
chronic prostaglandin inhibition on remnant nephron
hyperfunction. Nephrology, Dialysis, Transplantation 1986;
1: 97.
Better 0 S, Schrier R W. Disturbed volume homeostasis in
patients with cirrhosis of the liver. Kidney International
1983; 23: 303-311.
Bevan D R, MacFarlane N A A, Mills I H. The dependency of
urinary kallikrein excretion on renal artery pressure.
Journal of Physiology (London) 1974; 241: 34P-35P.
Bianchi C, Donadio M, Donadio C, Tramonti G, Figus S.
Measurement of glomerular filtration rate in man using DTPA
- 99mTc. Nephron 1979; 24: 171-178.
Bichet D G, Groves B M, Schrier R W. Mechanisms of
improvement of water and sodium excretion by immersion in
decompensated cirrhotic patients. Kidney International
1983; 24: 788-794.
Blantz R C, Rector F C, Seldin D W. Effect of hyperoncotic
albumin expansion upon glomerular ultrafiltration in the
rat. Kidney International 1974; 6: 209.
Bonner G. Effects of sodium-loading, desoxy-corticosterone
acetate, and corticosterone on urinary kallikrein excretion.
Hormone Research 1981; 14(2): 87-94.
Bonner G, Marin-Grez M. Measurement of kallikrein activity
in urine of rats and man using a chromogenic tripeptide
substrate. Journal of Clinical Chemistry and Biochemistry
1 981 ; 1 9: 1 65-1 68.
Bonner G, Autenrieth R, Marin-Grez M, Speck G, Gross F.
Steroid induced changes of the renal kallikrein-kinin system
in rats. Acta Endocrinologica 1984; 107: 131-140.
Bonner G, Deck D, Deeg M, Marin-Grez M, Gross F. Effects of
frusemide on the renal kallikrein-kinin system of the rat.
Clinical Science 1982; 63: 447-453.
Bonner G, Marin-Grez M, Beck D, Deeg M, Gross F. Changes in
renal and urinary kallikrein activity by mannitol-induced
osmotic diuresis. Clinical Science 1981; 61: 47-51.
1 72
Brenner B M, Hostetter T H, Humes H D. Molecular basis of
proteinuria of glomerular origin. New England Journal of
Medicine 1978; 298: 826.
Brouhard B H, Cunningham R J, Petrusick T W, Berger M,
Travis L B. Urinary kallikrein excretion in idiopathic
nephrotic syndrome. Journal of Urology 1979; 121: 672-674.
Brown E A, Markandu N M, Sagnella G A, Squires M, Jones B E,
McGregor G A. Evidence that some mechanism other than the
renin system causes sodium retention in nephrotic syndrome.
Lancet 1982; ii: 1237-1239.
Brownlee A A, Lee G, Mills I H, Spinelli F, Wakabayashi Y.
Stimulation of kallikrein excretion by infusion of atrial
natriuretic peptide (ANP) in rats; correlation with urine
flow, sodium and potassium excretion. Journal of Physiology
(London) 1986; 377: 52.
Carone F A, Pullman T N, Oparil S N, Nakamura S.
Micropuncture evidence of rapid hydrolysis of bradykinin by
rat proximal tubule. American Journal of Physiology 1976;
230: 1420-1424.
Carretero O A, Oza N B, Pwonska A, Ocholik T, Scicli A G.
Measurement of urinary kallikrein activity by kinin
radioimmunoassay. Biochemical Pharmacology 1976; 25: 2265-
2270.
Carretero O A, Miyazak S, Scicli A G. Role of kinins in the
acute anti-hypertensive effect of the converting enzyme
inhibitor, captopril. Hypertension 1981; 3: 18-22.
Chaimovitz C, Szylman P, Alroy G, Better 0 S. Mechanism of
increased renal tubular sodium reabsorption in cirrhosis.
American Journal of Medicine 1972; 52: 198-202.
Chao J, Margolius H S. Studies on rat renal cortical cell
kallikrein.II. Identification of kallikrein as an ecto-
enzyme. Biochimica Biophysica Acta 1979; 570: 330-340.
Cochrane C G, Revak S D, Aiken B S , Wuepper K D. The
structural characteristics and activation of Hageman factor.
In P Ward, IH Lepow (Eds) Inflammation: Mechanisms and
Control. Academic Press NY 1972, pp 119-129.
Coghlan J P, Aldred P, Haralambidis J, Niall M D, Penschow J
D, Tregear G W. Hybridisation histochemistry. Analytical
Biochemistry 1985; 149: 1-28.
Colman R W, Wong P Y. Participation of Hageman factor
dependent pathways in human disease states. Thrombosis and
Haemostasis 1977; 38: 751-775.
1 73
Conger J D, Falk S A, Guggenheim S J. Glomerular dynamics
and morphologic changes in the generalised Schwartzmann
reaction in post-partum rats. Journal of Clinical
Investigation 1981; 67: 1334-1346.
Croxatto H R, Albertini R, Arriagada R, Roblero J, Rojas M,
Rosas R. Renal urinary kallikrein in normotensive and
hypertensive rats during enhanced excretion of water and
electrolytes. Clinical Science and Molecular Medicine 1976;
51: 259S-261s.
Cumming A D, Robertson C E, Jeffrey S S, Robson J S,
Ledingham I McA. The plasma kallikrein-kinin system in
severely ill and traumatised patients. Archives of Emergency
Medicine 1984; 3: 135 - 142.
Cunningham R J, Brouhard B H. Captopril and kallikrein.
Lancet 1980; i: 832.
Cutler L S, Chaudhry A P. Release and restoration of the
secretory granules in the convoluted granular tubules of the
rat submandibular gland. Anatomical Records 1973; 176: 405-
41 9.
Dawborn J K. Applications of Heyrovsky's inulin method to
automatic analysis. Clinica Chimica Acta 1965; 12: 63-66.
De Bono E, Mills I H. Simultaneous increases in kallikrein
in renal lymph and urine during saline infusion. Journal
of Physiology (London) 1974; 241: 127P-128P.
De Wardener H E. The control of sodium excretion. American
Journal of Physiology 1978; 4: F163-F173.
Di Bona G F. The functions of the renal nerves. Reviews in
Physiology, Biochemistry and Pharmacology 1982; 94: 75-81.
DiBona G F. Catecholamines and neuroadrenergic control of
renal function. In: Renal Endocrinology. Dunn MJ (Ed),
Baltimore, Williams and Wilkins 1983, pp 323-366.
DiBona G F. Renal neural activity in hepatorenal syndrome.
Kidney International 1984; 25: 841-853.
Dorhout-Mees E J, Roos J C, Boer P, Yoe OH, Simatupang T A.
Observations on oedema formation in the nephrotic syndrome
in adults with minimal lesions. American Journal of Medicine
1979; 67: 378-384.
Dubovsky E V, Russell C D. Quantitation of renal function
with glomerular and tubular agents. Seminars in Nuclear
Medicine 1982; 12: 308-316.
1 74
Dzau V J, Burt D W, Pratt R E. Molecular biology of the
renin-angiotensin system. American Journal of Physiology
1988; 255: F563-F573.
Earley L E, Freidler R M. Changes in renal blood flow and
possibly the intrarenal distribution of blood during the
natriuresis accompanying saline loading in the dog. Journal
of Clinical Investigation 1965; 44: 929-941.
Elliot A H, Nuzum F R. Urinary excretion of a depressor
substance (kallikrein of Frey and Kraut) in arterial
hypertension. Endocrinology 1934; 18: 462-474.
Epstein M. Aldosterone in liver disease: in Epstein, M.





of renal sodium handling in
American Journal of Nephrology
Erdos E G. Angiotensin I converting enzyme. Circulation
Research 1975; 36: 247-255.
Erdos E G, Nakijima T, Oshima G, Gesce A, Kato J. Kininases
and their interaction with other systems. In Fogarty
International Center Proceedings, vol 27: Chemistry and
Biology of the Kallikrein-Kinin-System in Health and
Disease, ed by J J Pisano and K F Austen, pp 277-285. US
Government Printing Office, Washington, 1976.
Erspamer V. Active substances in the posterior salivary
gland of octopoda. Acta Pharmacologica Toxicologica 1948;
4: 213-247.
Fejes-Toth G, Naray-Fejes-Toth A, Rigter B, Frolich J C.
Urinary prostaglandin and kallikrein excretion are not flow
dependent in the rat. Prostaglandins 1983; 25:99-103.
Fejes-Toth G, Zahajszky T, Filep J. Effect of vasopressin
on renal kallikrein excretion. American Journal of
Physioiogy 1980; 239 : F388-392.
Ferreira S H, Vane J R. The detection and estimation of
bradykinin in the circulating blood. British Journal of
Pharmacology 1967; 29: 367-377 .
Fiedler F. Enzymology of glandular kallikreins. Handbook
of Experimental Pharmacology 1979. 25(suppl): 103-161.
Firth J D, Raine AEG, Ledingham J G G. Abnormal sodium
handling occurs in the isolated perfused kidney of the
nephrotic rat. clinical Science 1989; 76: 387-395.
1 75
Fray J C S. Stimulus - secretion coupling of renin.
Circulation Research 1980; 47: 485-492.
Frey, E K, Kraut H, Werle E (Eds) Kallikrein-Padutin,1950;
pp 157-168: F Enjke-Verlag, Stuttgart.
Friberger P, Eriksson E, Gustavsson S, Claeson G.
Determination of prekallikrein in plasma by means of a
chromogenic tripeptide substrate for plasma kallikrein.
Advances in Experimental Medicine and Biology 1978; 120A:
67-82.
Fritz H, Wunderer G. Biochemistry and applications of
Aprotonin, the kallikrein inhibitor from bovine organs.
Drug Research 1983; 33: 479-494.
Fuller P J, Funder J W. The cellular physiology of
glandular kallikrein. Kidney Intenational 1986; 29: 953-
964.
Funaki N, Kuroda M, Sudo J, Takeda R. Urinary
prostaglandins and kallikrein in the course of acute renal
failure. Prostaglandins, Leukotrienes in Medicine 1982;
9: 387-399.
Gallimore M J, Friberger P. Simple chromogenic peptide
substrate assays for determining pre-kallikrein, kallikrein
inhibition and kallikrein 'like' activity in human plasma.
Thrombosis Research 1982; 25: 293-298.
Gardiner D S, Lindop G B M. The granular peripolar cell of
the human glomerulus: a new component of the
juxtaglomerular apparatus? Histopathology 1985; 9: 675-685.
Geller R G, Margolius H S, Pisano JJ, Keiser HR. Effects
of mineralocorticoids, altered sodium intake and
adrenalectomy on urinary kallikrein in rats. Circulation
Research 1972; 31: 857-861.
Geller R G, Margolius H S, Pisano J J, Keiser H R. Urinary
kallikrein in spontaneously hypertensive rats. Circulation
Research 1975; 36/37: 103-106.
Glasser K J, Michael A F. Urinary kallikrein in
experimental renal disease. Laboratory Investigations 1976;
34: 616-622.
Glassock R J. Sodium homeostasis in acute glomerulonephritis
and the nephrotic syndrome. Contributions to Nephrology
1980; 23: 181-203.
Grausz H, Lieberman R, Earley LE. Effect of plasma albumin
on sodium reabsorption in patients with nephrotic syndrome.
Kidney International 1972; 1: 47-54.
1 76
Green R, Windhager E E, Giebisch G. Protein oncotic
pressure effects on proximal tubular fluid movement in the
rat. American Journal of Physiology 1974; 226; 265-276.
Haber Ef Koerner T, Paige L B, Kuman B, Purnode A.
Application of a radioimmunoassay for angiotensin I to the
physiologic measurement of plasma renin activity in normal
human subjects. Journal of Clinical Endocrinology and
Metabolism 1969; 29; 1349-1355.
Hall J E, Guyton A C. Changes in renal haemodynamics and
renin release caused by increased plasma oncotic pressure.
American Journal of Physiology 1976; 231; 1550-1556.
Halushka P V, Wohltmann H, Privitera P J, Horwitz D,
Margolius H S. A relationship between urinary prostaglandin
E-like material and kallikrein in children with Bartter's
syndrome: effects of indomethacin. Annals of Internal
Medicine 1977; 87: 281-286.
Hamilton G, Rosza I, Hutton R. Portal vein prostacyclin
activity in experimental portal hypertension in rats.
Clinical Science 1981; 60: 327-329.
Harrison T S, Birbari A, Seaton J F. Reinforcement of
reflex epinephrine release by angiotensin-II. American
Journal of Physiology 1973; 224: 31-34.
Harvey R B, Brothers A J. Renal excretion of para-
aminohippurate and creatinine measured by continuous in vivo
sampling of arterial and renal vein blood. Annals of the
New York Academy of Sciences 1962; 102: 46-54.
Heeg J E, De Jong P E, De Zeeuw D. Lisinopril and renal
failure. Lancet 1989; I: 846.
Heizer M L et al. Inhibition of bradykinin-induced and
kallikrein-induced cerebral vasospasm by a kinin receptor
antagonist. Stroke 1987; 18: 792-795.
Hostetter T H, Brenner B M. Glomerular adaptations to renal
injury. In - Chronic renal failure; Contemporary Issues in
Nephrology, 1981; 7: 1-27.
Hricik D E, Browning P J, Kopelman R, Goorno W E, Madias N
E, Dzau V J. Captopril-induced functional renal
insufficiency in patients with bilateral renal-artery
stenoses or renal-artery stenosis in a single kidney. New
England Journal of Medicine 1983; 308: 373-6.
Hsueh W A. Renin requires a structural alternation prior to
activation by renal kallikrein. Journal of Clinical
Endocrinology and Metabolism 1980; 51(4): 942-944.
1 77
Iannaccorie A, Porcelli G, Boscolo B. The urinary kallikrein
activity in cadmium exposure. Advances in Experimental
Medicine and Biology 1979; 120: 683-684.
Ichikawa I, Rennke H G, Hoyer J R, Badr K F, Schor N, Troy J
L, Lechene C P, Brenner B M. Role for intra-renal mechanisms
in the impaired salt excretion of experimental nephrotic
syndrome. Journal of Clinical Investigation 1983; 71: 91-
103.
Inokuchi K, Malik K U. Inhibition of bradykinin of renal
adrenergic effects in anesthetised rats. American Journal
of Physiology 1984; 246: F387-F394.
International Committee for Standardization in Haematology.
Standard techniques for the measurement of red cell and
plasma volume. British Journal of Haematology 1973; 25:
801.
Johnson M D, Shier D N, Barger A C. Circulating
catecholamines and control of plasma renin activity in
conscious dogs. American Journal of Physiology 1979; 236:
H463-H470.
Kaplan A P, Kay A B, Austen K F. Chemotactic activity of
kallikrein for human neutrophils. Arthritis and Rheumatism
1971 ; 1 4: 392-393.
Kaplan A P, Meier H L, Mandle R J. The role of Hageman
factor, prekallikrein and high molecular weight kininogen in
the generation of bradykinin and the initiation of
coagulation and fibrinolysis. Monographs in Allergy 1977;
12: 120-130.
Karlberg B E, Ohman K P, Nilsson O R, Wettre S. Captopril
lowers urinary kallikrein in hypertensive patients.
Lancet 1980; i: 150-151.
Kauker M L. Bradykinin action on the efflux of luminal 32
Na in the rat nephron. Journal of Pharmacology and
Experimental Therapeutics 1980; 214: 119-123.
Keiser H R. Urinary kallikrein excretion in hypertensive
man. Relationships to sodium intake and sodium retaining
steroids. Circulation Research 1974 b; 35: 820-825.
Kikeri D, Pennell J P, Hwang K H, Jacob A I, Richman A V,
Bourgoignie J J. Endotoxaemic acute renal failure in awake
rats. American Journal of Physiology 1986; 250: F1098-F1106.
Knox F G, Mertz J I, Burnett J C, Haramati A. Role of
hydrostatic and oncotic pressures in renal sodium
reabsorption. Circulation Research 1983; 52: 491-500.
1 78
Kotchen T A, Roy M W. Renin - Angiotensin. In: Renal
Endocrinology. Dunn M J (Ed) Baltimore, Williams and Wilkins
1983; pp 323-366.
Kramer G C, Harms B A, Bodai B I, Demling R H, Renkin E M.
mechanisms for redistribution of plasma protein following
acute protein depletion. American Journal of Physiology
1982; 243: H803-H809
Kramer H J, Klingmuller D, Glanzer K, Dusing R. Interaction
of the kinin and prostaglandin systems in mediating renal
function and intrarenal hemodynamics. Advances in
Experimental Medicine and Biology 1983; 156: 961-968.
Kramer H J, Dusing R, Glanzer K, Kipnowski J, Klingmuller D,
Meyer-Lehnert H. Effects of aprotonin on renal function.
Contributions to Nephrology 1984; 42: 233-241.
Kraut H, Frey E K, Werle E. Uber die Inakt ivierung des
Kallikreins; Hoppe-Seyler's Zeidschrift fur Physiologie
und Chemie 1930 ; 192: 1-21.
Kunitz M, Northrop J H. Isolation from beef pancreas of
crystalline trypsinogen, trypsin, trypsin inhibitor, and an
inhibitor trypsin compound. Journal of General Physiology
1936; 19:991-1007.
Lagrue G, Xheneumont S, Branellec A, Hirbec G, Weil B. A
vascular permeability factor elaborated from lymphocytes. I.
Demonstration in patients with nephrotic syndrome.
Biomedicine 1975; 23: 37-40.
Lawton W J. Abnormal urinary kallikrein in hypertension is
not related to aldosterone or plasma renin activity.
Hypertension 1980; 2: 787-93.
Levinsky N G. The renal kallikrein-kinin system.
Circulation Research 1979; 44: 441-451.
Levy S B, Lilley J J, Frigon R P, Stone R. Urinary
kallikrein and plasma renin activity as determinants of
renal blood flow. Journal of Clinical Investigation 1977;
60: 129-138.
Levy S B, Frigon R P, Stone R. The relationship of urinary
kallikrein activity to renal salt and water excretion.
Clinical Science and Molecular Medicine 1978; 54: 39-45.
Lewis H M, Wilkins M R, Selwyn B M, Yelland U J, Griffith M
E, Bhoola K D. Urinary guanosine 3:5-cyclic monophosphate
but not tissue kallikrein follows the plasma atrial
natriuretic factor response to acute volume expansion with
saline. Clinical Science 1988; 75: 489-494.
1 79
Lieberman F L, Denison E K, Reynolds R B. The relationship
of plasma volume, portal hypertension, ascites and renal
sodium retention in cirrhosis: the overflow theory of
ascites formation. Annals of New York Academy of Sciences
1970; 170: 202-212.
Lieberthal W, Arbeit L, Oza N, Bernard D B, Levinsky N G.
Reduced ratio of active-to-total urinary kallikrein in
essential hypertension. Hypertension 1983; 5: 603-609.
Lieberthal W, Oza N B, Arbeit L, Bernard D B, Levinsky N G .
Effects of alterations in sodium and water metabolism on
urinary excretion of active and inactive kallikrein in man.
Journal of Clinical Endocrinology and Metabolism 1983;
56: 513-519.
Light A, Danovitch G M. Sodium metabolism and volume
regulation. Current Nephrology 1983; 283-305.
McCarthy D A, Potter D E, Nicolaides E D. An in vivo
estimation of the potencies and half-lives of synthetic
bradykinin and kallidin. Journal of Pharmacology and
Experimental Therapeutics 1965; 148: 117-122.
MacFarlane N A A, Mills I H, Wraight E P. Increased
vascular permeability produced by kallikrein infusions and
its enhancement by nephrectomy. Journal of Physiology
(London) 1973; 231: 45P-46P.
MacFarlane N A A, Adetuyibi A, Mills I H. Changes in
kallikrein excretion during arterial infusion of
angiotensin. Journal of Endocrinology 1974; 61: 72.
McGiff J C. Interactions of prostaglandins with the
kallikrein -kinin and renin-angiotensin systems. Clinical
Science (suppl) 1980; 59 sup 6: 105s-116s.
McGiff J C, Itskovitz H D, Terragno A, Wong P Y-K.
Modulation and mediation of the action of the renal
kallikrein-kinin system by prostaglandins. Federation
Proceedings 1976; 35: 175-180.
McGiff J C, Nasjletti A. Kinins, renal function and blood
pressure regulation. Federation Proceedings 1976; 35: 172-
1 74.
Mackay I A, Nath K, Cumming A D, Muir A L, Watson M L.
Haemodynamic and endocrine responses of the kidney to
frusemide in mild essential hypertension. Clinical Science
1985; 68: 159-164.
Maier H, Adler D, Lenarz T, Muller-Esterl W. New concepts in
the reatment of chronic recurrent parotitis. Archives of
Oto-Rhino-Laryngology 1985; 242: 321-328.
1 80
Maier M, Binder BR. Dependence of urokallikrein excretion
on the perfusion pressure in explanted perfused kidneys.
Advances in Experimental Medicine and Biology 1979; 120B:
527- 538.
Malayan S A, Reid I A. Effects of a nonpressor analogue of
vasopressin on plasma renin activity and salt and water
excretion in water-loaded anesthetised dogs. Life Sciences
1982; 31; 2757-2763.
Manning R D, Guyton AC. Effects of hypoproteinaemia on fluid
volumes and arterial pressure. American Journal of
Physiology 1983; 245: H284-H293.
Marceau F, Lussier A, Regoli D, Giroud J P. Pharmacology
of kinins: their relevance to tissue injury and
inflammation. General Pharmacology 1983; 14; 209-229.
Margolius H S , Horvitz D, Geller R G, Alexander R W, Gill J
R, Pisano J J, Keiser H R . Urinary kallikrein excretion in
normal man. Relationships to sodium-retaining steroids.
Circulation Research 1974; 35: 812-819.
Margolius H S. Amiloride inhibits mammalian renal
kallikrein and a kallikrein-like enzyme from toad bladder
and skin. Journal of Clinical Investigation 1980;
65(6): 1343-1350.
Margolius H S. The kallikrein-kinin system, renal function
and hypertensive diseases. Progress in Biochemistry and
Pharmacology 1980; 17: 116-122.
Marin-Grez M. The influence of antibodies against
bradykinin on isotonic saline diuresis in the rat. Pflugers
Archives 1974; 350: 231-239.
Marin-Grez M, Bonner G, Gross F. Captopril, kallikrein and
hypertension. Lancet 1980; i: 1033.
Marin-Grez M, Schaechtelin G, Bonner G, Speck G, Ganten D,
Gross F. Renal kallikrein activity and urinary kallikrein
excretion in rats with experimental renal hypertension.
Clinical Science 1982; 63: 349-354.
Marks E S, Keiser H R. The role of the kallikrein-kinin
system in renal function: a new proposal. Advances in
Experimental Medicine and Biology 1983; 156B: 919-928.
Mason A J, Evans B A, Cox D R, Shine J, Richards R I.
Structure of mouse kallikrein gene family suggests a role in
specific processing of biologically active peptides.
Nature 1983; 303: 300-307.
1 81
Mason J W, Kleeberg U, Dolan P, Colman R W. Plasma
kallikrein and Hageman factor in gram negative bacteraemia.
Annals of Internal Medicine 1970; 73: 545-551.
Mayfield R K, Margolius H S, Bailey G S, Miller D H, Sens D
A, Squires J, Namm D H. Urinary and renal tissue kallikrein
in the streptozocin - diabetic rat. Diabetes 1985; 34: 22-
28.
Meltzer J I, Keim H Jf Laragh J H, Sealey J E, Kung-Ming J,
Chien S. Nephrotic syndrome: vasoconstriction and
hypervolaemic types indicated by renin-sodium profiling.
Annals of Internal Medicine 1979; 91: 688-696.
Millar J G Bf Campbell S K. Tissue kallikreins in pregnancy.
Prostaglandin Perspectives 1986; 2: 6-7.
Mills I H, MacFarlane N A A, Adetuyibi A, Wilson R J. On
the role of kallikrein in the renal adaptation to intra¬
arterial infusion of angiotensin II. 4th International
Congress of Endocrinology, Abstract No 586, 1972.
Mills I H, Paterson C L, Ward P E. The role of the kidney in
the inactivation of injected 1251-kallikrein. Journal of
Physiology 1975; 251: 281-286.
Mills I H, Ward P E. The relationship between kallikrein
and water excretion and the conditional relationship between
kallikrein and sodium excretion. Journal of Physiology
1975; 246: 695-707.
Mills I H, MacFarlane N A A, Ward P E, Obika L F O. The
renal kallikrein-kinin system and the regulation of salt and
water excretion. Federation Proceedings 1976; 35: 181-188.
Mills I H. Kallikrein, kininogen and kinins in control of
blood pressure. Nephron 1979; 23: 61-71.
Mills I H, Newport P A, Obika L F O. Interaction between
arterial pressure and vasoactive hormones in the release of
renal kallikrein. Advances in Experimental Medicine and
Biology 1979; 120B: 561-570.
Mills I H. The renal kallikrein-kinin system and sodium
excretion. Quarterly Journal of Experimental Physiology
1982; 67: 393-399.
Mitas J A, Levy S B, Holle R, Frigon R P, Stone R A.
Urinary kallikrein activity in the hypertension of renal
parenchymal disease. New England Journal of Medicine 1978;
299: 162-165.
1 82
Morrison D C, Cochrane C G. Direct evidence for Hageman
Factor (Factor XII) activation by bacterial
lipopolysaccharides (endotoxins). Journal of Experimental
Medicine 1974; 140: 787-811.
Mullane K M, Moncada S. Prostacyclin release and the
modulation of some vasoactive hormones. Prostaglandins
1980; 20: 25-49.
Murakami N, Hori S, Masumura S. Exercise proteinuria and
proteinuria induced by kallikrein. Nature 1968; 218: 481-
482.
Nasjletti A, Malik K U. Renal kinin-prostaglandin
relationship: implications for renal function. Kidney
International 1981; 19: 860-868.
Neiss A A, Forsyth R P, Williams H W, Melmon K L.
Contribution of kinins to endotoxin shock in unaesthetised
rhesus monkeys. Circulation Research 1968; 22: 155-164.
Nicholls K M, Shapiro M D, Groves B S, Schrier R W. Factors
determining renal response to water immersion in non-
excretor cirrhotic patients. Kidney International 1986;
30: 417-421.
O'Connor D T, Eurman G, Frigon R P, Stone R A
Antihypertensive mechanisms of chronic diuretic and
propranolol therapy. Kidney International 1977; 12: 471.
O'Donnell T F, Clowes G H A, Talamo K C, Colman R W. Kinin
activation in the blood of patients with sepsis. Surgery,
Gynaecology and Obstetrics 1976; 143: 539-545.
Olson J L, Rennke H G, Venkatachalam M A. alteration in the
charge and size selectivity barrier of the glomerular filter
in aminonucleoside nephrosis in rats. Laboratory
Investigation 1981; 44: 271-279.
Orce G G, Castillo G A, Margolius H S. Kallikrein inhibitors
decrease short-circuit current by inhibiting sodium uptake.
Hypertension 1981; 3: II 92-95.
Orstavvik T B, Nustad K, Brandtzaeg P, Pierce J V. Cellular
origin of urinary kallikreins. Journal of Histochemistry and
Cytochemistry 1976; 24: 1037-1039.
Orstavvik T B, Inagami T. Localization of kallikrein in the
rat kidney and its anatomical relationship to renin. Journal
of Histochemistry and Cytochemistry 1982; 30: 385-390.
183
Overlack A, Stumpe K O, Zywzock W, Ressel C, Druck F.
Defect in kallikrein-kinin system in essential hypertension
and reduction of blood pressure by orally given kallikrein.
Advances in Experimental Medicine and Biology 1979;
120B : 539-547 .
Overlack A, Stumpe K 0, Kuhnert M, Kolloch R, Ressel C, Heck
I, Kruck F. Evidence for the participation of kinins in the
antihypertensive effect of converting enzyme inhibition.
Klinische Wochenschrift 1981; 59: 69-74.
Overlack A, Stumpe K 0, Muller H-M, Kolloch R, Higuchi M.
Interactions of diuretics with the renal kallikrein-kinin
and prostaglandin systems. Klinische Wochenschrift 1982;
60: 1223-1228.
Oza N B, Leiberthal W, Bernard D B, Levinsky N G. Antibody
that recognises total urinary kallikrein.
Radioimmunological determination of inactive kallikrein.
Journal of Immunology 1981; 126: 2361-2364.
Perez-Ayuso R M, Arroy V, Camps J, Rimola A, Costa S, Gaya
J, Rivera F, Rodes J. Renal kallikrein excretion in
cirrhotics with ascites: relationship to renal
hemodynamics. Hepatology 1984; 4: 247-252.
Pierucci A, Simonetti B M, Pugliese F, Manzi M, Mene P,
Stirati G, Cinotti G A. Kallikrein-kinin system involvement
in chronic glomerular disease. Proceedings of the European
Dialysis and Transplant Association - European Renal
Association 1985; 22: 1057-1061.
Pisano J J. Chemistry and biology of the kallikrein-kinin
system. In - Proteases and biological control, Ed. Reich
E, Rifkin D B, Shaw E. Cold Spring Harbour Laboratories,
1 975.
Pisano J J. Observations on the kallikrein-kinin system in
the kidney . Advances in Experimental Medicine and Biology
1983; 156B: 929-938.
Plasma catecholamines, LCEC Application Note No. 14,
Bioanalytical Systems Inc., Purdue Research Park, West
Lafayette, IN., USA, 1985.
Proud D, Nakamura S, Carone F A, Pisano J J. Immunoreactive
kallikrein in rat renal lymph. Advances in Experimental
Medicine and Biology 1983; 156B: 889-896.
Proud D, Nakamura S, Carone F A, Herring P L, Kawamura M,
Inagami T, Pisano J J. Kallikrein-kinin and renin-
angiotension systems in rat renal lymph. Kidney
International 1985; 25: 880-885.
1 84
Pru C, Kjellstrand C M. Urinary diagnostic indices and
chemistries in the differential diagnosis of prerenal
failure and acute tubular necrosis. Seminars in Nephrology
1985; 5; 224-233.
Rabito S F, Orstavvik T B, Scicli A G, Schork A, Carretero 0
A. Role of the autonomic nervous system in the release of
rat submandibular gland kallikrein into the circulation.
Circulation Research 1983; 52: 635-641.
Raine AEG, Firth J G, Ledingham J G G. Renal actions of
atrial natriuretic factor. Clinical Science 1989; 76: 1-8.
Ratnoff 0 D, Pensky J, Ogston D et al. The inhibition of
plasmin, plasma kallikrein, plasma permeability factor, and
C1R subcomponent of the first component of complement by
serum C1 esterase inhibition. Journal of Experimental
Medicine 1969; 129: 315-331.
Regoli D, Barabe J, Park W K. Receptors for bradykinin in
rabbit aortae. Canadian Journal of Physiology and
Pharmacology 1977; 55: 855.
Regoli D, Barabe J. Pharmacology of bradykinin and related
kinins. Pharmacological Reviews 1980; 32: 1-46.
Regoli D, Marceau F, Lavigne J. Induction of B receptors
for kinins in the rabbit by a bacterial lipopolysaccharide.
European Journal of Pharmacology 1981; 71: 105-115.
Remuzzi G, Imberti L, Rossini M, Morelli C, Carminati C,
Cattaneo G M, Bertani T. Increased glomerular thromboxane
synthesis as a possible cause of proteinuria in experimental
nephrosis. Journal of Clinical Investigation 1985; 75: 94-
1 01 .
Richards A M, Tonolo G, Polonia J, Montorsi P. Contrasting
plasma atrial natriuretic factor concentrations during
comparable natriuresis with infusions of atrial natriuretic
factor and saline in normal man. Clinical Science 1988;
75: 455-462.
Richmond JM, Walker JF, Avila A, Petrakis A, Finley RJ,
Sibbald WJ, Linton AL. Renal and cardiovascular response to
nonhypotensive sepsis in a large animal model with
peritonitis. Surgery 1985; 97:-205-213.
Robinson J A, Klodnycky M L, Loeb MS, Rack M R, Gunnar R M.
Endotoxin, prekallikrein, complement and systemic vascular
resistance. Sequential measurements in man. The American
Journal of Medicine 1975; 59: 61-67.
1 85
Rodriguez-Portales, J A, Lopez-Morena J M, Mahana D.
Inhibition of the kallikrein-kinin system and vascular
reactivity in Barrters syndrome. Hypertension 1985; 7:
1017-1022.
Roulston J E, Wathen C G, Sanger B, Muir A L. Sample
collection and processing for the assay of plasma renin
activity. Annals of Clinical Biochemistry 1983; 20: 217-
219.
Ryan G B, Coghlan J P, Scoggins B A. The granulated
peripolar epithelial cell: a potential secretory component
of the renal juxtaglomerular complex. Nature 1979; 277:
655-656.
Ryan J W, Oza N B, Martin L C, Pena G A. Components of the
kallikrein-kinin system in urine. Advances in Experimental
Medicine and Biology 1979; 120A: 313-323.
Ryan G B, Alcorn D, Coghlan J P, Hill P A, Jacobs R.
U1trastructural morphology of granule release from
juxtaglomerular myoepithelioid and peripolar cells. Kidney
International 1982; 22 (suppl 12): s3-s8.
Saha H, Mustonen J, Helin H, Pasternack A. Limited value of
the fractional excretion of sodium test in the diagnosis of
acute renal failure. Nephrology, Dialysis and
Transplantation 1987; 2: 79-82.
Saito K. Determination of Hageman factor (HF, Factor XII)
and plasma prekallikrein (Fletcher factor) by
radioimmunoassays. Advances in Experimental Medicine and
Biology 1979; 120A: 165-172.
Schachter M, Uchida Y, Longridge DJ, Labedz T, Whalley E T,
Vavrek R J, Stewart J M. New synthetic antagonists of
bradykinin. British Journal of Pharmacology 1987; 43: 851-
855.
Schaller M D, Waeber B, Nussberger J, Brunner H R.
Angiotensin II, vasopressin and sympathetic activity in
conscious rats with endotoxaemia. American Journal of
Physiology 1985; 249: H1086-H1092.
Schreiber A D, Kaplan A P, Austen K F. Inhibition by CI INH
of Hageman Factor fragment activation of coagulation
fibrinolysis and kinin-generation. Journal of Clinical
Investigation 1973; 52: 1402-1409.
Schroeder E T, Anderson G H, Goldman S H, Streeten D H P.
Effect of blockade of angiotensin II on blood pressure,
renin and aldosterone in cirrhosis. Kidney International
1976; 9: 511-519.
1 86
Schuster V L, Kokko J P, Jacobson H R. Interactions of Lys-
bradykinin and antidiuretic hormone in the rabbit cortical
collecting tubule. Journal of Clinical Investigation 1984;
73: 1659-1667.
Scicli A G, Carretero 0 A, Oza N B, Schork A. Distribution
of kidney kininogenases . Proceedings of the Society for
Experimental Biology and Medicine 1976; 151: 57-60.
Scicli A G, Diaz M A, Carretero O A. Effect of pH and
amiloride on the intrarenal formation of kinins. American
Journal of Physiology 1983; 254: F198-F203.
Scicli A G, Orstavik T B, Rabito S F, Murray R D, Carretero
O A. Blood kinins after sympathetic nerve stimulation in the
rat submandibular gland. Hypertension 1 983; 5: 1101-1106.
Scicli A G, Carretero O A. Renal kallikrein-kinin system.
Kidney International 1986; 29: 120-130.
Sealey J Ef Atlas S A, Laragh J H. Linking the kallikrein
and renin systems via activation of inactive renin: new
data and a hypothesis. American Journal of Medicine 1978;
65: 994-1000.
Sealey J E, Atlas S A, Laragh J H, Oza N B, Ryan J W. Human
urinary kallikrein converts inactive to active renin and is
a possible physiological activator of renin. Nature 1978;
275: 144-145.
Seeber A M, Vila S B, Catanzaro O L. The mechanism of
urinary kallikrein excretion in the rat. Clinical Science
1982; 63: 217-218.
Seto S, Kher V, Scicli A G, Beierwaltes W H, Carretero O A.
The effect of aprotonin (a serine protease inhibitor) on
renal function and renin release. Hypertension 1983; 5:
893-899.
Shiigai T, Tomita K, Schichiri M, Andou R, Shinoda T,
Takeuchi J.
Increased urinary kallikrein-like activity in the syndrome
of inappropriate secretion of antidiuretic hormone
Advances in Experimental Medicine and Biology 1983;
156B: 995-1004.
Shimamoto K, Ando T, Nakao T, Tanakas S , Sakuma M, Miyahata
M. A sensitive radioimmunoassay method for urinary kinins
in man. Journal of Laboratory and Clinical Medicine 1978;
91: 721-728.
Skowsky R, Fichman M P. Physiology and disorders of water
metabolism. Current Nephrology, 1984, 7, 489-554.
1 87
Solez K, Ideura T, Silvia C B, Hamilton B, Saito H.
Clonidine after renal ischemia to lessen acute renal failure
and microvascular damage. Kidney International 1980; 18:
309-322.
Spragg J, Denney D L, Tilney N L, Austen K F. Kallikrein
excretion in renal transplant recipients and in
uninephrectomised donors. Kidney International 1985; 28:
75-81.
Stein J H, Congbalay R C, Karsh D L, Osgood R W, Ferris T F.
The effect of bradykinin on proximal tubular reabsorption in
the dog: evidence for functional nephron heterogeneity.
Journal of Clinical Investigation 1972; 51: 1709-1721.
Stewart J M. Structure-activity relationship in bradykinin
analogs. Federation Proceedings 1968; 27: 63-66.
Strauss J, Freundlich M, Zillervelo G. Nephrotic edema;
etiopathogenic and therapeutic considerations. Nephron
1984; 38: 73-75.
Sumida S. Experimental studies on the effect of
prophylactic proteinase inhibitor in shock. Advances in
Experimental Medicine and Biology 1979; 120B: 395-401.
Takada Y, Skidgel R A, Erdos E G. Purification of human
urinary pro-kallikrein. Identification of the site of
activation by the metalloproteinase thermolysin.
Biochemical Journal 1985; 232: 851-858.
Talamo R C, Goodfriend T L. Bradykinin radioimmunoassays.
Handbook of Experimental Pharmacology 1979; 25(suppl): 302-
309.
Thibault G, Garcia R, Contin Mf Genest J. Atrial
natriuretic peptide and urinary kallikrein in the rat:
antagonistic factors? Canadian Journal of Physiology and
Pharmacology 1984; 62: 645-649.
Tristani F E, Cohn J N. Systemic and renal hemodynamics in
oliguric hepatic failure: effect of volume expansion.
Journal of Clinical Investigation 1967; 46: 1894-1906.
Tulassay T, Rascher W, Lang R E, Seyberth H W, Scharer K.
Atrial natriuretic peptide and other vasoactive hormones in
nephrotic syndrome. Kidney International 1987; 31: 1391—
1 395.
Vandogen R, O'Dwyer J, Barden A. Effect of alpha-adrenergic
stimulation on prostacyclin and renin release in the rat
kidney. Prostaglandins 1982; 24: 815-825.
1 88
Vio C P, Bednar M M, McGiff J C. Prostaglandins as
mediators and modulators of the kailikrein-kinin system.
Advances in Experimental Medicine and Biology 1983;
156: 501-514.
Vio C P, Figueroa C D. Subcellular localisation of renal
kallikrein by ultrastructural immunocytochemistry. Kidney
International 1985; 28: 36-42.
Vio C P, Figueroa C D. Evidence for a stimulatory effect of
high potassium diet on renal kallikrein. Kidney
International 1987; 31: 1327-1334.
Vavrek R J, Stewart J M. Competitive antagonists of
bradykinin. Peptides 1985; 6: 161-164.
Waeber B, Aubert J-F, Fluckiger J-P, Nussberger J, Vavrek R
J, Stewart J M, Brunner H R . Role of endogenous bradykinin
in blood pressure control of conscious rats. Kidney
International 1988; 34,(Suppl 26): S63-S68.
Walker JF, Cumming AD, Lindsay RM, Solez K, Linton AL. The
renal response produced by non-hypotensive sepsis in a large
animal model. American Journal of Kidney Diseases 1986; 8:
88-97.
Wardle N. Acute renal failure in the 1980s; the importance
of septic shock and of endotoxemia. Nephron 1982; 30: 193—
200.
Webster M E, Clark W R. The significance of the callikrein-
callidinogen-cinin system in shock. American Journal of
Physiology 1959; 197: 406-412.
Webster M E, Pierce J V. Action of kallikreins on synthetic
substrates. Proceedings of the Society for Experimental
Biology and Medicine 1961; 107: 186-191.
Weidmann P, Hasler L, Gnadinger M P, Lang R E, Vehlinger D
E, Shaw S, Rascher W, Reubi F. Blood levels and renal
effects of atrial natriuretic peptide in normal man.
Journal of Clinical Investigation 1986; 77: 734-742.
Weinberg M, Belknap S, Trebbin B, Soloman R J. Effects of
changing salt and water balance on renal kallikrein,
kininogen and kinin. Kidney International 1987; 31:836-841.
Wilkinson S P, Jowett T P , Slater J D H, Arroyo V, Moodie
H, Williams R. Renal sodium retention in cirrhosis.
Relation to aldosterone and nephron site. Clinical Science
1979; 56: 169-177.
1 89
Werb R, Linton A L. Aetiology, diagnosis, treatment and
prognosis of acute renal failure in an intensive care unit.
Resuscitation 1979; 7; 95-100 .
Wichterman K A, Baur A E, Chaudry I H. Sepsis and septic
shock - a review of laboratory models and a proposal.
Journal of Surgical Research 1980; 29: 189-201.
Wong P Y, Talamo R C, Williams G H. Kallikrein-kinin and
renin-angiotensin systems in functional renal failure of the
liver. Gastroenterology 1977; 73: 1114-1118.
Yamada K, Hasunuma K, Shiina T, Ho K, Tamura Y, Yoshida S.
Inter-relationship between urinary kallikrein-kinins and
arginine vasopressin in man. Clinical Science 1989; 76: 13-
18.
Zinner S H, Margolius H S, Rosner B, Kass E H. Stability of
blood pressure rank and urinary kallikrein concentration in
childhood. An eight year follow-up. Circulation 1978;
58: 908-915
Zipser R D, Kerlin P, Hoefs J C, Zia P, Barg A. Renal
kallikrein excretion in alcoholic cirrhosis. American
Journal of Gastroenterology 1981; 75: 183-187.
Zschiedrich H, Fleckenstein P, Geiger R, Fink E, Sinterhauf
K, Philipp T, Distler A, Wolff H P. Urinary kallikrein in
normotensive subjects and in patients with essential
hypertension. Clinical & Experimental Hypertension 1980;
2: 693-708.
1 90
